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The Role o f  the Nitric Oxide-cGMP Pathway in the Kainic Acid Rodent Model o f  
Seizure
Anna Siobhan Cosgrave
Epilepsy is a common neurological disorder characterized by the recurrence of 
unprovoked seizures. Investigating the cellular and molecular events following a 
seizure leads to a greater understanding in the mechanisms that potentiate subsequent 
seizures. Nitric oxide (NO) regulates the excitatory neurotransmitter, glutamate, 
through N-methyl-D-aspartate (NMDA) receptors suggesting a role for NO in 
regulating neuronal excitability. NO is a gaseous molecule produced from L-Arginine 
via nitric oxide synthase (NOS) and can cross the plasma membrane of neighbouring 
cells to activate soluble guanylyl cyclase (sGC) by binding to the haem group of the 
enzyme to form guanosine-3’,5’-cyclic monophosphate (cGMP). This can then initiate 
physiological responses in the cell, primarily via the phosphorylation of proteins by 
protein kinases. NO can also directly influence cell signalling pathways by 
nitrosylating membrane bound and/or intracellular proteins and transcription factors.
Certain types of epilepsy such as temporal lobe epilepsy (TLE) are often 
associated with a distinct pattern of neurological damage, such as neuronal cell death 
in the hippocampus. The proteins vasoactive intestinal peptide (VIP) and activity 
dependent neuroprotective protein (ADNP) are neuroprotective both in vivo and in 
vitro and have also been shown to be involved in development and neurogenesis. To 
investigate the role of the NO-cGMP pathway in the regulation of these proteins 
following seizure the NOS inhibitor, N-nitro-L-arginine methyl ester (L-NAME, 50 
mg/kg), the neuronal NOS inhibitor, 7-nitroindazole (7-NI, 50 mg/kg) and the sGC 
inhibitor, lH-[l,2,4]oxadiazolo[4,3-a]quinoxalin-l-one (ODQ, 10 mg/kg) were used in 
the kainic acid (KA, 10 mg/kg) rodent model of epilepsy. 5-bromo-2-deoxyuridine 
(BrdU), a thymidine analogue which is incorporated into newly dividing cells, was 
used to investigate the role of NO in the regulation of these proteins in neurogenesis 
following KA treatment. All experiments were carried out in accordance with UK 
Home Office regulations.
Region-specific NO/NO-cGMP regulation of ADNP and VIP expression was 
observed in the hippocampus and DG at basal levels and following KA treatment. RT- 
PCR/QPCR and immunostaining showed that following KA treatment there was 
significant decrease in ADNP expression by 3 days in the hippocampus compared to 
vehicle controls. This was reversed by NOS and sGC inhibition suggesting the 
regulation of ADNP in the hippocampus to be via the NO-cGMP pathway. However, 
in the DG, regulation of ADNP was directly via NO and this regulation of ADNP was 
localized further to cell layers within the DG. VIP expression in the DG appeared to be 
via the NO-cGMP pathway following seizure, as a significant increase in VIP+ cells 
was observed with NO inihibition and KA treatment. NO also regulates VIP 
expression in the CA3 region, interestingly, by 3 days an inverse relationship showing 
an increase in VIP+ and a decrease in GFAP+ cells was observed following seizure 
suggesting NO is also involved in glial activation in this area following seizure. BrdU-
XI
labelling experiments showed NO regulated precursor cell proliferation and that this 
involved ADNP both in vivo and in vitro.
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CHAPTER 1
General Introduction
1.1 Overview o f  Introduction
The cellular and molecular processes following a seizure can lead to neurological damage 
and changes in the brains circuitry, developing the individuals propensity to have more 
seizures. Such events are characteristic of epilepsy, a complex neurological disorder, and 
as one of the oldest disorders known to man, an extensive sea of literature exists on the 
topic. To explain the background on which this study is based, I will review some general 
features of epilepsy and seizure-related disorders and the region of the brain, called the 
hippocampus, which is often seen to display distinct patterns of neurological changes in 
epileptic patients and animal models of epilepsy. Hence the different types of cell death 
and the role of glia in epilepsy will be discussed. Neuroprotection and a brief introduction 
to the proteins investigated in this study, activity dependent neuroprotective protein 
(ADNP) and vasoactive intestinal peptide (VIP), followed by neurogenesis will be 
discussed. Finally, the role of the gaseous molecule nitric oxide (NO) and its signal 
transduction pathway NO-cGMP will be reviewed.
1.2 Epilepsy
1.2.1 Epidemiology
The ancient Greek philosopher Hippocrates (460-3 77BC) was one of the first to propose 
the idea that epilepsy was a disease rather than a divine affliction, or indeed, a demonic 
possession! There are many seizure types and mechanisms by which the brain generates 
seizures. It is a common neurological disorder, affecting approximately 0.4-1% of the 
human population. Although this is the global mean, in fact, epilepsy is more prevalent in 
developing countries than in more developed areas of the world. In developing countries 
such as Colombia, Ecuador, India, Liberia, Nigeria and Panama it has been reported that 
more than 10 in a 1000 people have epilepsy compared to 50 in 100,000 in developed 
countries (WHO, 2001). This may be due to a higher risk of infectious diseases because 
of living conditions. There are also pre- and post-natal complications and malnutrition 
leading to permanent brain damage which may, in turn, lead to epilepsy. Epilepsy is 
associated with an increased mortality, maybe due to status epilepticus (SE), whereby 
seizures do not terminate after 5 minutes or occur continuously without time for recovery,
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which if untreated can cause brain damage and damage to other organs (WHO, 2001). 
Sudden unexpected death in epilepsy, termed SUDEP, is uncommon and the cause is 
unknown. Some studies have suggested that a part of the brain that controls breathing 
may be affected during a seizure causing the person to stop breathing. Although epilepsy 
can often be controlled with anti-epileptic drugs (AED’s), approximately one third of 
patients do not respond to AED’s, so-called ‘refractory epilepsy’ because of inadequately 
controlled seizures (Curry and Kulling, 1998). The long term side effects of AED’s, such 
as a higher risk of developing cancer and birth defects, are also becoming increasingly 
evident (Kaplan, 2004; Singh et al., 2005) which gives rise to the need to develop safer 
drugs and drugs for those patients who do not respond to current AED’s or surgery. 
Consequently, it is important to understand the cellular and molecular mechanisms 
leading to the development of epilepsy, a process which has been termed 
‘epileptogenesis’.
1.3 Seizure Types and Classification
A seizure (or ictus) is defined as a single episode of neurologic dysfunction generated by 
the hyperexcitability of neurons and hypersynchrony of neural circuits. This hyper- 
excitable state may be due to; alterations in voltage-gated ion channels (Lerche et ah,
2005), a decrease of inhibitory neurotransmission, usually facilitated by gamma amino 
butyric acid (GABA) or increased excitatory neurotransmission by glutamate (Noe & 
Manno, 2005). The period after a seizure is often referred to as the ‘postictal’ period and 
the interval between seizures is referred to as the ‘interictal’ period (or epileptiform). 
Epilepsy is the recurrence of unprovoked seizures, implying that there are permanent 
pathophysiological or structural changes in the brain which are supporting abnormal 
hypersynchronous neuronal firing. It should also be noted that the term ‘epilepsy’ does 
not pertain to a single disorder but rather a group of syndromes with different symptoms 
and etiologies. Such syndromes include; temporal lobe epilepsy (TLE), which involves 
the synaptic reorganization of limbic circuitry (Sutula et al., 1989), childhood absence 
epilepsy, which is due to a thalamocortical circuit malfunction (Blumenfeld & 
McCormick, 2000), benign familial neonatal convulsion, involving the mutation of 
potassium channels (Jentsch 2000; Cooper & Jan 2003) and Glut-1 deficiency, whereby a
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lack o f the glucose transporter protein can lead to epileptic encephalopathy (Klepper
2004).
Epilepsies are generally classified according to a number of criteria such as their initial 
etiology, semiology, the origin of the seizure in the brain, the syndrome and the event that 
triggers the seizure. The classification of epileptic seizures and syndromes is still a 
difficult practice for specialists in the field but is important because this has significant 
implications for treatment and prognosis. In 1970 the International League Against 
Epilepsy (ILAE) put forward the first proposal to distinguish seizures from epilepsies 
(Merlis, 1970) and since then classifications have been reviewed and up-dated (Seino
2006). From clinical and electroencephalographic (EEG) analysis, seizures can be 
broadly divided into generalized and partial seizures. An EEG is a record of electrical 
potential (voltage) differences at paired points of the brain and it is these EEG patterns 
which can be used to determine epileptiform activity. Neurons in chronic epileptiform 
foci undergo spontaneous long (100-200 ps) and high (10-15 mV) depolarisations, 
associated with spike activity. This depolarisation is called paroxysmal depolarisation 
shift (PDS) which has recently been associated with slow inward currents (SICs) 
recorded in hippocampal pyramidal neurons (Browne & Holmes, 2003; Tian et ah, 2005), 
however, PDS is not always a hallmark of epilepiform activity. Generalized seizures 
begin with a widespread electrical discharge involving both hemispheres of the brain, 
whereas partial seizures begin with an electrical discharge in a specific region of the 
brain. Partial seizures can be subclassified as simple or complex and can be caused by 
brain injury, infection, stroke and tumour; however, in most cases the cause is unknown. 
Additionally, not all epilepsy syndromes are permanent and some are only apparent 
during childhood.
1.4 The Hippocampus
1.4.1 Anatomical Organisation o f  the Hippocampus
Temporal lobe epilepsy (TLE) is the most common type of epilepsy in humans and is 
associated with a very distinct pattern of neurological damage that is seen in many, but 
not in all patients: neuronal cell death in the hippocampus, accompanied by fibrillary
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gliosis and sclerosis of the hippocampus (Honavar, 1997). The hippocampus is situated in 
the medial temporal lobe of the brain and forms part of the limbic system. Ramón y Cajal 
originally defined the regions of the hippocampus as regio inferior and regio superior; 
however, it was the terminology of Lorente de Nó that has come to define what we now 
know as the hippocampus. The hippocampal formation is composed of the dentate gyrus 
(DG); the subiculum and the hippocampus (or hippocampus proper), which is further 
subdivided into the cornu ammonis (CA)1, CA2 and CA3 (Fig 1.1). However, it is often 
accepted that the entorhinal cortex, presubiculum and parasubiculum are also included in 
the term ‘hippocampal formation’ (Amaral & Witter 1995). Their connectivity is largely 
unidirectional and the cells most susceptible to excitotoxity are the pyramidal neurons in 
the CA1 and CA3 regions of the hippocampus, while the CA2 is resistant. The neurons in 
the hilus of the dentate gyrus (also referred to as the CA4 region) can also be sensitive to 
excitotoxity and a large proportion of them degenerate (Lowenstein et al., 1992). The 
laminar organization of the hippocampus includes; the principal cell layer (more 
commonly termed the pyramidal cell layer), a relatively cell free layer located outside the 
pyramidal layer called the stratum oriens and distal to this is the fiber-containing alveus 
(Fig. 1.1). Specific to the CA3, is the stratum lucidum which is a narrow layer occupied 
by the mossy fibers projecting from the dentate gyms. Superficial to this layer in the CA3 
and immediately above the pyramidal cell layer in the CA2 and CA1, lies the stratum 
radiatum. This suprapyramidal region contains CA3 to CA3 associational connections 
and also CA3 to CA1 Schaffer collateral connections (Fig 1.2). The stratum lacunosum- 
moleculare is the most superficial portion of the hippocampus and it is here that the 
perforant pathway fibers from the entorhinal cortex terminate.
1.4.2 Cellular Organisation o f the Hippocampus
The principal neuronal cell type of the hippocampus is the pyramidal cell. These have a 
basal dendritic tree, the length of which is relative to its position along the transverse axis 
of the CA3; i.e. those closest to the dentate gyms have, on average, the smallest dendritic 
trees, whereas those in the distal part of the CA3 have larger dendritic trees. Other cell 
types of the hippocampus include a heterogenous population of basket cells, whose cell
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bodies reside in the pyramidal cell layer. They also have dendritic trees, but few dendritic 
spines. Other nonpyramidal cells of the hippocampus include various interneuronal cell 
types which are immunoreactive for GABA (Ribak et al., 1978). These intemeurons and 
their terminals can be subdivided according to their morphological characteristics, 
including the distribution of their axonal plexuses, and their neurochemical identity i.e. 
by their neuropeptide and calcium-binding protein content (Houser, 2007).
cerebellum
Figure 1.1 Schematic representation to show the three-dimensional organization of the 
rat hippocampus. A. Anatomy of the rat brain showing the C-shaped hippocampus in the 
septotemporal or longitudinal axis. B. Coronal cross section of the area represented by the 
red line in A. C. Magnification of the hippocampus highlighted to show the various cell 
layers. Adapted from Cheung & Cardinal, 2005 and http://www.uni- 
leipzig.de/~vetana/Hippocampus/hippocampus-farbig.jpg.
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1.4.3 Pathways o f  the Hippocampus
The hippocampal circuitry is complex, its unidirectional connectivity is described in the 
context of a trisynaptic circuit, whereby afferent input from the entorhinal cortex via the 
perforant path synapses onto the dentate granule cells. The axons of the dentate granule 
cells (known as mossy fibres), in turn, project to the pyramidal cell layer (Fig 1.2). 
Initially, the mossy fibres synapse with the CA3 pyramidal cells, which then, via the 
Schaffer collaterals, synapse with the CA1 pyramidal cells and continue through the 
subiculum as efferent output to the cerebral cortex. However, it has recently been 
postulated that the CA3 also receives input from other pathways, suggesting the CA3 as 
another point of entry to the hippocampus rather than the DG. It is becoming increasingly 
evident that a ‘backprojection’ from the CA3 to the dentate gyrus exists and may be 
exerting its influence indirectly on granule cells via the GABAergic neurons (Scharfman,
2007). The main changes observed in the hippocampus which are associated with 
epileptogenesis include; selective neuronal loss, axonal and dendritic reorganisation, 
including ‘mossy fibre sprouting’ (Koyama and Ikegaya, 2004), dispersion of the dentate 
granule cell layer (Houser, 1990), changes in glial architecture (D’Ambrosio, 2004) and 
the altered expression of neurotransmitters and their receptors (Koyama and Ikegaya,
2005).
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Figure 1.2 Pathways of the hippocampus. Afferents mainly arise from layers II and III, 
but also from deeper layers IV and V of the entorhinal cortex (EC-lateral entorhinal 
cortex, LEC; medial entorhinal cortex, MEC). Axons from layers II/IV synapse onto the 
granule cells of the dentate gyrus (DG) and CA3 pyramidal neurons via the perforant path 
(PP- lateral perforant path, LPP; medial perforant path, MPP). Mossy fibres (MF) of the 
DG also project to the CA3, the CA3 cells then project to the CA1 pyramidal cells via the 
Schaffer collateral pathway (SC) and to the contralateral CA1 via the Associational 
Commissural pathway (AC). Axons from layers III/V of the EC input directly onto the 
CA1 which projects to the subiculum (Sb) to output back to the EC. Taken from 
http://www.bris.ac.uk/Depts/Synaptic/info/pathway/figs/hippocampus.gif
1.4.4 The Dentate Gyrus
A three-dimensional view of the dentate gyrus shows an elongated curved structure 
folded within the hippocampus (Fig. 1.1). A transverse section through the dentate gyrus 
reveals a C or V shape, the dorsal limb referred to as the suprapyramidal blade (above the 
CA3) and the ventral limb referred to as the infrapyramidal blade (below the CA3). It is 
composed of three layers; i) a primarily cell free layer called the molecular layer (or 
stratum moleculare) which is mainly occupied by dendrites of the dentate granule cells 
and fibers of the perforant path that originate from the entorhinal cortex. A small number 
of intemeurons are also found in the molecular layer along with fibers from other 
extrinsic inputs, ii) The principal cell layer of the dentate gyrus is known as the granule 
cell layer (or stratum granulosum) and is mainly composed of densely packed granule 
cells, however, other neuronal types can be found on the border between the granule cell 
layer and the hilus (or polymorphic layer) (Fig.l .1) e.g. the dentate pyramidal basket cell.
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iii). The hilus, which is surrounded by the granule cell layer contains a number of cell 
types, mainly glutamatergic mossy cells and GABAergic intemeurons. Distinct neuronal 
populations in the dentate gyrus, e.g. hilar neurons, display differential vulnerability to 
various forms of insult such as traumatic brain injury, ischaemia and epilepsy 
(Lowenstein et al., 1992; Jiao & Nadler, 2007).
1.5 Models o f  Seizure
In order to understand epilepsy and find new treatments, model systems must be 
employed. For this puipose, the use of animal models has disclosed much of what we 
have learnt about epilepsy and seizures. Animal models of epilepsy can include genetic 
abnormalities such as the WAG/Rij rat, alternatively, seizures can be induced via 
electrical stimulation e.g. the perforant path model or via chemical convulsants such as 
pilocarpine, bicuculline and kainic acid (KA) (Fisher, 1989). Kindling is a process by 
which the duration and behavioural involvement of induced seizures increases after 
seizures are induced repeatedly until a plateau is reached and so repeated stimulation 
‘lowers the threshold’ for more seizures to occur (Racine, 1972).Kindling is usually 
earned out by focal electrical stimulation in the brain.The term ‘seizures beget seizures’ 
is often used to study this phenomenon, whereby a seizure may increase the likelihood 
that more seizures will occur. In the kindling model, seizures begin to occur 
spontaneously after repeated subconvulsive stimuli leading to self-sustaining status 
epilepticus (SSSE). However, the relevance of the kindling model in animals compared to 
epileptogenesis in humans is still widely debated and although there are a number of 
well-described anatomical changes associated with kindling (glial activation, decreased 
neuronal density, some mossy fiber sprouting), the changes are much less pronounced 
and widespread than those seen in epilepsy in humans (Cavazos and Sutula, 1990; 
Bertram, 2007).
1.5.1 Kainic Acid Model o f Seizure
Kainic acid (KA) has long been established as a model for complex partial seizures 
(Nadler et al., 1978; Ben-Ari, 1985) and it induces an acute or subacute model of seizure 
which can last for hours or days. It is thought that subsequent hippocampal cell death
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may confound the model. Alternatively, it can be used to investigate the pattern of limbic 
cell damage or the cellular and molecular changes leading to epileptogenesis following 
status epilepticus. Kainic acid is an excitatory amino acid (EEA) and is a cyclic analogue 
of the endogenous excitatory neurotransmitter, glutamate (McGreer et al, 1978) (Fig. 
1.3). During the early 1950’s a report by Hayashi described how the endogenous amino 
acids L-glutamate and L-aspartate induced tonic convulsion when topically applied to the 
motor cortex of the rat (Hayashi, 1954). This prompted the pioneering work of 
MacLennan, Curtis and Watkins who discovered that amino acids could have either 
excitatory or inhibitory effects on the central nervous system (CNS) and that there were 
distinct receptors for EAA’s (Curtis et al., 1959; Curtis & Watkins 1965). EEA’s are 
generally classified into ionotropic glutamate receptors (iGluRs) and metabotropic 
glutamate receptors (mGluRs) (Monaghan et al., 1989). Based on electrophysiological 
and pharmacological studies, iGluRs were further classified into three receptor classes 
named after their agonists, kainate, N-methyl-D-aspartate (NMDA) and a-amino-3- 
hydroxy-5-methyl-4-isoxazolepropionate (AMPA). It is becoming increasingly evident 
that as well as exerting their ionotropic effects, kainate receptors expedite long-lasting 
signalling by novel metabotropic modes of action (Rodríguez-Moreno & Sihra, 2007). 
KA can activate NMDA and AMPA receptors as well as KA receptors and is well known 
for its excitotoxic effects (discussed later), but even at doses insufficient to cause cell 
death it can induce seizures in the hippocampus. At 4 mg/kg i.v. or 0.8-2.0 pg intra- 
hippocampally, animals can still display complex motor activity, masticatory movements, 
periodic arrest of activity and sometimes tonic-clonic activity (Lothman et al, 1981; 
Cavalheiro et al, 1982). For the purpose of animal models, the ‘strength’ of the seizure 
can be monitored according to the Racine scale (Racine, 1972), whereby the development 
of motor seizures is given a score from 1 to 5. These are as follows: (1) mouth and facial 
movements, (2) head nodding, (3) forelimb clonus, (4) rearing and (5) rearing and falling. 
The Racine scale is often used for various animal models of seizure including the KA 
model, the perforant path model, the pilocaipine and kindling model.
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Figure 1.3 The structure of glutamic acid and its analogues N-methyl-D-aspartate 
(NMDA), kainic acid (KA) and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate 
(AMPA). The nomenclature of these prototypic agonists is also given to the particular 
subtypes of excitatory amino acid receptors which they act upon.
1.5.2 Seizure Control by Diazepam
For ethical reasons it is often common practice to administer diazepam after inducing 
seizures with KA to reduce mortality and status epilepticus. Diazepam and related 
compounds are routinely used in the treatment of epilepsy and are members of the 
benzodiazepine family, the actions of which are to potentiate neural inhibition mediated 
by gamma-aminobutyric acid (GABA), the brain’s main inhibitory neurotransmitter. This 
potentiation is confined to ionotropic GABAa receptors (as opposed to the metabotropic 
GABAb receptors) in the CNS to produce an increased chloride conductance. The 
GABAa receptor is formed by the assembly of multiple subunits (mainly a, P, y, 8) into a 
pentamer. Benzodiazepines act allosterically via a specific site on the GABAa receptor 
independent from the GABA binding site to increase the affinity of the receptor for 
GABA. The presence of GABA to form this receptor-ion-channel complex then 
produces the main effects of sedation, hypnosis, decreased anxiety, anterograde amnesia, 
centrally mediated muscle relaxation and anti-convulsant activity. It has been shown that 
prolonged seizures or SE can lead to progressive alterations of GABAa receptors, 
including reduced surface expression of these receptors by receptor trafficking, which 
may be the cause of benzodiazepine pharmacoresistance in refractory epilepsy (Olsen & 
MacDonald, 2002; Jones et al., 2002; Loscher, 2007; Leidenheimer, 2008). Early 
discontinuation of SE with diazepam may reduce the intensity or delay the onset of 
recurrent spontaneous seizures and subsequently protect against hippocampal cell loss 
(Brandt et al., 2003; Pitkànen et al., 2005). Diazepam has also been shown to prevent the
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seizure-induced increase in nitric oxide levels leading to lipid peroxidation which may 
subsequently cause neurodegeneration (Rajasekaran 2005).
1.6 Seizure Related Cell Death
The first reports of brain damage in epileptic patients go back as far as 1825 when 
Bouchet and Cazauvielh autopsied epileptic patients and reported elements of 
hippocampal sclerosis and hippocampal softening (Bouchet & Cazauvielh, 1825). 
Subsequently in 1880, Sommer went on to describe Ammon’s horn (hippocampal) 
sclerosis (AHS) further. AHS is commonly seen in patients with TLE and is characterized 
by granule cell dispersion, reactive gliosis and a loss of pyramidal neurons in the 
CA1/CA3 and /or hilar neuronal cell loss (Margerison & Corsellis, 1966). Animal models 
of SE revealed a similar pattern of neuronal cell death (Meldrum et al., 1973; Olney et al., 
1974; Ben-Ari, 1985).
How these cells die is not entirely understood, but it has been shown that both apoptosis 
and necrosis are involved in seizure-induced, region/cell-specific damage and that 
different cell death pathways are activated in different seizure models (Narkilahti et al., 
2003; Fujikawa, 2005; Fujikawa et al., 2007). The main features of necrosis are ATP 
depletion and ionic disregulation leading to the swelling of mitochondria and 
endoplasmic reticulum. Subsequently, the entire cell swells, which eventually leads to the 
disruption of the plasma membrane and cell lysis (Saelens et al., 2005). Apoptosis is a 
form of programmed cell death (PCD). In the literature the terms PCD and apoptosis have 
been synonymous; however, not all kinds of genetic PCD are apoptotic in terms of the 
original definition. Apoptosis is a genetically regulated form of cell death, which plays an 
important role in tissue homeostasis, differentiation and development and is involved in 
many degenerative diseases, more relevantly, epilepsy. Typical morphological changes 
associated with apoptosis include plasma membrane blebbing, shrinkage of the cytoplasm, 
dilation of endoplasmic reticulum, nuclear chromatin condensation (pyknotic nuclei) and 
fragmentation into apoptotic bodies that are phagocytosed by neighboring cells. There are 
two apoptotic signal transduction pathways, the intrinsic pathway which is initiated 
through the release of cytochrome c from the intermembrane space of mitochondria, often
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through the activation of proapoptotic members of the Bcl-2 family and the extrinsic 
pathway, which is receptor-mediated and involves the binding of death ligands such as 
hormones, growth factors and NO to cell surface receptors resulting in the recruitment of 
the adaptor molecule to the cytosol. NO may induce apoptosis by helping to dissipate the 
membrane potential of mitochondria, therefore making it more permeable for cytochrome 
c release to trigger apoptosis (Briine, 2003). Whether a cell undergoes apoptosis or 
necrosis depends largely on the intracellular ATP concentration. It has been proposed that 
NO may alter ATP concentrations and the establishment of amplifying or inhibiting 
feedback loops that normally accelerate or prevent apoptotic cell death depends on the 
overall redox-state of the cell (Leist et ah, 1999). Other types of cell death include 
autophagy, anoikis, Wallerian degeneration and excitoxicity. Following status epilepticus 
(SE), neuronal cell death is morphologically necrotic which is caused by the activation of 
intracellular proteases and neuronal nitric oxide synthase, with generation of free radicals, 
and damage to cellular membranes, structural proteins, and essential enzymes. 
Programmed cell death mechanisms, such as p53 activation, activation of cell death- 
promoting Bcl-2 family members, and endonuclease-induced DNA laddering, also occur 
in SE-induced neuronal cell death (Fujikawa, 2005).
1.6.1 Excitotoxicity
During some pathological conditions such as traumatic brain injury (TBI), stroke and 
epilepsy the resultant increase in glutamate causes the overactivation of NMDA, AMPA 
or KA receptors. The main mechanisms for glutamate-induced toxicity are post-synaptic 
Ca2+ influx leading to the activation of Ca2+ dependent intracellular signals and oxidative 
stress and free radical damage to DNA, lipids and proteins (Choi 1987). The neurotoxic 
effects of KA in the brain were primarily discovered when the stereotaxic injection of KA 
into the rat striatum was found to cause neuronal degeneration whilst sparing axons of 
passage, i.e. axons which pass through or terminate in the injected area (Coyle, 1978). 
KA induces seizures by causing the depolarization of cortical neurones via an increase in 
intracellular Ca2+ to trigger Ca2+-dependent pathways. This excessive excitation can then 
lead to cell death either by apoptosis or necrosis in various regions of the brain 
(Fujikawa, 2005).
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The excitotoxic effects of KA have been well documented. In particular, the CA1 and 
CA3 pyramidal neurons of the hippocampus show neurodegenerative characteristics, 
similar to the pathophysiology seen in the hippocampus of human TLE as previously 
discussed (Meldrum et al., 1973; Olney et al., 1974; Ben-Ari, 1985). It is still to be 
discerned how exactly KA exerts its toxic effects on the hippocampus even when injected 
systemically or into regions outside of the hippocampus (Olney et al, 1974). KA-induced 
selective vulnerability in the hippocampal neurons is thought to be related to the 
distribution and selective susceptibility of the AMPA/kainate receptors in the brain. It has 
been shown that the CA3 and CA1 show high expression levels of the kainate receptor 
genes for GluR6 and KA2 (Wisden & Seeburg 1993; Bureau et ah, 1999). GluR6" mice 
where shown to be resistant to seizures by KA injection (Mulle et al, 1998). Also, using 
slice preparations from these GluR6"" mice, it was shown that ablation of GluR6 prevents 
kainate-induced gamma oscillations or epileptiform bursts (Fisahn et al, 2004). The 
immediate early gene c-fos is thought to regulate the expression of GluR6 during KA- 
induced seizures in mice (Zhang et al 2002).
Other mechanisms via which KA may mediate its neurotoxic effects may be through the 
activation of intracellular proteases and nitric oxide synthase (NOS) and the generation of 
free radicals which can cause damage to cellular membranes, structural proteins, and 
essential enzymes. PCD mechanisms, such as p53 (a tumour suppressor gene) activation, 
activation of cell death-promoting Bcl-2 family members, and endonuclease-induced 
DNA laddering, occur in SE-induced neuronal death (Leist et ah, 1999; Chipuk et ah, 
2004; Fujikawa, 2005). Glial-mediated inflammatory responses may also be involved in 
neurodegeneration (Myer et ah, 2006).
1.7 Glia in Epilepsy
Glial cells (also called ‘neuroglia’ or simply ‘glia’) provide support for neurons and are 
important for development, synaptic plasticity and synaptogenesis (Christopherson et ah, 
2005) and play an important role in neuronal excitability and survival (Vezzani et ah,
2008). The KA model of seizure can also be used to study the activation of glial cells and
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inflammatory responses typically found in neurodegenerativo diseases. Once merely 
considered the ‘glue’ in the nervous system, the role of glial cells in aberrant network 
excitability is being revised and is the subject of considerable interest yet again (Sun et 
al., 2006; Wetherington et al., 2008). Unlike neurons, which are thought to be post­
mitotic, glia can undergo mitosis. The different types of glial cells in the CNS include 
microglia, astrocytes (also called astroglia), oligodendrocytes, ependymal cells (also 
termed ependymocytes), radial glia cells and NG2 cells (often referred to as 
oligodendrocyte progenitor cells). Radial glia cells play an important role as precursors 
during neurogenesis and it is now known that these cells can differentiate into neurons in 
the adult mouse brain (Merkle et al., 2004).
Astrocytic processes ensheath neurons and other glia to mediate glutamate reuptake, 
control interstitial volume and the ionic environment, notably potassium, and they can act 
as a component of the neurovascular system to regulate permeability of the blood brain- 
barrier (Ridet et al., 1997; Abbott et al., 2006). Astrocytes are activated (reactive) in 
response to many CNS pathologies, hence the term ‘reactive gliosis’, a reaction with 
specific structural and functional characteristics which has long been defined in the 
pathology of TLE. This process can involve the morphological and biochemical changes 
of pre-existing astrocytes but also the generation of new astrocytes from stem cells 
(Binder & Steinhäuser 2006; Ravizza et al., 2008; Borges et al., 2006). The inflammatory 
process involves the hypertrophy of astrocytic cellular processes to accentuate their 
stellate morphology and is associated with the upregulation of intermediate filament 
proteins such as glial fibrillary acidic protein (GFAP), vimentin, and nestin. Other 
proteins upregulated are mGluR3, mGluR5, mGluR8, NGF and its receptors; cytokines 
upregulated include TGFß, TNFa, VEGF, interleukins 1,4,6 and 10, and the enzyme 
iNOS is also upregulated (Ridet et al., 1997; Lederboer et al., 2000). In contrast, 
glutamine synthetase, which converts glutamate to glutamine in astrocytes which is then 
cycled back to neurons to be converted back into glutamate is downregulated in sclerotic 
brain tissue removed during epilepsy surgery (Eid et al., 2004) The role of neuron- 
astrocytic-neuron signalling in abnormal neuronal synchronization in epilepsy may be 
due to these changes in expression or via other mechanisms such as; glutamate release
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from astrocytes to modulate neuronal excitability (Jourdain et al., 2007), glutamate 
transporters via impaired glutamate uptake (Tanaka et al., 1997), water and potassium 
homeostasis leading to a reduction in extracellular space to cause hyperexcitability, 
possibly via aquaporin or potassium channels, AQP4 and Kir4.1, respectively (Dudek et 
al., 1990; Manley et al., 2000; Shang et al., 2005) and finally via gap junctions (Wallraff 
et al., 2006). It is not known whether reactive gliosis acts to oppose or exacerbate 
seizures. In a transgenic mouse model expressing a GFAP-herpes simplex virus- 
thymidine kinase transgene, reactive astrocyte ablation with the antiviral ganciclovir was 
found to potentiate neuronal degeneration and inflammation after controlled cortical 
impact (CCI), a model of traumatic brain injury (TBI) (Myer et al., 2006). Conversely, 
glia have previously been shown to be neuroprotective in both the CNS and PNS 
(Trendelenburg & Dimagl 2005; Thippeswamy et al., 2005).
1.8 Neuroprotection
The prevention of neuronal cell death has been the ‘holy grail’ of many scientists for 
decades. Following seizure it is becoming increasingly apparent that neuroprotection 
involves the preservation of neuronal and network function (Sutula et al., 2003). The 
prevention of cell death does not necessarily prevent seizures (Milward et al., 1999), in 
contrast, some neuroprotective mechanisms may indeed promote seizures. The most 
effective course for neuroprotection in seizure is to arrest seizure activity, for example, 
treating status epilepticus in the premonitory phases can prevent seizure-related damage 
(Chen & Wasterlain 2006; Walker et al., 2002). Neuronal survival involves a number of 
signalling pathways such as the phosphoinositide 3-kinase (PI3-kinase)/protein kinase B 
(Akt) which inactivates proapoptotic proteins such as Bad and caspase-9 (Datta et al., 
1997; Cardone et al., 1998) and the extracellular signal regulated kinase 1/2 (ERK1/2) 
pathways which may be activated by neurotrophins or Ca2+ influx via the NMDA 
receptor (Hetman & Gozdz, 2004). Thus, low level and chronic activation of NMDA 
receptors is associated with their neuroprotective affects, whereas sudden and excessive 
activation of extrasynaptic NMDA receptors are attributed to their neurotoxic effects. A 
similar dual role is seen with NO and is discussed later. BDNF and NGF, belong to a 
family of neurotrophic factors that promote cell survival, neurite outgrowth, phenotypic
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maturation and synaptic functioning and have neuroprotective properties in vitro and in 
vivo (Shigeno et al., 1991; Guegan et al., 1998; Poo, 2001; Schabitz et al., 1997). It has 
been proposed that seizure-induced expression of neurotrophic genes may underlie the 
sprouting of the axons of dentate granule cells (mossy fibres) (Sutula et al., 1996). 
Endogenous neuroprotective mechanisms may also involve the glial trophic factor, 
vasoactive intestinal peptide (VIP), and its responsive gene product, activity dependent 
neuroprotective protein (ADNP).
1.9 Vasoactive Intestinal Peptide (VIP)
VIP is a widely distributed neuropeptide with neuroprotective and neurotrophic 
properties (Delgado et al., 2004; Gozes, 2002). Despite its name, ‘vasoactive intestinal 
peptide’ is also expressed in the brain as well as in the gastrointestinal tract, where its 
effects were first identified (Said & Mutt, 1970). VIP also acts as a neuromodulator, and 
is co-released from neurons with their principal neurotransmitter e.g. it is present in 
cholinergic neurons in the cortex and GABAergic intemeurons in the hippocampus 
(Bayraktar et al., 1997; Sloviter et al., 1987). VIP has been implicated in epilepsy were it 
was shown to excite hippocampal CA1 and CA3 neurones (Phillis et al., 1978). It was 
also shown that chemically induced seizures result in the release of VIP from synapses in 
the hippocampus and other areas of the brain (Marksteiner et al., 1989). In the 
hippocampus, VIP is contained in the synapses of hilar intemeurons which are resistant to 
seizure-induced damage (Sloviter, 1987). The regulation of VIP via the NO-cGMP 
pathway will be investigated in this thesis and will be discussed in more detail in Chapter 
5.
1.10 Activity Dependent Neuroprotective Protein (ADNP)
The neuroprotective effects of VIP have lead to increasing interest to develop the peptide 
as a potential neuroprotective drug candidate, however, it subsequently became apparent 
that VIP-based drug design was hindered due to the instability and limited bioavailability 
of the peptide (Gozes et al., 2003). In order to exploit VIP as a potential therapeutic 
agent, potent neuroprotective lipophilic analogues of VIP were synthesized e.g. stearyl- 
norleucine-17 VIP (SNV). Also, potent neuroprotective peptide derivatives were
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identified such as ADNP, activity dependent neurotrophic factor (ADNF) and shorter 
peptide derivatives such as ADNF-9, ADNF-14 and the eight amino acid NAP. NAP was 
subsequently shown to exert a protective effect on glia-depleted neurones in culture 
(Zemylak et al., 2000). Since the cloning of its gene (Bassan et ah, 1999), ADNP has 
been shown to be an important player in embryogenesis, brain development, cancer and 
neuroprotection (Mandel et ah, 2007; Pinhasov et ah, 2003; Gozes et ah, 2003). It may be 
predicted that, as an adaptive mechanism, neurons produce ADNP in response to seizure. 
This may be particularly true in areas where new neurons are being produced 
(neurogenesis), such as in the subgranular zone (SGZ). In view of this, the regulation of 
ADNP via the NO-cGMP pathway during basal conditions or following seizure and the 
interactions between NO-ADNP and neurogenesis are a primary focus of this work and 
so ADNP will be discussed in more detail in Chapters 3, 4 and 6.
1.11 Neurogenesis
Neurogenesis is the birth of new neurons in the adult mammalian brain. This 
phenonomenon only occurs in specific loci of the brain, these mainly being the 
sub ventricular zone (SVZ) and the SGZ of the dentate gyrus (Altman & Das, 1965; Kuhn 
et ah, 1996). Neurogenesis occurs mainly in three stages; precursor proliferation, 
migration and differentiation, and integration and survival. The molecular mechanisms by 
which progenitor cells (or neural stem cells) differentiate and acquire their identity are 
just beginning to emerge. These neural stem cells are a subtype of radial glia-like 
astrocyte that expresses GFAP and nestin (Seri et ah, 2001; Filipov et ah, 2003). These 
proliferate, which gives rise to clusters of transit amplifying precursors that then divide 
further to generate neuroblasts. The identification of these SGZ precursors and 
neuroblasts is characterized by a sequence of marker expression as they mature 
(Kempermann et ah, 2004) (Fig. 1.4). Progenitor cells are imunopositive for doublecortin 
(DCX) and polysialated neural cell adhesion molecule (PSA-NCAM) during proliferation 
and as early postmitotic neurons. After further differentiation they start to express 
calretinin (a calcium binding protein) and the transcription factors Prox-1, NeuN and Tuj- 
1. After subsequent differentiation into mature granule neurons, they become 
immunopositive for Prox-1, calbindin, NeuN and Tuj-1 (Fig. 1.4). In order to study
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proliferating cells and hence, neurogenesis, a thymidine analogue called 5-bromo-2- 
deoxyuridine (BrdU) is often used. It is incorporated into the newly synthesized DNA of 
proliferating cells (during the S phase of the cell cycle) and consequently antibodies 
specific to BrdU can be used to detect proliferating cells. In order for the antibody to 
bind, this method of detection requires denaturating the DNA, by exposure to acid or 
heat. In the dentate gyrus, adult-bom granule cells integrate into the existing hippocampal 
circuitry which may provide network plasticity necessary for learning and memory. It is 
thought that neurogenesis may play a role following brain injury or neurodegeneration. It 
has been found that prolonged seizures lead to an increase in the proliferation of granule 
cell progenitors in the dentate gyrus. This increased neurogenesis contributes to abberant 
network reorganization the hippocampus (Gray et al., 1998; Parent et al., 1997).
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Figure 1.4 Hippocampal neurogenesis. Proliferation occurs in the subgranular cell 
layer/zone (SGL/SGZ) situated between the hilus and granular cell layer (GL), where 
cells then migrate and differentiate into mature neurons. The stages of neuronal 
development can be identified using specific cell markers (Abrous et al., 2005).
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1.12 Nitric Oxide
Since the discovery that NO was, in fact, the molecule responsible for the effects of 
endothelial derived relaxing factor (EDRF) (Palmer et al, 1987; Garthwaite et al, 1988), 
the complex and intriguing biological activity of this free radical has been extensively 
studied over the years and is still the subject of much research. Generally, but not always, 
the direct effects of NO are attributed to low and brief NO production, supporting 
signaling and protective functions under normal conditions. Conversely, the indirect 
effects of NO are attributed to elevated and sustained NO production, consequently 
leading to toxic reactions such as oxidation, nitrosylation/nitrosation and nitration of 
proteins, such as those encountered during pathophysiological conditions such as; 
Alzheimers disease, multiple sclerosis, Parkinson’s disease, epilepsy and stroke. The role 
and effects of NO vary with each biological system, cell type and the amount of NO 
within that system. Also, most of what we know about NO production in the brain has 
been obtained from the rodent model and may not always be applicable to other species. 
NO is produced from its substrate, L-Arginine, by either; neuronal nitric oxide synthase 
(nNOS), inducible nitric oxide synthase (iNOS) or endothelial nitric oxide synthase 
(eNOS) depending on the cell type. NO can directly modulate proteins and ion-channels 
via s-nitrosylation and/or activate soluble guanylyl cyclase (sGC) to generate a second 
messenger molecule, cGMP via guanosine-5’- triphosphate (GTP).
1.12.1 Structure and Distribution o f  NOS
NO has 6 valence electrons from oxygen and 5 from nitrogen, and an unpaired electron in 
the last orbital confers its classification as a free radical. NO, along with citrulline, is 
produced from L-Arginine via NOS, as previously mentioned. This process requires the 
co-factor nicotinamide diphosphonucleotide (NADPH) and molecular oxygen. The 
structure of NOS has been well characterized and in its active form is often alluded to as 
a dimeric complex i.e. the binding of two NOS monomers. However, in this active state 
two calmodulin (CaM) molecules are also bound, in actual fact, making the active form 
of NOS a tetramer. Each isoform of NOS possesses flavin adenine dinucleotide (FAD),
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flavin adenine mononucleotide (FMN), iron protoporphyrin IX (haem) and (6R)-5,6,7,8- 
tetrahydrobiopterin (BH4). These four prosthetic groups have specific roles vital for the 
activity of the enzyme with BH4 and haem constituting the substrate channel and FAD, 
FMN and haem all being involved in the redox reactions to produce NO itself (Wei et al., 
2003; Mayer et al., 1991). The N-terminal domain of NOS has oxygenase activity with 
BH4, haem and L-Arginine binding sites. Meanwhile, at the C-terminal reductase 
domain, upon binding of calcium/calmodulin, this causes an influx of electrons to the 
active centre of NOS (Stuehr, 1999; Abu-Soud and Stuehr, 1993), thus activating the 
enzyme to generate NO from its substrate L-Arginine.
1.12.2 Nitric Oxide Synthase Isoforms and Splice Variants
NO is mainly produced from three NOS isoforms: neuronal NOS (nNOS, also referred to 
as Type I, NOS-I and NOS-1) and endothelial NOS (eNOS, also known as Type III, 
NOS-III and NOS-3), which are calcium/calmodulin-dependent enzymes and 
constitutively expressed in mammalian cells, and inducible NOS (iNOS, also known as 
Type II, NOS-II and NOS-2), which is calcium/calmodulin-independent and is 
synthesised de novo (Yun, 1997). In the nervous system, nNOS is present in neurons, 
astrocytes, and a subset of rat brain blood vessels (Law, 2001; Arbones, 1996; Nozaki, 
1993). The eNOS isoform is present predominantly in endothelial cells and to a lesser 
extent, in astrocytes and neurons (Law, 2001; Colasanti; 1998; Dinerman, 1994). The 
iNOS isoform is inducible in cells of the immune system, and astrocytes, microglia and 
neurons (Law, 2001; Heneka, 2001). In addition to these well classified NOS isoforms, 
there are also spliced and post-translationally modified variants, such as nNOSp, nNOSy, 
nNOSp and mitochondrial NOS (mtNOS), which is an isoform of nNOS found in the 
inner membrane of mitochondria (Bates et al., 1995, Elfering et al., 2002). Interestingly, 
both nNOSP and nNOSy lack PDZ domains and consequently do not bind PSD-95 from 
brain synaptic densities and do not associate with synaptic membranes (Brenman et al.,
1996). Under normal physiological conditions, eNOS and nNOS produce NO in 
nanomolar concentrations for short periods in response to a transient increase in 
intracellular calcium. This is essential for normal brain function, such as 
neurotransmission, cerebral blood flow, synaptic plasticity, learning and memory,
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neuroendocrine responses and behavioural activity such as stress and pain (Guix et al., 
2005).
1.12.3 The Chemistry o f  NO
NO can undergo several chemical reactions to form nitrites (NO2"), nitrates (NO3 ) and 
peroxynitrites (ONOO'). Consequently, during nitrate production, other highly reactive 
intermediate products are also formed, such as hydroxyl radicals (OH‘) and nitrite 
radicals (‘NO2) (Beckman and Koppenol, 1996). The peroxynitrite anion (ONOO") is 
formed due to the affinity of 0 2‘" being greater for NO than for superoxide dismutase 
(SOD), an antioxidant enzyme (Cudd and Fridovich, 1982). Thus, NO may act as an 
oxidant whereby the effects of free radical oxidation of brain proteins leads to oxidative 
damage, subsequently, accelerating the aging process (Butterfield, 1997). However, other 
chemical reactions of NO such as protein nitration, nitrosylation/nitrosation and 
nitrotyrosination, play an important part in the physiology of the nervous system. Protein 
nitration involves the addition of a nitro group (N 02) to the protein, generally with 
tyrosine residues. Although this is not the only form of protein nitration, one of the main 
molecules to nitrate proteins is peroxynitrite itself. It has been shown that leukocyte 
peroxidases can also nitrate proteins after the stimulation of immune cells (Eiserich et al., 
1998; Brennan et al., 2002). The reaction of NO with the sulphur from a cysteine thiol 
leads to nitrosylation and nitrotyrosination. The nitration of active-site tyrosine residues 
is a post-translational modification which can alter protein structure and function and is 
produced in abundance during pathological conditions (Stamler et al., 1997; Tedeschi et 
al., 2007).
Despite being a free radical, NO has relatively weak reactivity and only interacts with 
other free radicals, oxygen and transition metals. Depending on the redox state of a cell, 
NO may also exist as a nitrosonium ion (NO+), making it thermodynamically unstable 
(Stamler et al., 1992). Hence the chemistry of NO and its gaseous nature make it easy for 
NO to diffuse from producing cells into adjacent cells and act as a versatile biological 
messenger (Beckman et al., 1996), thus setting off the production of the classical second 
messenger pathway cGMP (Miki et al., 1977; Garthwaite et al., 1988).
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1.12.4 Physiological Targets o f  NO
Since NO is a highly reactive and diffusible gaseous molecule it can function in an 
autocrine or a paracrine fashion. NO mediates its cellular signaling effects via several 
mechanisms, the main one being sGC leading to the formation of cGMP (Ignarro, 1991). 
The reaction of NO with the haem group of sGC gives rise to a conformational change, 
which in turn causes sGC to catalyze the conversion of GTP into cGMP. cGMP itself can 
then activate several downstream elements such as cGMP-dependent protein kinases e.g. 
PKGIa (where PKG iso from expression can vary in dorsal root ganglia (DRG), spinal 
cord and brain regions), cGMP-regulated phosphodiesterases e.g. PDE5 and cyclic 
nucleotide-gated (CNG) cation channels (Denninger and Marietta, 1999) to mediate or 
modify neurotransmission and other cell functions such as smooth muscle relaxation or 
platelet aggregation. Excessive stimulation of the NMDA receptor subtype of glutamate 
receptors allows the influx of Ca2+ into neurones, which may augment NO production. 
The main intracellular action of NO is activation of sGC, but apart from increasing cGMP 
levels, NO also induces feedback inhibition of the NMDA receptor through a redox 
modulatory site on the receptor complex or via S-nitrosylation.
Cytochrome c oxidase is another protein target of NO which competes with oxygen 
during energy metabolism (Brown, 2001). The cytochrome c oxidase complex contains 
two haems and two copper centres. Binding of NO to this haem-copper centre inhibits 
cytochrome c oxidase (Cooper, 2002). However, this is only temporary inhibition, as NO 
readily dissociates from this complex, thereby causing the intermittent regulation of 
cytochrome c oxidase. Intermittent regulation of cytochrome c oxidase by NO is believed 
to regulate ATP production, oxygen consumption and possibly mitochondrial functions 
involved in neuroprotection or neurototoxicity (Beltran et al., 2000; Paxinou et ah, 2001).
Other cellular signaling effects of NO include interaction with the mitochondrion 
(dem enti et ah,1998), oxidation and nitrosative stress, DNA and protein damage and S- 
nitrosylation (SNO) of intracellular and membrane bound proteins (PSNO). S- 
nitrosylation is the reaction of an NO group with cysteine residues in proteins, resulting
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in an adduct called nitrosothiol. Previously, nitrosylation was largely overlooked as it was 
thought that the free radical NO lacked control and specificity to regulate signal 
transduction like other post-translational modifications such as phosphorylation. 
However, it is becoming increasingly evident that nitrosylation has more in common with 
phosphorylation than was originally thought such as reversibility, substrate specificity 
and spatio-temporal regulation. Due to the development of techniques such as the biotin 
switch assay, the detection of nitrosylated proteins has been made easier and hence the 
identification and characterization of nitrosylated proteins in recent years has escalated 
(Jaffrey & Synder (2001). S-nitrosylation of proteins can affect the function of many 
proteins including ion channels and nuclear regulatory proteins and the emerging roles of 
S-nitrosylation in protein misfolding and neurodegenerative diseases (Nakamura & 
Lipton, 2008) provide evidence that nitrosylation can regulate the overall physiology and 
pathophysiology of the nervous system.
1.12.5 NO in Epilepsy
Depending on the seizure stimulus, the cellular source of NO, and the activation of 
specific NOS isoforms, there is conflicting evidence regarding the role of NO either as an 
anti-convulsant (Penix et ah, 1994, Kendrick et ah, 1996; Gabriel et ah, 2000; Sardo and 
Ferraro, 2007; Royes et ah, 2007) or pro-convulsant (De Sarro et ah, 1993; Tutka et ah, 
1996). The differing conclusions are mainly due to the complex interaction between the 
excitatory and inhibitory neurotransmitter pathways of the CNS. In the CNS, the release 
of glutamate by pre-synaptic neurons is regulated by GABAergic inhibitory input to 
presynaptic neurons. Glutamate binding activates NMDA receptors of postsynaptic 
neurons leading to the activation of calcium-calmodulin dependent nNOS to generate 
NO. It has been hypothesised that the downstream effects of NO modulate NMDA 
receptor (NR2B) function to prevent further calcium influx and/or suppress further 
glutamate release from the presynaptic neurons thus preventing seizures (Kalmer et ah, 
2005; Takata et ah, 2005). The other hypothesis is that NO could also regulate 
GABAergic input to presynpatic neurons thus enabling NO to function indirectly as a 
pro-convulsant. iNOS as well as nNOS also appears to be increased during the acute 
phase of seizures (Murashima et ah, 2002; Yang et ah, 2003).
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The role of NO in the cerebrovascular response to seizures has been elegantly 
demonstrated in the eNOS-/- and nNOS-/- mice in the kainic acid model, which has 
shown that NO is the mediator of all vascular changes. eNOS, either derived from 
endothelial cells or astrocytes, appears to mediate hyperaemia within the epileptic focus 
and together with nNOS participates in the maintenance of local cerebral blood flow in 
distant areas (Pereira de Vasconcelos et al., 2006). In addition, Chavko and colleagues 
have demonstrated that seizures produce a significant increase in nityrosine residues (the 
footprint of ONOO-) and that nNOS inhibition by 7-NI retards seizures (Chavko et al., 
2003). Theses studies provide evidence that the NOS pathway is involved in seizure and 
also oxidative stress.
1.12.6 NO and Neurotransmitters
Pioneering techniques such as intracerebral microdialysis have allowed us to investigate 
neurochemical processes in the brain (Bito et al., Ungerstedt and Pycock, 1974). Due to 
the fact that measurements can be taken from discrete areas of the living brain, this has 
made possible direct comparisons of behavioural and neurochemical effects. Such studies 
have shown the modulation of NO/cGMP production by glutamatergic receptors in the 
cerebellum (Vallebuona and Raiteri, 1993), the cerebellum being abundant in glutamate 
receptors and glutamate mediated NOS/sGC production. Granule cells of the cerebellum 
contain high levels of NOS (Bredt and Synder 1990) as well as glutamate receptors 
NMD A, AMPA and metabotropic receptors (Nicoletti et al., 1986; Garthwaite and 
Brodbelt, 1989). The relationship between NO and neurotransmitters/neuropeptides, 
especially the brains major excitatory neurotransmitter, glutamate, is becoming 
increasingly evident. NO-mediated glutamate regulation via NMD A receptor activation 
can cause activation of nNOS, a process described in brain regions such as the 
hypothalamus, hippocampus, striatum and locus coeruleus (Prast 1996; Fedele et al., 
2001; Trabace et al., 2004; Maura et al., 2000). This association of nNOS and the NMDA 
receptor forms a complex via the binding to the abundant postsynaptic density-95 protein 
(PSD-95) (Christopherson, 1999). It has been shown that NO enhances glutamate release 
in some brain regions and spinal cord and this regulation of glutamate by NO is thought
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to be important for synaptic activation for long term potentiation (LTP) in learning and 
memory (Zorumski, 1998).
1.12.7 NO and Glutamate
Depending on the concentration of NO, its effects on glutamate transmission are biphasic, 
the most common example being during excitotoxity. Apoptosis, or programmed cell 
death, is an important process for neurophysiological homeostasis and initiation of the 
NO-cGMP pathway can lead to the activation of cGMP-dependent protein kinases and 
the inhibition of caspase activity (Dash et al., 2003). NO may inhibit apoptosis through 
cGMP dependent and cGMP independent mechanisms, such as that shown in stressed 
DRG neurons involving the suppression of bax, caspase-3 and -9 activation by NO 
(Thippeswamy et al., 2001). Activation of the NFkB pathway and the Jun-kinase 
pathways by NO can induce many genes in the regulation of neuroprotection and 
neurotoxity (Park et al.,1996; O’Neill and Kaltschmidt, 1997). A neuroprotective 
mechanism of NO, via feedback inhibition, has recently been demonstrated through 
Poly(ADP-ribose) polymerase (PARP), a zinc-finger DNA-binding “nick-sensing” 
enzyme, which is abundantly expressed by stressed neurons (Diaz-Hemandez et al., 
2007). Upon binding to DNA, PARP becomes activated and cleaves NAD+ into 
nicotinamide and ADP-ribose. PARP then polymerises ADP-ribose on to nuclear receptor 
proteins including histones, transcription factors and PARP itself. It was recently shown 
that using PARP-1 knockdown by RNA interference relieved the inhibitory effects of NO 
on iNOS promoter activity. From biotin switch assays it was concluded that NO feedback 
inhibits iNOS gene transcription by S-nitrosylating the trans-activator PARP-1 and 
decreasing its binding and/or action at the iNOS promoter (Yu et al., 2006).
Stimulation of the NMDA receptor by glutamate via calcium influx to activate nNOS 
may exert a neuroprotective role via inhibition of caspases, conversely, sustained NMDA 
receptor activation leading to high concentrations of NO can cause neurotoxicity (Dash et 
al, 2003; Dawson et al., 1991). Interestingly, increased endogenous NO and/or calcium 
concentration as a result of sustained NMDA receptor activation can lead to 
autoinhibition of nNOS (Rogers and Ignarro, 1992) and/or S-nitrosylation of the NMDA
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receptor to prevent neurotoxicity (Reveiwed Nelson et al., 2003). Recent studies on 
NMDA receptor sub-units have shown that NR2A, rather than NR2B, receptors 
predominantly co-immunoprecipitated with nNOS suggesting a more precise mechanism 
by which NMDA receptors may be interacting with nNOS (Al-Hallaq et al., 2007).
1.12.8 NO and GABA
As with glutamate, depending on the concentration of NO, its effects on GABA release 
are also biphasic. At basal levels NO can cause a decrease in GABA release, but at high 
concentrations NO can cause an increase in GABA release (Getting et al., 1996). 
GABAergic intemeurons possess NOS and glutamate receptors (Chan Palay, 1982), 
however, Purkinje cells in the cerebellum have been found to express the NO target sGC, 
the cGMP dependent protein kinase and the G-substrate but not NOS, maybe suggesting 
a paracrine role for NO. Recent innovative experiments by Wang et al determined more 
accurate NO physiological concentrations in the nucleus tractus solitarii (NTS), a 
brainstem nucleus involved in processing central and sensory information, including 
cardiovascular function. Using rat brainstem slices they described that, while lower 
concentrations of NO may be important for fine tuning of glutamatergic transmission, 
higher concentrations are required to directly engage GABAergic inhibition in the NTS 
(Wang et al., 2007). GABA release by NO is thought to be mediated via two 
mechanisms; a Ca2+-dependent release system and a Na+-dependent carrier-mediated 
GABA uptake system (Ohkuma et al., 1996). In the hippocampus it has recently been 
shown that intemeurones express sGC in their presynaptic GABAergic terminals, 
suggesting a role for retrograde NO signaling in these intemeurones (Szabadits et al., 
2007).
1.12.9 NO in Neurogenesis
The role of NO in neurogenesis is the subject of recent interest and it has been shown that 
NO reversibly inhibits cell division (Garg and Hassid, 1990) and that it inhibits cell 
proliferation in the adult mammalian brain (Packer et al., 2003). However, it has also 
been shown that induction of neurogenesis is attributed to the production of NO via iNOS 
or eNOS (Reif et al., 2004; Zhu et al., 2003). Recently, evidence for the role of NO in
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neurogenesis in the adult rat dorsal root ganglion has emerged. NO was shown to regulate 
neural stem cell proliferation and differentiation both in vitro and in vivo which was 
correlated with the modulation of the transcription factor, neuron-restrictive silencer 
transcription factor (NRSF/REST) during nerve injury (Arora et al., 2007) . Trafficking 
of NOS within the cell is of great importance and recently identified proteins such as 
NOSTRIN (NOS traffic inducer) and NOSIP (NOS interacting protein) have been shown 
to regulate intracellular trafficking of eNOS and possibly other proteins in the plasma 
membrane which may be of importance for cell proliferation or apoptosis (Icking et ah, 
2005; Schleicher et ah, 2005). The role of NO in neurogenesis, like most of its other 
functions, is complicated and how it regulates neurogenesis normally, may not be how it 
is regulating neurogenesis under pathological conditions. To this end, I have investigated 
the relationship of NO and ADNP in neurogenesis following seizure. Hence, the role of 
NO in neurogenesis and cell proliferation will be discussed further in Chapter 6 .
1.12.10 Intervention o f the NO-cGMP Pathway
The pharmaceutical industry contstantly endeavours to produce more potent and selective 
NO inhibitors in the hope of finding more specific therapeutic agents for disorders such 
as osteoarthritis, tumours and asthma. The selectivity of NOS ihibitors is of much debate 
with regard to what constitutes selectivity (fold difference), how it is defined (ratio of 
IC50 values or ratio of K{ values) and determined (the effects on isolated enzymes in cells 
or in vivo). Also, assays to screen NOS inhibitors have been carried out over short 
periods of time with no pre-incubation, which can lead to the underestimation of the 
potency and efficacy of slow onset inhibitors (Alderton et al., 2001). Many NOS 
inhibitors have been synthesized and these can be used as pharmacologial tools to study 
the role of nitric oxide. Some of the most widely used are L-NMMA, L-NNA and its 
methyl ester prodrug L-NAME (//'-nitro-L-arginine methyl ester) (Fig. 1.5). These are 
non-selective NOS inhibitors and act to inhibit all forms of NOS. 7-NI has been described 
as an nNOS inhibitor however, its actions may not be highly selective but it has been 
extensively used in the absence of a more potent highly selective nNOS inhibitor. In the 
quest for highly selective inhibitors, the most progress has been made with iNOS with 
compounds like 1400W, GW273629 and GW274150 (Garvey et al., 1997; Alderton et
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al., 2005). To investigate downstream 3',5'-cyclic guanosine monophosphate (cGMP) 
pathway of NO, the potent inhibitor of the soluble guanylyl cyclase (sGC), 1H- 
[l,2,4]oxadiazolo[4,3-a]quinoxalin-l-one (ODQ), has been widely used.
Figure 1.5 Intervention of the nitric oxide-3',5'-cyclic guanosine monophosphate (NO- 
cGMP) pathway with pharmacological inhibitors of nitric oxide synthase (NOS) and 
soluble guanylyl cyclase (sGC).
The relationship of NO in epilepsy and hippocampal cell death is not completely 
understood as it has been shown to have both anti-convulsant (Penix et al., 1994, 
Kendrick et al., 1996; Gabriel et al., 2000; Sardo and Ferraro, 2007; Royes et al., 2007) 
and pro-convulsant actions (De Sarro et al., 1993; Tutka et al., 1996), depending on the 
species studied and epilepsy model employed. Several factors may contribute to 
hippocampal cell death in epilepsy such as excessive gulatamate realease and activation 
of NMDA receptors leading to calcium-induced cell death. The calcium influx activates 
neuronal nitric oxide synthase (nNOS) to produce NO (Garthwaite, 2005). NO activates 
soluble guanylyl cyclase (sGC) to generate cGMP which can initiate physiological 
responses in the cell, primarily via the phosphorylation of proteins by protein kinases. NO 
can also directly modulate the expression of transcription factors, such as, CREB (a 
transcription factor known to regulate neurotrophin and neurotransmitter genes such as 
BDNF and somatostatin) mediates a cGMP/PKG-dependent anti-apoptotic signal cascade 
activated by NO (Nagai-Kusuhara et al., 2007; Zhuravliova et al., 2007; Riccio et al.,
2006). As discussed previously ADNP and VIP were found to have neuroprotective
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properties and we have recently shown ADNP epxpression in neurons, (in the cytoplasm 
and axons) and in glial cells of the rat brain (Cosgrave et al., 2008; Gennet et al., 2008). 
These proteins may represent new targets for brain injury and a potential mechanism of 
action via which these proteins and their gene expression may be regulated may be via 
the NO-cGMP pathway. Therefore, using the general NOS inhibitor L-NAME, the nNOS 
inhibitor 7-NI and the sGC inhibitor ODQ in this thesis I have investigated the regulation 
of ADNP and VIP expression via the NO-cGMP pathway following seizure.
1.13 Aims o f Thesis
As mentioned previously, one of the main changes observed in the hippocampus 
associated with seizures includes the altered expression and release of neurotransmitters/ 
glial trophic factors leading to neurological changes in the brain. The overall aim of this 
project was to investigate the NO-cGMP pathway in the regulation of gene and protein 
expression of ADNP and VIP at basal levels and following KA-induced seizure. Hence:
• ADNP expression and regulation via the NO-cGMP pathway was studied in the 
hippocampus and DG following seizure.
• VIP expression and regulation via the NO-cGMP pathway was studied in the 
hippocampus and DG following seizure.
• As previously discussed, the DG is one of the few sites of postnatal neurogenesis 
in the brain and so the role of NO and ADNP in neurogenesis and cell 
proliferation/neurotrophic effects was also investigated.
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CHAPTER 2
Materials and Methods
2.1 Animals
Experiments were carried out on 30-40 day old male Wistar rats (Biomedical Services 
Unit, University of Liverpool, UK) preferably from the same litter. Rats were housed 
under controlled environmental conditions (19-23 °C, 12 hrs light, 12 hrs dark) with food 
and water available ad libitum. Animals were culled according to local and national 
Schedule 1 requirements and all procedures carried out in compliance with the Animal 
Scientific Procedures Act (1986).
2.1.1 In Vivo Nitric Oxide Synthase Inhibitor and Kainic Acid Experiments
A circadian variation in nitric oxide synthase (NOS) response to NOS inhibitors has 
previously been reported, in that NO levels are higher during the day than at night 
(Dzoljic et al., 1997). Also NO production displays a cyclic pattern in the hippocampus 
(Bush & Pollack, 2001). It has previously been shown that multiple-dose administration 
of NOS inhibitors can result in inhibition for an extended period of time (Bush & Pollack,
2001), hence in order to achieve maximum NOS inhibition a 3 dose regimen was carried 
out 24 hrs prior to KA (Tocris,UK) treatment (10 mg/kg i.p.) where L-NAME (Tocris, 
UK) (50 mg/kg i.p.), 7-NI (Sigma,UK) (50 mg/kg i.p.) and ODQ (Tocris, UK) (10 mg/kg 
i.p.) were administered 3 times over the duration of the 24 hrs (Fig. 2.1). Drug 
concentrations were determined from the literature (Borowicz et ah, 2000; Di Matteo et 
ah, 2006; Kawaguchi et ah, 1999; Martinez-Quiroz et ah, 2005). Time points were also 
derived from the literature, mRNA and cellular changes were observed by 3 hrs and 3 
days, respectively (Mikuni et ah, 2001; Faherty et ah, 1997; Najm et ah, 1998; Lee et ah,
1997). Following KA treatment, seizures were classified according to the Racine scale 
(Racine, 1972) and upon the manifestation of a full generalised seizure, half of the 
animals were euthanized (no more than 3 hrs post KA). The other half were administered 
diazepam (10 mg/kg i.p.) after the initial seizure to avoid SE or mortality. These animals 
were allowed to recover and 3 days later tissue was collected. For each time point 3 hrs 
and 3 days half the animals from each group were perfused intracardially with 4% 
paraformaldehyde (PFA), the brains dissected and post-fixed in 25% sucrose for 
immunostaining. The other half of the group were euthanised by schedule 1 and the
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hippocampi and/or the dentate gyri were taken for RNA extraction (one hippocampus) 
and protein analysis (the other hippocampus).
Dose Dose 
2 3 KA
I 1 li
I Day 1...  j Day 2 ... I.... Day 3 I Day 4 I.... Day 5 " I
3 hr post KA 
group taken
t
3 day post KA 
group taken*
Perfused and tissue 
processed for 
immunostaining n=30
Tissue processed for 
RNA & Protein 
Extraction n=30
Dose 1,2,3 = Either saline, L-NAME (50mg/kg), DMSO, 7-NI (50mg/kg) or ODQ (10mg/kg) given i.p. 
(n=30 represents an n of 3 for each pre-treatment group with and without KA).
* 3 day group administered diazepam (10mg/kg) after the first seizure
Figure 2.1 Schematic representation of the protocol carried out for in vivo experiments. 
A total o f 120 animals were used and injected with either; vehicle control (saline/10% 
DMSO), L-NAME (50 mg/kg), 7-NI (50 mg/kg) or ODQ (10 mg/kg) (n=24). Half of the 
animals from each pre-treatment group were then given kainic acid (KA; 10 mg/kg) and 
taken at 3 hrs or 3 days post KA (along with those not given KA i.e. pre-treatment 
controls). For both time points tissues were processed for immunostaining or RNA and 
protein extraction. n=30 represents an n of 3 for the 5 pre-treatment groups with and 
without KA. See Table 2.1.
Saline D M SO
(v e h ic le  
control for  
L -N A M E )
Saline
+K A
L -N A M E L-N A M E
+K A
(v eh ic le  
control for 
7-N I and
D M SO
+K A
7-N I 7-NI
+K A
O D Q O D Q
+K A
n=3 n=3 n=3 n=3 O D Q )
n=3
n=3 n=3 n=3 n=3 n=3
Table 2.1 n numbers for each pre-treatment with and without kainic acid (KA)
2.2 Nitrite Detection
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2.2 Nitrite Detection
The Greiss assay is a popular assay for the detection of NO in tissue samples and 
biological fluids. It specifically measures nitrite (NO2-), one of two primary, stable and 
nonvolatile breakdown products of NO. It is based on the diazotization reaction originally 
described by Greiss in 1897. The Greiss Reagent System (Promega, UK) uses 
sulfanilamide and N- 1 -napthylcthylenediamine dihydrochloride (NED) under acidic 
(phosphoric acid) conditions. The sulfanilamide solution and NED solution were allowed 
to equilibrate at RT for 15-30 minutes. A Nitrite Standard reference curve was produced 
by diluting the 0.1M Nitrite Standard 1:1000 to give 100 pM nitrite solution, 100 pi of 
this was pippetted in triplicate into the first row (A) of a 96 well plate. 50 pi of the 
appropriate buffer (that samples were collected in) was added in triplicate to rows B-H. 2- 
fold serial dilutions were then immediately performed by pipetting 50 pi from row A to 
row B, mixing then pipetting 50 pi from row B to C and so on until row G where 50 pi 
was discarded from each well in this row and row H contained no nitrite solution to give 
a blank of 0 pM. Ultimately the nitrite concentration range was 0-100 pM. 50 pi of each 
experimental sample was then added to the remaining wells in triplicate. Using a 
multichannel pipettor and taking care not to contaminate samples, 50 pi of the 
sulfanilamide solution was then added to all wells containing standards and samples and 
incubated for 5-10 minutes at RT, protected from light. 50 pi of the NED solution was 
then added and incubated for 5-10 minutes at RT, protected from light. Within 30 
minutes a purple coloured azo compound was formed and the optical density was 
measured at 540 nm on a scanning multiwell spectrophotometer (Thermofisher Scientific, 
UK). The nitrite concentration was quantified in Excel (Microsoft) by interpolating the 
standard curve as previously described (BCA assay).
2.3 Tissue Processing for Immunofluoresence
2.3.1 Cryopreservation
Animals were euthanized using halothane and perfused intracardially with 4% PFA in 
0.1M phosphate buffered saline (PBS) pH 7.4. ) 0.1M PBS was prepared from a 0.2M
stock of sodium dihydrogen phosphate (NaHiPC^.^O) and a 0.2M stock of disodium
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hydrogen orthophosphate (NaiHPCU.^tbO) with 0.15M NaCl in distilled water (DW). 
Brains were then dissected out and further post-fixed in 4% buffered PFA for 4 hrs at 
4°C, cryo-preserved in 25% sucrose for a few days and then gelatin embedded.
2.3.2 Gelatin Embedding o f Tissue
Gelatin solution containing 7.5% porcine gelatin (Sigma, UK), 15% sucrose (BDH, UK) 
and 0.1% sodium azide (BDH, UK) in PBS was heated to 45-50°C. This was then cooled 
to 38°C and tissues incubated in a labeled petridish containing gelatin for 3 hrs at 38°C. 
After this time the tissue was left overnight at 4°C to allow the gelatin to set.
2.3.3 Chrome Alum Gelatin (CAG) Coating o f  Slides
A gelatin solution containing 0.5% porcine gelatin (Sigma, UK), in dd^O  was heated to 
45-50°C and 0.8% chrome alum (Sigma, UK) dissolved in the solution. 0.25% sodium 
azide (BDH, UK) was then added and the solution filtered and stored at RT. Slides were 
dipped in the CAG solution and left to air dry in dust free conditions overnight in a class 
B fume hood. Once dry, slides were stored in boxes at RT.
2.3.4 Cryosectioning
Gelatin embedded tissues were blocked and stuck onto a labelled cork disk using 
TissueTek® (Alpha labs, UK) and frozen in liquid nitrogen cooled isopentane prior to 
sectioning on a cryostat. The brains were cut into 15 pm sections and mounted onto 
chrom alum coated slides (BDH Laboratory Supplies, UK). Sections were collected 
consecutively from the start of the hippocampus onto 1 0  different slides and then 
collected again onto the first slide. Four sections per slide were collected so that on any 
given slide there was a 600 pm range throughout the hippocampus. As shown in Figure 
2.2. The brain sections were allowed to dry onto the slides at RT for 30 minutes, then 
stored at -40°C.
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Figure 2.2 Schematic representation to show the chronological order of sections on each 
slide, so that each slide contains an approximate cross-section of 600 pm throughout the 
brain.
2.3.5 Immunofluorescence
Sections or dissociated hippocampal cultures were washed in PBS for 10 minutes (x3) at 
RT to remove PFA. Sections/cultures were then blocked with 10% donkey serum (DS) 
for lhr at RT. Double or triple staining was carried out sequentially, all antibodies were 
diluted in diluting solution (0.1M PBS, pH 7.2, 0.1% Triton X-100, 2% DS and 0.1% 
sodium azide), 3-4 washes with PBS were applied between each step. For 
immunostaining, the appropriate concentrations of primary antibodies were applied 
overnight at 4°C (Table 2.2). The next day donkey raised appropriate secondary 
antibodies either biotinylated or flourochrome-conjugated (Jackson Immunoresearch 
Laboratories, Inc) were applied at for lhr at RT, washed 3x in PBS, followed by the 
appropriate streptavidin conjugated-FITC/Cy3/Marina blue (from Vector Laboratories, 
Jackson Immunoresearch Laboratories, Inc and Molecular Probes, respectively) for lhr at 
RT and then washed 3x in PBS (Table 2.3). For triple immunostaining, a third primary 
antibody was applied overnight at 4°C and processed as previously described with the 
appropriate secondary antibody. Sections/cultures were then covered with VectaShield 
(Vector Laboratories), coverslipped and then viewed using a Nikon inverted microscope 
(Nikon,UK). Images were captured using IPL lab software (Nikon,UK). Sections were
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(Nikon,UK). Images were captured using IPL lab software (Nikon,UK). Sections were 
covered with VectaShield (Vector Laboratories), coverslipped and viewed with a Nikon 
inverted microscope (Nikon,UK) using the appropriate wavelength filter for each 
fluorochrome and images merged using IPL lab software (Nikon, UK).
Antibody Species Raised 
In
Primary Antibody 
Dilution
Source
Anti-nNOS Sheep 1:1000 Dr P.C. Emson
Anti-iNOS Rabbit 1:300 Chemicon
Anti-ADNP Rabbit 1:300 Chemicon
Anti-VIP Rabbit 1:200 Chemicon
Anti-GFAP Rabbit/ Mouse 1:200 Sigma
Anti-NeuN Mouse 1:50 Chemicon
Anti-BrdU Mouse 1:100 Molecular Probes
Table 2.2 Details of primary antibodies used for immunostaining.
Antibody Species 
Raised In
Secondary 
Antibody Dilution
Source
Anti-Mouse Biotinylated Donkey 1:200 Jackson ImmunoResearch
Anti-Rabbit Biotinylated Donkey 1:500 Jackson ImmunoResearch
Anti-Sheep Biotinylated Donkey 1:200 Jackson ImmunoResearch
CY3 Anti-Rabbit Donkey 1:200 Jackson ImmunoResearch
Streptavidin CY3 - 1:200 Jackson ImmunoResearch
Streptavidin FITC - 1:80 Vector Laboratories
Streptavidin Marina 
Blue
- 1:100 Molecular Probes
Table 2.3 Details of secondary antibodies used for immunostaining.
2.6 TUN EL Staining
For the detection of apoptosis at the single cell level, Terminal Transferase (TdT) and 
Biotin-16-dUTP (TUNEL) staining is often employed. This method labels double 
stranded and single stranded DNA breaks (nicks) which occur during apoptosis. The free
37
3’-OH terminal is labelled with modified nucleotides in an enzymatic reaction. For 
positive controls sections were incubated with DNase I (3000 U/ml in 50mM Tris-HCl, 
pH 7.5, 1 mg/ml BSA) for 10 mins at RT to induce DNA strand breaks prior to the 
labeling procedure. Also sections from the rat intestine ileum were used as known 
positive controls. For negative controls sections were incubated with label solution only 
instead of TUNEL reaction mixture. Sections were washed 3 times for 10 mins in ddHiO 
then incubated with 0.2% Triton X-100 in PBS-Tween for 30 mins. Sections were then 
treated with proteinase K (10 pg/ml) at RT for 15 mins and then washed twice in PBS- 
Tween for 2 mins. Then, sections were incubated in TdT Reaction Buffer (25mM Tris- 
HCl, 200mM, Sodium Cacodylate, 0.25 mg/ml BSA, ImM Cobalt Chloride) for 10 mins 
and then incubated in TdT Reaction Mixture which was composed of 100 pi solution A 
(TdT (Roche Diagnostic, UK) 4 pi in 100 pi TdT Storage buffer (60mM potassium 
phosphate, pH 7.2, 150mM KC1, ImM 2-Mercaptoethanol, 0.5% Triton X-100, 50% 
glycerol) and 100 pi solution B (4 pi Biotin-16-dUTP (Roche Diagnostic, UK) in lml 
TdT Reaction Buffer) for 2 hrs at 37°C in a humidified chamber. Sections were then 
incubated in Stop Wash Buffer (300 mM NaCl, 30 mM Sodium Citrate) for 10 mins and 
then washed 3 times in PBS-Tween for 2 mins. Immunofluorescence was then carried out 
by incubating the sections in streptavidin-FITC (Vector Laboratories) at 1:80 for 1 hr at 
RT and then washed 3 times in PBS-Tween and mounted with Vectashield.
2.7 Cell Quantification
Three concurrent sections per rat from each of the cranial, middle and caudal l/3ld region 
of the hippocampus were selected for counting from control and drug treated samples that 
were processed for double/triple immunostaining simultaneously using the same reagents 
and/or antibodies. All slides were given a code and the code revealed after statistical 
analysis for unbiased cell counting. The appropriate wavelength filter for each 
fluorochrome was used to visualize immunopositive cells, the image captured and then 
the filter was changed (without changing the field of view) to view a second or a third 
marker. Using IPL image analysis software, a threshold was set for each fluorochrome 
and the same threshold was used for both drug and appropriate control. A minimum of 
three animals from each group was used for cell counting. The average cell numbers were
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calculated for each animal, the SEM calculated for each treatment group and p values 
obtained using one-way ANOVA with Bonferroni post-hoc test a ‘p’ value of less than 
0.05 was considered to be significant. (*p <0.05, **p <0.01, ***p <0.001). (Graphpad 
software Inc, USA)
2.8 Tissue Culture Methods
2.8.1 General Cell Handling
All cell culture work was carried out under aseptic conditions in a class II laminar flow 
cabinet. Cells were cultured in 24 well plates (Greiner bio-one, UK) and incubated at 
37°C in water-saturated air with 5% C 0 2. All media was filter sterilised through a 0.22 
pm filter (Millipore, USA) and pre-warmed to 37°C in an incubator (Sanyo, Japan) prior 
to plating or media changes.
2.8.2 Preparation o f 24- well plates
Poly-D-Lysine solution, 300 pi (0.1 mg/ml; Sigma, UK) was added to each well of a 24 
well plate and incubated in the laminar flow hood at RT for 1 hr. The poly-D-lysine was 
then removed and the wells washed three times with 500 pi of sterile distilled water 
(DW), each wash was for 20 minutes. After the third wash the Dw was removed and the 
plates left to completely dry in the laminar flow cabinet for at least 1 hr.
2.8.3 Dissection o f Dentate Gyri
All surgical instruments were cleaned and sterilised by autoclaving prior to dissection. 
All dissections were carried out in a horizontal laminar flow cabinet. Experiments were 
carried out on 6-9 day old male Wistar rats (Biomedical Services Unit, University of 
Liverpool) preferably from the same litter. Following culling of the animals in 
accordance with Schedule I of the Animal Scientific Procedures Act (1986), the brain 
was exposed and carefully removed into a petridish containing chilled dissection media, 
Geys balanced salt solution (Sigma, UK) containing 4.5 mM glucose (Sigma,UK) 
(Appleton Woods, UK). The cerebellum and brain stem were removed and the brain split 
sagitally into the two hemispheres to expose the hippocampi. The hippocampus from 
each hemisphere was then removed using paddle pastettes (Alpha labs, UK) and placed
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onto a melinex strip (Agar Scientific, UK), a polyester film approximately 5 cm by 4 cm. 
The aligned hippocampi were sliced using a Mcllwain tissue chopper (Mickle Laboratory 
Engineering Co. Ltd., UK) to give 1 mm thick transverse slices. The slices were then 
placed into fresh dissection media and the dentate gyrus was cut from the rest of the 
hippocampus with a sterile needle (Terumo, UK) and blade (Appleton woods, UK) (Fig. 
2.3) under a dissecting microscope (Zeiss, UK). The dentate gyri and hippocampi were 
collected on ice into separate 6  cm petridishes containing dissection media.
2.8.4 Dissociation and Plating
The dissection medium was carefully removed from the dishes and tissues were washed 
in approximately 3-5 mis of Neurobasal-A supplemented with 2% B27+ media 
(NB/B27+). This was then removed and replaced with NB/B27+ containing papain (2 
mg/ml) (Sigma, UK) to aid enzymatic digestion and cell release and incubated for 30 min 
at 37°C, agitating every 10 mins. After 30 mins the NB/B27+ containing papain was 
carefully removed, and cells washed twice with NB/B27+. The cells were then triturated 
by pipetting approximately 1 0  times until a homogenous cell suspension was acquired 
and then transferred to a 15ml centrifuge tube. An OptiPrep gradient was prepared by 
gently pipetting 10% Optiprep (made up in NB/B27+) on top of 20% Optiprep. The cell 
suspension was then applied gently to the top of this 2-step density OptiPrep gradient and 
centrifuged for 15 mins at room temperature at 1900 rpm to partially separate cells from 
debris. The fraction between the 10% and 20% gradient containing the cells was gently 
pipetted out and diluted into 2 mis NB/B27+ and centrifuged for 2 mins at RT at 1100 
rpm. The supernatant was removed and the cell pellet was re-suspended in 4 mis 
NB/B27+. Following trituration, 30pl of cell suspension was added to 50 pi of trypan 
blue stain (Sigma, UK), mixed well, and counted using a haemacytometer. Viable cells 
were counted by trypan blue exclusion and diluted to have a cell density of 1 0 0 , 0 0 0  
cells/ml, subsequently 500 pi was added to each well of a 24 well plate, previously coated 
with poly-D-lysine. A media change was carried out the next day to remove any cell 
debris and non-adherent cells. Plating media contained a combined antibiotic/antimycotic 
250 pM (Pen/Strep and Fungizone, Gibco, UK), 500 pM L-Glutamine (Sigma, UK) and 
10% FCS (Gibco, UK). After three days FCS was excluded from the media to promote
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neuronal differentiation, and thereafter a media change was carried out every 3 days. 
Immunofluorescent staining on cultures was carried out as previously described.
Figure 2.3 Schematic diagram illustrating the removal of the dentate gyrus from the 
hippocampus. A needle was placed in the CA3 region to hold down the section whilst 
using a scalpel to cut and lever out the dentate gyrus from the rest of the hippocampus.
2.9 Molecular Biology Methods
2.9.1 General Molecular Biology Procedures
All plasticware, glassware, equipment and working areas were autoclaved or cleaned with 
RNase Away (Molecular Bioproducts, UK) and PCR was carried out in a PCR laminar 
flow cabinet (Labcaire Systems Limted, UK) to reduce contamination of samples.
2.9.2 RNA Extraction
Experimental and control tissues were collected in 1ml of Trizol (Invitrogen, UK) /50 mg 
tissue, homogenised as rapidly as possible using decreasing sized gauge needles on ice at 
4°C, until a smooth, lysed homogenous suspension was obtained. For cells, the media was 
removed and cells washed with chilled PBS which was then removed and 250 pi of trizol 
added to each well (for a 24-well plate). The cells were then scraped using a pipette tip 
and placed in a 1.5 ml eppendorf (Appleton Woods, UK). In a fume hood, 200 pi of 
chloroform per 1 ml of Trizol was then added. The suspension was shaken vigorously for 
15 seconds and incubated for 3 minutes at RT. The suspension was then spun down at
41
12,000 g for 15 minutes at 4°C and the supernatant removed and transferred to a sterile 
(RNase free) eppendorf. DNA and protein were removed through salt-precipitation, by 
adding 500 pi of isopropanol per 1 ml of Trizol. The RNA was allowed to precipitate at 
RT for 15 minutes and then spun down at 12,000 g for 15 minutes at RT. The supernatant 
was discarded and the RNA pellet washed twice with 1ml of 75% ethanol. The pellet was 
vortexed after each wash and spun at 7,500 g for 3 minutes at 4 °C to remove any residual 
ethanol. The RNA pellet was allowed to dry at RT for 10 minutes and resuspended in 
RNase free water 1 pi per lmg tissue. This was then vortexed, left on ice for 10 minutes, 
heated to 65°C for 10 minutes and left on ice before storage at -80°C.
2.9.3 DNase Digestion
RNA was digested with RQ1 RNase-free DNase (Promega, UK), to remove DNA 
contaminants. 8 pl of RNA was digested with lpl (=1 unit) RQ1 RNase-free DNase and 
lpl o f RQ1 lOx buffer (Promega, UK), in a total volume of lOpl at 37°C for 30 minutes, 
lpl o f Stop-solution (Promega, UK) was then added and the enzyme inactivated at 65°C 
for 10 minutes. Successful removal of DNA was determined by visualisation of RNA and 
DNase treated RNA on a 1% agarose gel via electrophoresis. The concentration of each 
sample o f RNA was determined with a Gene Meter spectrophotometer (ABgene, UK). A 
1:100 dilution of the RNA to water was used to determine the concentration and water 
alone was used as a no RT-control for semi-quantitative PCR analysis (Absorbance 
A260/280 x dilution factor x 40). 200 ng of DNase digested RNA was used for reverse 
transcription.
2.9.4 Reverse Transcription
Reverse Transcription using Invitrogen’s Superscriptll system was carried out on 200 ng 
of RNA for each sample and the manufacturer’s instructions followed. Initially, RNA 
was mixed with dNTP’s and oligo dT as follows:
Oligo (dT) 12-18 (500 ug/ml) 
dNTP mix (10 mM) 
RNA/control 
RNase-free water 
Total volume:
1 pi 
1 pi
variable
variable
12  pi
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The reaction was heated to 65°C for 5 minutes, chilled on ice immediately and spun 
down. Then to each sample added:
5x First Strand Buffer 4 pi
DTT(lOOmM) 2 pi
RNaseOUT Recombinant Ribonuclease Inhibitor (40units/ul) 1 pi
Each tube was inverted and reaction mixed gently, this was then incubated at 42 °C for 2 
minutes, 1 pi of Superscriptll (200 units) was then added to each sample and incubated at 
42 °C for a further 50 minutes. The reaction was then inactivated at 70 °C for 15 minutes 
and kept at 4 °C for 5 minutes to keep the cDNA in a denatured state. For quantitative 
PCR (qPCR), the cDNA concentration was determined with a spectrophotometer 
(Absorbance A260/280 x dilution factor x 50) and diluted to 25 ng/pl stocks in nuclease- 
free water. The cDNA was stored at -20° C and subsequently 8 pi (200 ng) was used as a 
template for qPCR.
2.9.5 Semi-Quantitative Polymerase Chain Reaction (PCR)
Polymerase Chain Reaction (PCR) was used for the semi-quantitative analysis of mRNA 
expression. PCR was performed in an Eppendorf Mastercycler Gradient (Eppendorf,UK) 
thermal cycler. Taq DNA polymerase was obtained from Promega, dNTPs were from 
Invitrogen and prepared as a stock solution containing 10 mM of each dNTP. Primers 
were obtained from MWG Biotech, Germany and reconstituted with the appropriate 
volume of RNase free H20  stated in the oligo synthesis report to give a 100 pM stock and 
stored at -20°C. All primer stocks were then diluted to 10 pM concentration stocks for 
direct use in PCR and qPCR. Two microlitres of cDNA was used as template in a 
standard 50 pi PCR reaction with Taq DNA polymerase as follows:
Template 2  pl
10x PCR buffer 5 pl
MgCE (50mM) 1.5 pl
dNTP mix (lOmM) 1 pl
Forward primer (lOOpM) 1 pl
Reverse primer (lOOpM) 1 pl
Taq DNA polymerase 0.4 pl
ddH20 38.1 ul
Total volume: 50 pl
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Reaction mixtures were prepared in 0.2ml capped thin walled tubes (Eppendorf, UK). 
PCR programmes were adapted from a standard protocol. Rat ADNP and VIP mRNA 
levels were carried out with ADNP forward 5’-GGA CCA CAT TGT CAA TTC AC A 
CC-3’ and ADNP reverse primer 5’-GGA CAA GCG CTG CAG CAG AAA GG-3\ VIP 
forward primer 5’-TAA AAG CAG ACT CTG ACA TCT TG-3’ and VIP reverse primer 
5’-GAA GTT GTT TTC TTG AAT TAG AT-3’ with 40 amplification cycles. mRNA 
levels for nNOS and iNOS were carried out with nNOS forward primer 5’-GAA CCC 
CCA AGA CCA TCC and nNOS reverse primer 5’-GGT TTG CTC CCA CTG TT-3’. 
iNOS forward primer 5’-CAC ATC TGG CAG GAT GAG AA-3’ and iNOS reverse 
primer 5’-TTG TCA CCA CCA GCA GTA GTT-3’. As a control for the amount of 
cDNA used in the reactions, rat p-actin levels were also analysed, using b-actin forward 
5’-ACG GTC AGG TCA TCA CTA TGG-3’and reverse primers 5’-AGC CAC CAA 
TCC ACA CAG-3’. Most PCR programmes were as follows:
Temperature Time Number of Cycles Function
94°C 5 minutes 1 Initial dénaturation
94°C 1 minute Denaturation
60°C 1 minute 40 Annealing
72°C 1 minute Extension
72°C 5 minutes 1 Strand completion
Table 2.4 Details of PCR programmes.
2.9.6 Agarose Gel Electrophoresis
PCR products were visualised by agarose gel electrophoresis. Agarose (1%) (Bioline,UK) 
was melted in 0.5x TBE buffer in a 250 ml Erlenmeyer flask, by boiling for 20 seconds in 
a microwave and then cooled to approximately 55°C. 4pl of ethidium bromide was then 
added (lOmg/ml aqueous solution) (Sigma, UK) to the gel. Gels of 150ml were cast in 
12x14cm or 20.5x10cm trays, which were taped either end, and appropriate combs 
inserted. The gel was allowed to set for approximately 30 minutes at RT and was then 
submerged in a horizontal gel electrophoresis tank (Hybaid turn and cast submarine gel 
system, Hybaid, or Savant HG 350 tank) containing 0.5x TBE buffer and the combs 
carefully removed. Samples were mixed with 6 x loading buffer (AB gene, UK) and 
loaded into the wells. Five microlitres of lOObp DNA ladder (AB gene, UK) was also
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loaded to compare the size of products. The gel was then run at 120-150V (Hybaid) or 
80V (Savant).
2.9.7 Generation o f  Standards for Quantitative Real Time PCR (qPCR)
Plasmid standards provide a method for determining gene copy numbers in qPCR. All 
standards for qPCR were generated and kindly donated by Dr Nicole Gennet. The 
standards were generated as follows; P-actin and ADNP cDNA PCR products were 
produced as described in (Reverse Transcription section) and (PCR section). The PCR 
products were ran on a 1 % agarose gel and excised from the gel using a sterile scalpel 
blade under a UV transluminator. The DNA was then purified from the agarose using the 
QIAquick Gel Extraction Kit (Qiagen, UK) and cloned into the pGEM®-T vector system 
(Promega, UK). Different insert:vector ratios were used, ranging from 5:1 to 1:5. The 
amount of insert required was calculated using the following calculation^ 
ng vector x Kb size of insert x insert ratio = ng of insert 
Kb size of vector vector ratio
The appropriate volume of insert and 1 pi (50ng) of pGEM®-T vector DNA were mixed 
together with 1 pi 1 Ox ligase buffer and 1 pi of T4 DNA ligase (3 units) (Promega, UK) 
in a total volume of 10 pi and incubated at 4°C overnight in a 1.5 ml centrifuge tube. 
Transformation of the plasmid DNA into Escherichia coli JM109 (Promega, UK) cells 
was as follows; cells were thawed on ice and 2-3 pi of the ligation reaction, added. This 
mixture was incubated on ice for a further 30 min, then heatshocked at 42 °C for 45 
seconds in a waterbath and incubated on ice for 2 min. 950 pi of warmed Luria-Bertani 
Broth (LB) medium was added to the cells and the culture incubated at 37 °C for 1 hour 
on a shaker at 225 rpm. 100 pi of this culture was then spread onto LB agar plates 
(containing 100 pg /ml ampicillin) which had previously been streaked with 40pl of X- 
gal solution (50mg/ml, Promega) and 16pl of IPTG (Promega, lOOmM) per 10cm and 
incubated at 37°C overnight. The next day, white positive colonies were picked and 
analysed for the correct insert. A small scale preparation of plasmid DNA for each colony 
was carried out using the QIAprep Spin Miniprep Kit (Qiagen, UK). A restriction 
endonuclease digest was then carried out to establish the correct ligation and a large scale
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preparation of the correct plasmid was then performed using the QIAGEN Plasmid Maxi 
Kit (Qiagen, UK).
The plasmid DNA concentration was determined by reading absorbance at A260 using a
spectrophotometer. By knowing the concentration and the size of the overall construct,
the copy number could then be determined using the following equation:
Copy No per pi = \grams of DNA1 x T6.022 x 10231 
construct size (bp) x 660*
*660 = M, of a nucleotide.
Serial dilutions of the plasmids ranging from 1.0 x 108 to 1.0 x 103 copies were produced 
for ADNP and the (3-actin housekeeping gene.
2.9.8 Quantitative Real Time PCR
Stocks of standards were thawed on ice along with cDNA samples, reactions were set up 
in a pre-cooled 96 well ice block. 1 pi of each standard for ADNP or p-actin was mixed 
with 7 pi H20 . 12pl of master mix (lpl H20, 0.5pl forward primer, 0.5pl reverse primer 
and lOpl Finnzymes DyNAmo™ SYBR® Green master mix (containing modified 
Thermus brockianus (Tbr) DNA polymerase, SYBR Green I, optimized PCR buffer, 
5mM MgCl2, dNTP mix including dUTP)) was added to each standard and to 200ng 
(8pl) of each cDNA sample to give a total volume of 20 pi.
qPCR cycling steps were carried out as follows; block pre heating 94°C for 10 minutes, 
then 45 cycles of; initial denaturation 94°C for 10 minutes, annealing 60°C for 20 
seconds, extension at 72°C for 15 seconds and strand completion 72°C for 1 second. 
Continous fluorescence was detected using the DNA Engine Opticon™ System (CFD 
3200, Opticon detector and PTC 200 DNA engine cycler) (MJ Research Inc.). SYBR 
Green I binds to double-stranded DNA and fluoresces when bound to the amplified 
double-stranded PCR product, allowing the direct quantification of amplified DNA 
(amplicons) without the use of labelled probes. A standard curve for each housekeeping 
gene or gene of interest was generated and used to calculate the relative copy number of 
unknown samples. Melting curve analysis was earned out to confirm the specificity of
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the products between 65-95 °C with 0.2 °C increments. The content of unknown samples 
was calculated from the amount of the target gene, normalised to the amount of a 
housekeeping gene, (3 actin, with each derived from separate standard curves.
2.10 Protein Extraction
In vivo tissue samples were collected in 500 pi RIPA buffer (50 mM Tris-HCl pH7.4, 
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1% Protease 
Inhibitor Cocktail (all from Sigma, UK)) on ice. In vitro, media was removed and cells 
were washed with ice cold PBS, 200 pi of RIPA buffer was then added to the wells. 
Subsequently, the cells were scraped with a pipette tip and collected into a 1.5 ml 
eppendorf tube. Samples were then pipetted several times to aid lysis and the protein 
concentration then determined using the BCA assay.
2.10.1 Determining the Protein Concentration o f Samples
To determine the protein concentration of samples for western blotting a protein assay 
was carried out using the bicinchoninic acid (BCA)1M Protein Assay Kit (Pierce, UK). 
This assay involves the reduction of Cu2+ ions to Cu+ ions by protein under alkaline 
conditions, also known as the Biuret reaction. The Cu+ ions are then detected by a 
colorimetric reaction using BCA in which the chelation of two BCA molecules with one 
Cu+ ion generates a purple coloured reaction product. The intensity of the colour reaction 
can be used to determine unknown protein concentrations by comparing them to a set of 
standards with known protein concentrations. A set of standards with protein 
concentrations ranging from 25 pg/ml to 2000 pg/ml including a blank of 0 pg/ml were 
made up along with the working reagent (WR) which was made up from reagents A and 
B in a ratio of 8:1. The samples to be assayed were used neat, or diluted in order to 
achieve a concentration within the range of the standards. 25 pi of each standard and 
sample were pipetted in triplicate into a clear 96 well microplate and 200 pi of WR multi- 
pippetted into these wells, taking care to avoid contamination between wells. The plate 
was covered and incubated at 37°C for 30 minutes. The plate was then cooled to RT, and 
the optical density was measured at 540nm on a scanning multiwell spectrophotometer 
(Thermofisher Scientific, UK). The protein concentration was quantified in Excel
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(Microsoft) by interpolating the standard curve using the linear equation y = mx + c
(where excel fits gradient and y intercept):
Concentration = [(Absorbance)-(v intercept))
Gradient
2.10.2 Western Blotting
Proteins were resolved using the NuPAGE®Novex® 10% Bis-Tris pre-cast gels 
(Invitrogen, UK) and the XCell SureLock™ Mini-Cell electrophoresis system. The 
appropriate volume for 1 0  pg of each sample was added to an eppendorf then all samples 
were made up to an equivalent volume with ddH20  and finally NuPAGE® LDS Sample 
Buffer (4X) and NuPAGE® Reducing Agent (10X) were added to the samples. Samples 
were then heated to 70°C for 10 mins. IX SDS Running Buffer was prepared by diluting 
20X NuPAGE® MOPS SDS Running Buffer in ddH20 . The wells of the pre-cast gels 
were washed twice with IX Running Buffer and then filled to displace air bubbles. The 
gel cassettes were then locked into the buffer chamber which were then filled with IX 
running buffer. 35 pi of samples were loaded and 5 pi SeeBlue® Pre-Stained Standard 
ladder (Invitrogen, UK) and ran for 60 mins at 200 V (time varied according to the size of 
band being investigated). IX NuPAGE® Transfer Buffer was then prepared by diluting 
20X NuPAGE® Transfer Buffer in ddH20  (800 ml) and adding 200 ml methanol and 1 
ml NuPAGE® Antioxidant. The gels, nitrocellulose membranes (Invitrogen, UK), filter 
paper ((Invitrogen, UK) and blotting pads (Invitrogen, UK) were pre-soaked in IX 
NuPAGE® Transfer Buffer and then locked into the blot module which was filled with 
IX NuPAGE® Transfer Buffer, the outer chamber was filled with ddH20 . Proteins were 
then electrophoretically transferred to the nitrocellulose membranes at 60V for 1 hr.
2.10.3 Processing o f Western Blots
Detection of proteins was carried out using the WestemBreeze® Chromogenic 
Immunodetection Kit (Invitrogen, UK). Blocking solution was made up according to 
manufacturers guidelines using Diluent A and Diluent B and the nitrocellulose 
membranes blocked for 1 hr on a rotary shaker set at 1 revolution/ second. Membranes 
were then washed twice with dH20  and incubated with primary antibodies (ADNP, 
1:1000, Chemicon, UK; or (3-actin 1:500, Sigma, UK) overnight at 4°C. The next day the
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membranes were washed 3 times with Antibody Wash, prepared according to 
manufacturers guidelines, and then incubated with the Secondary Antibody Solution for 
30 mins at RT. The membranes were then washed 4 times for 5 mins with Antibody 
Wash, then 3 times for 2 mins with dFLO. The Chromogenic Substrate was then added to 
the membranes until purple bands developed (between 10- 30 mins), then the membranes 
were washed 3 times for 2 mins with dFLO and left to air dry.
2.11 BrdU labeling
2.11.1 Detection o f  Proliferating Cells In Vivo
5-bromo-2-deoxyuridine (BrdU) (100 mg/kg) was administered 3 days prior to KA and 
other pre-treatments carried out as described previously i.e. 24 hrs prior to KA treatment 
(10 mg/kg), L-NAME (50 mg/kg) and saline controls were administered 3 times over the 
duration of the 24 hrs (Fig 2.1). Following KA treatment, seizures were classified 
according to the Racine scale (Racine, 1972) and rats administered diazepam (10 mg/kg) 
after the initial seizure to avoid SE or mortality. These animals were allowed to recover 
and 3 days later the animals were perfused with 4% paraformaldehyde, the brains 
dissected and post-fixed in 30% sucrose for immunohistochemistry.
2.11.2 Detection o f Proliferating Cells In Vitro
Dentate gyms cells were cultured and maintained as described previously. To study the 
longer term effects of NO inhibition and KA treatment on proliferation in vitro, BrdU (10 
pM) was added to the media along with either saline (vehicle control) or L-NAME (500 
pM) and incubated for 30 mins at 37°C, 5% CO2. KA (10 pM) was then added to either 
saline (vehicle control) or L-NAME (500 pM) treated cells and incubated for 3 days. 
Then the cells were fixed in 4% PFA and processed for BrdU immunostaining. For short 
term effects on cell proliferation cells were fixed 6  hrs post KA treatment.
2.11.3 BrdU Immunostaining
BrdU a thymidine analogue is incorporated into the newly synthesized DNA of 
proliferating cells both in vitro and in vivo and consequently antibodies specific to BrdU 
can be used to detect proliferating cells. Identification of the labelled cells can be applied
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both in vitro and in vivo to produce a nuclear staining pattern. Tissue or cells were fixed 
with 4% PFA, in vivo tissue had previously been fixed with 4% PFA, for in vitro cultures 
the media was removed and cells were washed with 0.1M PBS, then 200 pi of 4% PFA 
was added to the cells for 30 mins at RT. Following fixation, cells/tissue sections were 
washed twice with PBS. For denaturing of DNA, the cells/tissue sections were incubated 
with 50% formamide in 2x SCC (0.3 M NaCl and 0.03m sodium citrate) at 65°C for 90 
mins. After 90 mins the cells/tissue sections were washed twice with 2x SCC for 5 mins 
and then incubated for 30 mins in 2N HC1 at 37°C. After 30 mins the acid was 
neutralized by washing the slides in 0.1M boric acid (ph8.5) for 10 minutes followed by 
five washes in PBS at RT. The cells/ tissue sections were then incubated with 10% 
donkey serum for 1 h at RT and the primary antibody anti-BrdU (mouse) at 1:100 
incubated at 4°C overnight. Immunostaining was then carried out as described 
previously.
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CHAPTER 3
The Regulation o f ADNP via the NO-cGMP 
Pathway in the Hippocampus Following
Seizure
3.1 Introduction
Activity dependent neuroprotective protein (ADNP) is widely expressed in many tissues, 
including heart, skeletal muscle, kidney, and placenta. It is also expressed in the brain in 
regions such as the cerebellum and cortex, where its expression is higher compared to 
other tissue (Zamostiano et al., 2001). The human ADNP gene is approximately 45 kb 
and contains 13 alternatively spliced exons which produce 5 splice variants (a-e). These 
have not been fully characterised, but four of these five splice variants are likely to 
produce the same protein, only splice variant (e) is significantly different in that it does 
not contain either of the alternative exons 10-13 which encode the largest portion of the 
ADNP protein. All ADNP references herein, refer to splice variant (c). Cloning of the 
ADNP gene also revealed that the deduced protein structure contained nine zinc fingers, a 
proline-rich region, a nuclear bipartite localization signal, and a homeobox domain 
profile, suggesting a transcription factor function of ADNP (Zamostiano et al., 2001). 
Part o f the ADNP gene sequence was found to code for the eight amino acid peptide NAP 
(short for NAPVSIPQ, its one letter amino acid sequence) (Bassan et al., 1999; 
Zamostiano et al., 2001). NAP was then shown to have a potent neuroprotective function, 
even at femtomolar concentrations (Bassan et al., 1999; Zemlyak et al., 2000; Gozes et 
al., 2003; Furman et al., 2004; Zaltzman et al., 2005). In a mouse model of head trauma, 
NAP protected neurons from death (Gozes et al 2005; Zaltzman et al., 2005). In another 
study using the hydrogen peroxide-induced stress model, ADNP reduced the pro- 
apoptotic p53 protein in rat pheochromocytoma (PC 12) cells, implying its role in 
programmed cell death (Steingart and Gozes, 2006). Importantly, a recent study by 
Vulih-Shultzman and colleaugues demonstrated that heterozygous ADNP"17- mice have 
increased phosphorylated tau, the hallmark of neurodegenerative diseases (Vulih- 
Shultzman et al., 2007). ADNP has also been shown to be essential for brain formation 
and development (Pinhasov et al., 2003; Mandel et al., 2007), however, its role in the 
pathophysiology of disease processes such as epilepsy has not been investigated.
The KA animal model of epilepsy, a model resembling human TLE, has been previously 
discussed. As described in the general introduction, analysis of hippocampal pathology in 
human TLE exhibits neuronal loss and gliosis (Nadler et al., 1978; Ben-Ari, 2000; De
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Lanerolle et al. 2003). Gene expression in TLE samples is also consistent with increased 
glutamate release by astrocytes (Lee et al., 2007). The relationship of NO in epilepsy and 
hippocampal cell death is not completely understood as it has been shown to have both 
anti-convulsant (Penix et al., 1994, Kendrick et al., 1996; Gabriel et al., 2000; Sardo and 
Ferraro, 2007; Royes et al., 2007) and pro-convulsant actions (De Sarro et al., 1993; 
Tutka et al., 1996), depending on the species studied and epilepsy model employed. 
Several factors may contribute to hippocampal cell death in epilepsy such as excessive 
glutamate realease and activation of NMDA receptors leading to calcium-induced cell 
death. The calcium influx activates neuronal nitric oxide synthase (nNOS) to produce NO 
(Garthwaite, 2005). All three NOS isoforms are expressed during epilepsy, for example, 
eNOS is upregulated in a rodent model of SE within 3-24 hours of intracranial injection 
of KA (Chuang et al., 2007; Liu et al., 2007), whilst nNOS and iNOS are upregulated in a 
mouse model of electrically-induced SE (Catania et al., 2003). NO activates soluble 
guanylyl cyclase (sGC) to generate cGMP which can initiate physiological responses in 
the cell, primarily via the phosphorylation of proteins by protein kinases. NO can also 
directly modulate the expression of transcription factors, for example, CREB (a 
transcription factor known to regulate neurotrophin and neurotransmitter genes such as 
BDNF and somatostatin) mediates a cGMP/PKG-dependent anti-apoptotic signal cascade 
activated by NO (Nagai-Kusuhara et al., 2007; Zhuravliova et al., 2007; Riccio et al., 
2006).
We have recently shown ADNP expression in neurons, (in the cytoplasm and axons) and 
in glial cells of the rat brain (Cosgrave et al., 2008; Gennet et al., 2008). In this chapter I 
have investigated the regulation of ADNP expression via the NO-cGMP pathway in the 
hippocampus, following seizure.
3.2 Materials and Methods
Materials and methods were carried out as previously described for in vivo injections of 
NO inhibitors and KA. Tissues were processed for immunofluorescence, PCR, qPCR and 
western blotting and measurement of nitrite also as described in the methods section.
53
3.3 Results
3.3.1 Effect o f  NOS or sGC inhibition on nitrite levels in the hippocampus and following 
the onset o f  the first seizure
Nitric oxide (NO) has a very short half life in vivo and is predominantly converted to 
nitrate (NO3') and nitrite (NO2"). These products are more stable and so NO activity could 
be assessed by quantitating NO2’ levels in hippocampal homogenates using the Griess 
assay. L-NAME (50mg/kg), 7-NI (50mg/kg) and ODQ (lOmg/kg) pre-treatment all 
caused a significant decrease in NO2 levels compared to their vehicle control (Fig. 3.1). 
Following KA treatment and after the first seizure there was a significant increase in 
NO2" levels (Fig. 3.1) compared to vehicle control, this is consistent with previous 
findings (Radenovic & Selakovic 2005). Only L-NAME pre-treatment caused a 
significant decrease in NO2' levels following the first seizure, whereas 7-NI and ODQ 
pre-treatment did not have any significant effect on NO2' levels following the first seizure 
compared to vehicle control (Fig. 3.1).
3.3.2 Kainic acid treatment increases nNOS and iNOS mRNA and protein synthesis in the 
hippocampus
PCR analysis of mRNA for nNOS and iNOS revealed a significant increase in their 
expression in the hippocampus of KA-treated animals (3 h post-KA) compared to the 
vehicle control (Fig. 3.2). Immunostaining for nNOS and iNOS revealed that by 3 days 
post-KA there was an increase in the number of nNOS+ cells (predominantly neurons) 
and iNOS+ cells (predominantly microglia and astrocytes) compared to control (Fig. 
3.2B). The SL and the SLM had greater numbers of nNOS and iNOS cells (Fig. 3.2) 
compared to other areas of the hippocampus. In addition, in 3 day post-KA treatment 
there was increased nNOS staining in the neurites, whose cell bodies were located in the 
outer margins of the pyramidal layer (Fig. 3.7) in the CA3 and CA1 regions suggesting an 
increase in the local release of NO.
3.3.3 Effect o f  NOS or sGC inhibition on ADNP expression under basal physiological 
conditions in the hippocampus
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ADNP mRNA and protein was present in the hippocampus as revealed by RT-PCR and 
immunostaining (Fig 3.3). Cellular localization using cell-specific markers with 
double/triple immunostaining revealed that ADNP was present in both neurons and glia 
cells in the CA1 and CA3 regions of the hippocampus (Fig. 3.3B). Interestingly, apical 
dendrites in the stratum oriens (SO) of the CA1 pyramidal neurons were intensely stained 
for ADNP (Fig. 3.7). Pyramidal cells in the CA1/CA3 and intemeurons/astrocytes in the 
SO, stratum radiatum (SR) and stratum lucidum (SL) also contained ADNP in their cell 
bodies (Fig. 3.3, 3.7).
In order to determine whether the NO-cGMP pathway has a role in the physiological 
expression of ADNP under control conditions in the hippocampus, animals were treated 
with the NOS or sGC inhibitor (without the induction of seizure by KA). N.B. these 
animals were controls for the 3 hr post-KA group and were approximately euthanized 30 
hr after the initial administration of drug (see Fig. 2.1) but will subsequently be referred 
to as the ‘3 hr’ time point. ADNP mRNA expression was reduced by L-NAME, 7NI or 
ODQ compared to controls (DW or DMSO) in the 3 hi' group but not in the 3 day control 
group (these animals were the controls for 3 day post-KA) (Fig. 3.3A). This shows that 
after a transient block of the NO-cGMP signalling system, ADNP production is inhibited 
but recovers to control levels within 3 days.
The effect of NOS or sGC inhibition on the topographic distribution of ADNP containing 
neurons in the CA3 and CA1 regions of the hippocampus was further examined by 
immunostaining (Fig. 3.3B). In the 3 hr group, the number of ADNP+ neurons in the CA3 
region of the hippocampus was significantly reduced with L-NAME compared to the 
vehicle control (Fig. 3.3B, Fig. 3.4). Similarly, 7-NI or ODQ treatment also caused a 
reduction in the number of ADNP+ neurons in the CA3 compared to the vehicle (DMSO) 
group (Fig. 3.3, Fig. 3.4). However, 3 days post drug treatment, there was no significant 
difference in ADNP+neuron numbers compared with appropriate vehicle control groups 
(Fig. 3.4).
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3.3.4 Effect o f  NOS or sGC inhibition prior to kainic acid treatment on ADNP in the 
hippocampus
Following seizure (KA treatment) a significant reduction of both ADNP mRNA and 
protein synthesis was observed by 3 days as revealed by RT-PCR/qPCR, immunostaining 
and Western blot analysis (Fig. 3.5, Fig. 3.6). Immunostaining for ADNP/NeuN/DAPI 
and TUNEL in the hippocampus from 3 day post-KA animals did not show cell loss/ 
apoptosis indicating that the reduction in ADNP is not due to cell loss (Fig. 3.9, Fig. 
3.10).
The suppression of ADNP mRNA by KA alone (without NOS or sGC inhibitor pre­
treatment) was evident in the 3 day post-KA treated animals but not in the 3 hr post-KA 
group. However, L-NAME, 7-NI or ODQ pre-treatment reduced ADNP mRNA levels in 
the 3 hr post KA group, compared to appropriate vehicle pre-treatment groups within this 
group (vehicle + KA) (Fig 3.5, Fig. 3.6). This implies that this initial reduction in ADNP 
mRNA levels was due to reduced production of NO and cGMP as opposed to the effects 
of KA (for 3 hr), which correlates with the effects of these drugs seen under basal 
conditions (Fig. 3.3, Fig. 3.4). Interestingly, by 3 days post-KA treatment, ADNP 
reduction was reversed in the hippocampus in the NOS or sGC inhibitor pre-treated group 
but not in the vehicle pre-treated groups (Fig 3.5, Fig 3.6). This indicates that increased 
NO levels, as evident from increased nNOS and iNOS mRNA expression and 
immunostaining (Fig. 3.2) following KA treatment (by 3 days), decreases ADNP. ADNP 
immunostaining of the CA3 and CA1 regions of the 3 day post-KA treated animals, 
showed that a decrease in ADNP synthesis was evident in both neurons and astrocytes 
(Fig. 3.6, 3.7). In the control group ADNP was observed throughout the soma and apical 
dendrites of the CA1 pyramidal neurons (SO), while in the 3 day post-KA treatment 
group ADNP staining was observed in clusters and/or in punctate form within the nucleus 
of neurons in the pyramidal layer (SP). ADNP was almost completely suppressed in the 
apical dendrites in the SO (Fig. 3.7).
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3.3.5 Effect o f NOS or sGC inhibition prior to kainic acid treatment on onset o f  the first 
seizure
Following KA administration, animals were monitored and the symptoms leading to the 
onset of the first full generalised seizure were scored according to Racine’s seizure 
severity scale (stages 1-5) as described previously. In the KA treated group, without 
NOS or sGC inhibitor treatment, animals progressed steadily from stage 1 to 5 within 90 
mins of KA treatment. In general, L-NAME pre-treated animals exhibited the first full 
generalised seizure sooner (25 ± 15 min) than animals that had been pre-treated with 
vehicle control (DW or DMSO), 7-NI or ODQ (70 ± 20 min). This may suggest that the 
inhibition of all NOS isoforms by L-NAME, advances the onset of KA-induced seizure 
activity whilst a more selective inihibition does not. It is possible that decreased ADNP 
expression by L-NAME treatment prior to KA may play a part in this.
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Figure 3.1 The effect of NOS inhibitor L-NAME (50 mg/kg i.p.), neuronal NOS 
inhibitor 7-NI (50 mg/kg i.p.), sGC inhibitor ODQ (10 mg/kg i.p.) and KA 
treatment (10 mg/kg i.p.), on nitrite concentration in the hippocampus. Samples 
were taken after the initial seizure (3 hr group) and show an increase in nitrite 
levels following seizure, whereas L-NAME, 7-NI and ODQ showed a decrease in 
nitrite levels (**p>0.01, ***p>0.001 n=3).
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Figure 3.2 Kainic acid (KA)-induced seizures increase NOS expression in the 
hippocampus. A. RT-PCR analysis and B. immunocytochemistry for nNOS and 
iNOS show that KA increases gene transcription by 3 hr after KA treatment (A) 
and protein synthesis by 3 days (B). nNOS+ (green) cells indicated by arrows in 
(i) and (ii) represent nNOS+ neurons and red cells in (iii) are iNOS+ 
(predominantly glia), (v) and (vi) represent higher magnification views of nNOS+ 
and iNOS+ cells denoted by the box in (i) and (iii) respectively. Note that there is 
an increase in nNOS and iNOS cells in KA-treated animals compared to vehicle 
control. Scale bar: 100 pm (i)-(iv), 25 pm (v)-(viii).
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Figure 3.3 Effect o f NOS or sGC inhibition on ADNP in the hippocampus in vivo. 
A. ADNP mRNA expression. L-NAME, 7-NI and ODQ reduced the amount of 
ADNP mRNA in the 3hr group compared with control. Three days after treatment, 
ADNP mRNA levels returned to basal levels. B. Immunostaining. Effect o f NOS or 
sGC inhibition (3 hr group) on ADNP+ (red), nNOS+ (green, except in vi) and 
GFAP+ (blue) cells in the CA3 region. Vehicle control treatments (i) DW and (ii)
10% DMSO had no effect on ADNP staining or distribution. The 3 hr group 
showed that with L-NAME treatment (ii) ADNP was markedly reduced in the CA3 
and a smaller reduction was seen with 7-NI (iv) and ODQ (v) treatment. At higher 
magnification, ADNP co-immunostained in both neurons (vi, green cells are 
NeuN+) and in astrocytes (vii, blue cells are GFAP+). Scale bar: 100 pm (i-v), 50 
pm (vi). 2 0  pm (vii).
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Figure 3.4 Quantification o f ADNP+ neurons in the CA3 following NOS and sGC 
inhibition. In the 3 hr group, NOS or sGC inhibitor treatment, caused a significant 
reduction in the number of ADNP+ neurons compared with the appropriate control (*p 
<0.05, **p <0.01, ***p <0.001; n=3). By 3 days the number o f ADNP+ neurons had 
nearly returned to basal levels.
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Figure 3.5 KA-induced seizure significantly reduces ADNP mRNA expression 3 days 
Pre-treatment with the NOS inhibitors, L-NAME/7-NI or the sGC blocker, ODQ 
reverses the effects o f KA-induced ADNP suppression. RT-PCR (A) and qPCR (B) 
analysis o f ADNP mRNA revealed that KA suppresses ADNP mRNA by 3 days post 
KA treatment, but not by 3 hrs (A). Treating with 7-NI or ODQ prior to KA reverses 
ADNP mRNA levels to nearly basal levels by 3 days.
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Figure 3.6 KA-induced seizure significantly reduces ADNP expression in the 
hippocampus by 3 days. A Immunostaining in the CA3 treated with appropriate 
vehicle control (i, DW and vi, DMSO), KA treatment following these controls (ii, 
DW+KA and vii, DMSO+KA) produced a significant decrease in ADNP+ cells by 
3days. Pre-treatment with the NOS or the sGC inhibitors (iii, L-NAME +KA, viii, 
7NI+KA, ix, ODQ+KA) reversed this effect. The higher magnification images 
show in more detail a decrease in ADNP expression in the soma o f CA3 neurons 
after KA treatment (v) compared with vehicle control (iv) (the areas correspond to 
the boxed regions in i and ii.). Scale bar: 100 pm (i-iii and v-ix) and 20 pm (i and 
ii) B. Quantification of ADNP+ neurons. KA treatment for 3 days significantly 
decreased the number of ADNP+ neurons in the CA3 region compared with the 
appropriate control and pre-treatment with NOS or sGC inhibitors reversed KA- 
induced ADNP reduction (*p <0.05, **p <0.01, ***p <0.001; n = 3).
C. Western blot analysis o f ADNP from the whole hippocampus also reveals a 
decrease ADNP protein following KA treatment which is partially reversed by 
pre-treatment with L-NAME.
Figure 3.7 Effect of KA and NOS or sGC inhibition on ADNP in the CA1 region of 
the hippocampus in vivo A . Immunostaining. (i) In vehicle control immunostaining of 
ADNP is seen in the cell bodies of CA1 pyramidal neurons in the stratum pyramidale 
(sp). (ii) Higher magnification of the area shown by the box in (i), shows intense 
ADNP staining in apical dendrites of the pyramidal neurons traversing the stratum 
oriens (so), (iii) KA-induced epilepsy increases the number of nNOS+ cells (green) 
whilst dramatically reducing ADNP+ (red) in the pyramidal cells o f CA1 region of the 
hippocampus, (iv) Increased nNOS is primarily in the soma and dendrites of neurons. 
ADNP is confined mainly to the nucleus o f a few neurons in the stratum pyramidale 
(sp). (v) Higher magnification o f the area indicated by the box in iii (in the ‘so’ region) 
shows the loss of ADNP staining from the apical dendrites and reveals nNOS staining 
in some fibres. Scale bar: 100 pm (i) and (iii), 20 pm (ii, iv and v).
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Figure 3.8 ADNP+ neuronal quantification in the CA1 region o f the hippocampus 
in vivo with NOS and sGC inhibitors 3 days after KA treatment. ADNP+ neurons 
were counted from the CA1 stratum pyramidale. In controls, ADNP expression was 
reduced by 3 days following KA treatment. Almost complete reversal was seen 
with NOS or sGC inhibitor pre-treatment. *p <0.05, **p <0.01, ***p <0.001; n=3.
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Figure 3.9 CA3 region of the hippocampus from vehicle control (i-vi) and vehicle+KA 
treated (vii-xii) animals (3 day group) stained for ADNP (red), NeuN (green) and DAPI 
(blue). Merged images (iii, vi, ix and xii) show co-immunostaining of ADNP+ cells 
NeuN/DAPI. NeuN and DAPI staining show the presence o f neuronal cells/nuclei in the 
CA3 following KA, suggesting that a decrease in ADNP expression in the hippocampus 
is not due to cell loss. Scale bar: 100pm.
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Figure 3.10 TUNEL staining in hippocampus (CA3) o f vehicle control and KA 
treated animals. Lack of TUNEL+ cells in the CA3, suggest that that a decrease in 
ADNP expression in the CA3 is not due to cell loss, (iii) shows positive control 
tissue for TUNEL+ staining carried out alongside sections shown in (i) and (ii) 
Arrows in (iii) indicate TUNEL+ cells.
3.4 Discussion
The neuroprotective role for VIP-responsive ADNP and its derivative peptides, such as 
NAP, have previously been discussed (Gozes, 2007). Although studies of ADNP in 
experimental epilepsy have not been reported VIP does seem to have a role. VIP levels 
fall acutely in experimentally induced seizures (Romualdi et al., 1992), whilst post­
mortem hippocampus samples from human TLE have increased VIP binding (De 
Lanerolle et al., 1995). Initial studies of ADNP suggested that it was primarily located in 
glia cells (Gozes, 2007). Previously, Bassan et al. (1999) showed increased basal levels of 
ADNP mRNA in astrocytes in response to VIP and, interestingly, VIP and/or its 
derivative peptides induce NO and cGMP production in cortical cultures (Ashur-Fabian 
et al., 2001). An important role for NO in neuron-glia communication and 
neuroprotection has previously been reported (Thippeswamy et al., 2005, 2007a). It is 
thus plausible that NO could be involved in regulating VIP-responsive ADNP function. 
These results show that ADNP was detectable under basal conditions in the pyramidal 
neurons and intemeurons of the hippocampus in addition to astrocytes. The antibodies 
used were raised against the peptide sequence 989-1015 of the human ADNP 
homologous to the rat and mouse sequence and does not share homology with other 
proteins in a BLAST search. Interestingly, ADNP staining in the apical dendrites of the 
pyramidal cells in the SO was intense under basal conditions, suggesting large amounts 
of the protein under basal conditions (Fig. 3.7A), but was conspicuously absent in the SL 
and mossy fibres. This reveals a highly selective distribution indicating a cell-specific, as 
opposed to, a generalised function.
At the doses used in these experiments, KA initially activates kainate receptors in the 
hippocampus (Ben-Ari and Cossart, 2000) but this rapidly leads to more widespread 
neuronal depolarisation and release of transmitters such as glutamate acting on both 
AMPA and NMDA receptors. The neuron depolarisation and NMDA channel activation 
leads to calcium influx resulting in activation of NOS and subsequent NO production 
(Kato et al., 2005). NO released from nNOS activates sGC to produce cGMP in many 
areas of the brain including the hippocampus (Garthwaite et al., 1989; Teunissen et al., 
2001). In this chapter the effects of NO and cGMP on ADNP distribution and synthesis
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were examined in the presence and absence of NOS and sGC inhibitors in the 
hippocampus. The sGC inhibitor, ODQ was used to inhibit cGMP production to 
understand whether ADNP is also regulated by the sGC-cGMP pathway. Several others 
have used these NOS or sGC blockers, in vivo, via the intraperitoneal route and have 
demonstrated that they cross the blood brain barrier (Bagetta et ah, 2002; Catania et ah, 
2003; Gupta and Dettbam 2003; Kato et ah, 2005; Chuang et ah, 2007; Liu et ah, 2007; 
Parathath et ah, 2007). The decreased nitrite content in the hippocampus of animals 
treated with NOS or sGC inhibitor confirmed that the drugs were effective in inhibiting 
NO and cGMP production (Fig. 3.1).
KA treatment significantly reduced ADNP mRNA and protein synthesis by 3 days 
following seizure, but not by 3 hrs suggesting a complex pathway involving KA-induced 
ADNP suppression. Immunostaining with the neuronal marker NeuN and TUNEL 
staining for apoptosis in the hippocampus from these animals confirmed that there was no 
cell loss (Fig. 3.9, Fig. 3.10). The delay in suppression of ADNP synthesis coupled with 
the later loss of ADNP staining in the CA regions studied could result from increased 
NO production by KA-induced seizures. The 3 day post-KA group were treated with 
diazepam after the initial seizure to prevent SE and mortality. It has been previously 
demonstrated by Du et al. (1995) that diazepam rescues neurons from calcium-induced 
death in a KA model of epilepsy. This, coupled with the lack of cell death seen in our 
model, infer that the decrease in ADNP mRNA and protein in KA-treated animals is not 
merely a manifestation of cell loss. Diazepam also limits the severity of seizures 
(Pitkànen et al. 2005) and this would be predicted in turn to reduce excessive NO 
production, thus reducing the neurotoxic actions of NO (Rajasekaran, 2005; Chuang et 
al., 2007). In the present study, the animals that received diazepam and NOS or sGC 
inhibitors showed complete reversal of ADNP reduction 3 days after KA treatment. 
These results suggest that the use of antiepileptic drugs combined with NOS inhibition 
may be beneficial (Paul, 2003; Luszczki et al., 2006).
To elucidate the precise mechanism of KA-mediated ADNP suppression by NO will 
require more detailed research. However, following KA treatment it was noted that
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ADNP was mainly located in the nuclei of the pyramidal neurons while in the animals 
pre-treated with the NOS blocker, it was distributed throughout the soma and dendrites. 
As ADNP is synthesised in the cytoplasm, the presence of peptide in the nucleus is 
indicative of translocation and it is possible that ADNP may function as a DNA binding 
protein/transcription factor to regulate gene expression. Zemlyak et al (2007) have 
recently shown that the ADNP-derivative, NAP protects KA-treated hippocampal 
neurons in culture by interacting with microtubule-associated protein (MAP).
Increased NO concentration in the CNS causes DNA damage, altered mitochondrial 
membrane potential and activation of polyADP-ribosylation leading to neuronal death 
(Zhang et al., 1994; Dawson and Dawson, 1995; Wallis et al., 1996). Depending on the 
NO levels, it can modulate DNA-binding activities of the cAMP response element­
binding protein (CREB, a transcription factor) to mediate the cGMP-PKG-dependent 
anti-apoptotic signals induced by NO (Nagai-Kusuhara et al., 2007; Zhuravliova et al., 
2007; Riccio et al., 2006). Interestingly another VIP-derived peptide, ADNF-9, also 
protects neurons from iNOS-mediated toxicity in the hippocampus in a hypoxic-ischemia 
model (Kumral et al., 2006). Low concentrations of NO found during basal conditions are 
known to be beneficial (Contestabile and Ciani, 2004; Thippeswamy et al., 2006; 
Calabrese et al., 2007). The reduction of ADNP produced by the inhibition of NOS or 
sGC (in the absence of seizure) suggests that the basal production of NO may be 
important for maintaining ADNP synthesis in the hippocampus. Based on these 
observations it is plausible that ADNP and NO may interact to regulate neuronal survival. 
Recent studies have shown that NO interacts with ADNP downstream targets. Recently, 
Stroissnigg and colleagues demonstrated that MAP can undergo S-nitrosylation and that 
this is involved in regulation of growth cones morphology (Stroissnigg et al., 2007). In 
the present study, KA-induced NO suppression of ADNP in apical dendrites of the 
pyramidal neurons may also suggest an NO-ADNP interaction in orchestrating the onset 
morphological following seizure.
In summary, during physiological conditions, a low concentration of NO appears to 
promote ADNP synthesis since the inhibition of NO decreases ADNP and advances the
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onset of the first seizure in the KA-induced model of epilepsy. KA increases NO 
production in the hippocampus and these increased levels of NO may suppress ADNP. 
Treating animals with the NOS or sGC inhibitor prior to KA reverses ADNP suppression 
by 3 days post-KA treatment, implying its regulation via the NO-cGMP pathway.
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CHAPTER 4
The Regulation o f ADNP via the NO-cGMP 
Pathway in the Dentate Gyrus Following
Seizure
4.1 Introduction
The dentate gyrus (DG) forms part of the hippocampal formation and plays a vital role in 
learning and memory. More recently, it has become the subject of extensive research 
attributable to it being one of the few sites to display postnatal neurogenesis (Kuruba & 
Shetty, 2007; Taupin, 2006). Distinct neuronal populations in the dentate gyrus, for 
example hilar neurons, display differential vulnerability to various forms of insult such as 
traumatic brain injury, ischaemia and epilepsy (Lowenstein et al., 1992; Jiao and Nadler,
2007). The processes following seizure activity and the subsequent fate of cells in the 
DG are still to be discerned. However, analysis of genes expressed in the DG during 
development and epileptogenesis suggest that genes involved in neurite outgrowth and 
neurogenesis are involved (Elliot et al., 2003). ADNP and NAP have been shown to 
modulate polyADP-ribosylation (PARP) to promote neuronal differentiation and survival 
via MAPK-PEK/Akt pathways (Mandel et al., 2007; Mandel & Gozes 2007; Pascual & 
Guerri, 2007), similar to the effect caused by NGF on PCI2 cells (Visochek et al., 2005). 
In addition, the genes involved in cell survival or death and plasticity in the DG, for 
example, neurotrophins are also differentially expressed during epileptic conditions 
(Sutula et al., 2003; Soriano et al., 2006; Walker, 2007) suggesting the relevance of the 
neurotrophic actions of VIP/ADNP in seizure.
We and others have shown that following kainic acid (KA)-induced seizure both 
inducible NOS (iNOS) and neuronal NOS (nNOS) are upregulated (Chuang et al., 2003; 
Cosgrave et al., 2008; Zaja-Milatovic et al., 2008). NO generates cGMP in many areas of 
the brain including the hippocampus which can activate transcription factors (Garthwaite 
et al., 1989; Teunissen et al., 2001; Matsumura et al., 2008). The ADNP sequence 
contains a homeobox domain, which is a DNA binding domain, many homeotic 
transcription factor genes are essential during development which ADNP has been shown 
to be involved in (Mandel et al., 2007). The presence of zinc finger domains in the ADNP 
gene sequence and the homeobox domain suggest that ADNP may act as a transcription 
factor.
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ADNP has been expression in the DG has not yet been characterised, however, in the 
hippocampus VIP is contained in the synapses of hilar intemeurons which are resistant to 
seizure-induced damage (Sloviter, 1987). In the previous chapter we demonstrated that 
ADNP synthesis was significantly suppressed in the CA3 and CA1 pyramidal neurons of 
the hippocampus following KA-induced seizure in rats which could be reversed if they 
were pre-treated with NOS or sGC inhibitor (Cosgrave et al., 2008). This implies that the 
NO-cGMP pathway regulates ADNP synthesis in the hippocampus. Following on from 
these observations this chapter will investigate the role of the NO-cGMP pathway in the 
regulation of ADNP expression in different layers of the DG following seizure.
4.2 Materials and Methods
Materials and methods were carried out as previously described for in vivo injections of 
NO inhibitors and KA. Tissues were processed for immunofluorescence, PCR, qPCR as 
described in the methods section.
4.3 Results
4.3.1 Effect o f NOS or sGC inhibition on ADNP expression under basal physiological 
conditions in the dentate gyrus
Immunostaining using cell-specific markers revealed that ADNP was present in both 
astrocytes and neurons in the DG (Fig. 4.1, Fig 4.10) and that ADNP was uniformly 
distributed in the cytoplasm of the cell bodies of neurons and astrocytes. Astrocytic 
processes did not show ADNP. The apical dendritic processes of the granule cells in the 
SG that projected into the outer molecular layer (OML) contained ADNP but the distal 
processes in the hilus did not. Polymorphic cells in the subgranular zone (SGZ) and 
intemeurons and astrocytes in the hilus were immunostained for ADNP (Fig. 4.1).
In order to investigate whether the NO-cGMP pathway has a role in the physiological 
expression of ADNP under basal conditions in the DG, animals treated with the NOS or 
sGC inhibitor without the induction of seizure with KA were examined. ADNP inRNA 
analysis of the DG and immunostaining for ADNP did not reveal a significant change in
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7-NI or ODQ treated animals compared to appropriate controls (Fig. 4.2). In contrast, the 
broad spectrum NOS inhibitor, L-NAME caused a reduction in the number of ADNP+ 
cells both in the 3 hr and 3 day groups (Fig. 4.2, Fig. 4.3).
The effect of L-NAME on the topographic distribution of ADNP+ cells in different layers 
of the DG was further examined by immunostaining. ADNP staining was suppressed in 
the granule cells of the SG in the L-NAME 3 hr group (Fig. 4.1, Fig. 4.3, and Fig. 4.11) 
and in the vast majority of neurons in the hilus (Fig. 4.10, Fig. 4.11). Interestingly, ADNP 
in the SGZ and the apical dendrites of granule cells in the OML were not affected. In the 
3 day group, ADNP staining was lost from the apical dendrites of granule cells in the 
OML (Fig. 4.1(v)).
4.3.2 Effect o f NO inhibition on ADNP expression in the dentate gyrus 3 hours post-KA 
treatment
KA on its own had no significant effect on ADNP mRNA expression by 3 hrs but pre- 
treatment with L-NAME significantly increased its expression (Fig. 4.4). L-NAME alone 
also did not change ADNP mRNA expression levels. In the 3 hr post-KA group that were 
pre-treated with L-NAME, immunostaining for ADNP revealed a significant increase in 
ADNP+ granule cells in the SG and hilar neurons when compared with appropriate 
control (Fig 4.5(iv), Fig. 4.6). RT-PCR and qPCR of the DG also showed an increase in 
mRNA expression by 3 hrs in L-NAME+KA treated animals (Fig. 4.4). Both KA and L- 
NAME on their own suppressed ADNP in granule cells in the SG by 3 hrs (Fig. 4.5, Fig. 
4.6). L-NAME suppressed ADNP in hilar neurons (Fig. 4.5 (ii), Fig. 4.11), while KA did 
not (Fig. 4.5(iii), Fig. 4.11) for the 3hr group. Analysis of ADNP+ cell counts from 
different layers of the DG showed that KA alone caused a slight decrease in ADNP+ cells 
in the OML and in the SG, but had no effect on the SGZ and hilar cells (Fig. 4.6, Fig.
4.1 IB) compared with appropriate controls for the 3 hi- group. L-NAME treatment prior 
to KA resulted in a significant increase in the number of ADNP+ granule cells in the SG 
compared with control (Fig. 4.6).
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4.3.3 Effect o f NO inhibition on ADNP expression in the dentate gyms o f 3 days post-KA 
treatment
Interestingly, in the 3 day post-KA group ADNP mRNA and protein synthesis decreased 
in the L-NAME pre-treated group compared with L-NAME on its own or vehicle (Fig. 
4.7). Analysis of ADNP immunostaining of DG layers of L-NAME pre-treated rats (that 
received KA) further revealed 3 main differences: an increase in the number of ADNP+ 
cells in the SGZ (Fig. 4.8(iv), Fig. 4.9), a decrease in the number of ADNP+ neurons in 
the hilus (Fig. 4.10, Fig 4.11) and a decrease in the number of ADNP+ granule cells in the 
SG (Fig 4.8, 4.9). L-NAME alone also suppresses ADNP in granule cells in the SG 
compared to vehicle controls (Fig 4.8, 4.9). In L-NAME pre-treated, 3 d post-KA group 
that were double stained for NeuN and ADNP, hilar neurons showed an eccentric nucleus 
with an irregular cell boundary (Fig. 4.10 (vi), (b), (c)) compared with a centrally placed 
nucleus and smooth cell boundary in controls (Fig. 4.10(v), (a)). Hilar neuron counts 
(NeuN+) from sections representing approximately the same region of the DG in 3 d post- 
KA group (Fig. 4.10), KA caused a small reduction in the number of NeuN+ neurons 
compared with vehicle control (Fig. 4.11). 7-NI and ODQ did not cause any significant 
change in ADNP expression in the DG of normal rat brain or KA-treated animals by 3 hrs 
or 3 days.
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Figure 4.1 Effect of L-NAME treatment on ADNP+ cells in different layers o f the 
DG. All sections were immunostained for ADNP (red), GFAP (blue) and nNOS 
(green), (i) Different layers o f the dentate gyrus: OML, outer molecular layer; SG, 
stratum granulosum; SGZ, subgranular zone. Large cells (neurons) in the hilus are 
ADNP+ and some small nNOS+ neurons were located close to the SGZ and in the 
outer molecular layer. Some ADNP+ neurons in the hilus also co-immunostain with 
nNOS. (ii) L-NAME treatment in the 3 hr group suppresses ADNP in the granular 
cell layer and neurons in the hilus. However, nerve fibres in the OML were intensely 
stained for ADNP compared to vehicle control, (iv) Represents a higher 
magnification of the area indicated by a box in (ii) showing intense ADNP+ nerve 
fibres (red), (iii) L-NAME treatment, continues to suppress ADNP in granule cells by 
3 days, however, ADNP expression returned in hilar neurons by 3 days. The neurites 
in the OML were not ADNP+. (v) Represents a higher magnification o f the area 
indicated by a box in (iii)- nerve fibres in the OML show no staining for ADNP. Scale 
bar: 1 0 0  pm.
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Figure 4.2 Quantification of ADNP+ cells (neurons and astrocytes) from the DG of 
animals treated for the 3 hr and 3 day control group (without KA) with vehicle control 
(DW or 10%DMSO, NOS or sGC inhibitor). The neuron specific NOS inhibitor, 7-NI 
and sGC inhibitor, ODQ had no effect on the overall ADNP+ cell numbers compared 
with their vehicle control, DMSO. However, L-NAME caused a significant reduction 
in the number o f ADNP+ cells by 3 days compared to vehicle control and the 3 hr 
group (* p < 0.05, ** p< 0.01; n=3).
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Figure 4.3 Cell counts (ADNP+ neurons and astrocytes) from different layers o f the DG 
from the 3 hr and 3 day control groups. A significant reduction in ADNP+ cells in the SG 
was seen by 3 hrs with L-NAME and was still evident by 3 days. ADNP+ cell numbers 
were also reduced in the OML and SGZ in the 3 d group. (* p < 0.05, ** p< 0.01; n=3).
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Figure 4.4 Effects of KA (3 hr post-KA) and L-NAME (3 hr) on ADNP mRNA 
and protein expression in the dentate gyrus. RT-PCR (A) and qPCR (B) analysis 
showed an increase in ADNP in L-NAME pre-treated animals compared with KA 
alone. L-NAME or KA on its own did not alter ADNP mRNA levels.
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Figure 4.5 ADNP Immunostaining of L-NAME pre-treated animals confirmed an 
increase in ADNP+ cells (red) in the SG and the hilus following KA-induced seizure 
(iv). L-NAME or KA on its own suppressed ADNP in many granule cells in the SG 
(indicated by arrows in (ii) and (iii) as examples' however, ADNP+ hilar neurons 
varied. L-NAME (ii) suppressed ADNP in hilar neurons but KA (iii) did not. Green 
labelled cells in (i), (iii) and (iv) are nNOS+ neurons which are absent in (ii). GFAP+ 
cells (blue) appear to be down-regulated when treated with L-NAME (ii). Scale bar, 
100 pm. D. Detailed analysis of ADNP + cell counts (neurons and astrocytes) from 
different layers of the dentate gyrus. KA on its own caused a slight decrease in 
ADNP+ cells in the OML and in the SG when compared with appropriate controls 
(** p < 0.01, n=3) but had no effect on the SGZ and the hilus. L-NAME treatment 
prior to KA significantly increased the number of ADNP+ granule cells in the SG, 
and marginally in the OML, compared with controls (*** p< 0.001, * p< 0.05, n=3). 
However, L-NAME on its own suppressed ADNP in a few granule cells in the SG 
compared to vehicle control (* p< 0.05).
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Figure 4.6 Detailed analysis o f ADNP+ cell counts (neurons and astrocytes) from 
different layers o f the dentate gyrus. KA on its own caused a slight decrease in ADNP+ 
cells in the OML and in the SG when compared with appropriate controls (** p < 0.01, 
n=3) but had no effect on the SGZ and the hilus. L-NAME treatment prior to KA 
significantly increased the number of ADNP+ granule cells in the SG, and marginally in 
the OML, compared with controls (*** p< 0.001, * p< 0.05, n=3). However, L-NAME 
on its own suppressed ADNP in a few granule cells in the SG compared to vehicle 
control (* p< 0.05).
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Figure 4.7 Effects of KA (3 d post-KA) and L-NAME (3 day group) on ADNP mRNA and 
protein expression in the dentate gyrus. RT-PCR (A) and qPCR (B) analysis showed a 
decrease of ADNP mRNA levels in L-NAME pre-treated animals compared with KA alone 
or other controls. L-NAME or KA on its own did not change ADNP mRNA levels. Western 
blot analysis (C) of proteins extracted from the dentate gyrus confirmed overall suppression 
o f ADNP in the 3 d post-KA group that was pre-treated with L-NAME for > 24 hours.
(i) Vehicle (1)W) (3 d) (ii) L-NAME (3d)
*
(iii) Vehicle+KA (3 d) !
„
(iv) L-NAME+KA (3 d)
SG
/  6
SG
Figure 4.8 Immunostaining of L-NAME pre-treated animals (iv) confirmed a decrease
of ADNP+ cells (red) GFAP+ (blue) in the SG and the hilus following KA-induced 
seizure. More cells in the SGZ were intensely stained for ADNP in L-NAME pre-treated 
(iv) animals (a few examples are indicated by arrows). KA (iii) or L-NAME (ii) on its 
own continue to suppress ADNP in many granule cells. L-NAME on its own appears to 
have a long-term effect on suppression of GFAP (ii). Scale bar, 100 pm.
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Figure 4.9 ADNP+ cell counts (both neurons and astrocytes) from different layers of 
the dentate gyrus. KA alone suppressed ADNP in a few granule cells in the SG but 
had no effect on the OML, the SGZ and the hilus compared with appropriate 
controls. L-NAME prior to KA significantly increased the number of ADNP+ granule 
cells in the SGZ compared with controls, but decreased in other layers except the 
hilus. However, L-NAME on its own decreases ADNP+ cells in the OML and the SG 
compared to vehicle control (*p< 0.05, ** p<0.01, *** p< 0.001, n=3).
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Figure 4.10 NeuN (green) and ADNP (red) immunostaining of the dentate gyrus 
from animals treated with L-NAME or vehicle with or without KA. The number of 
NeuN+ hilar neurons containing ADNP was significantly reduced by 3 hr with L- 
NAME (iii) compared with the vehicle (i) and 3 days after the last dose of L-NAME 
(v) suggesting L-NAME mediated suppression of ADNP in some hilar neurons. By 
3 hrs post-KA treatment (ii and iv) the average number of ADNP+ hilar neurons did 
not change, but L-NAME pre-treatment caused a significant decrease in the number 
o f NeuN+ hilar neurons by 3 days post KA-injection (vi) and the vast majority of the 
remaining neurons in the hilus were ADNP+. Higher magnification o f the SGZ [(a), 
(b) and (d)] indicated by boxes in v) to vii) show a significant increase in the 
number of ADNP+ cells in the SGZ (b). Morphology of the remaining ADNP+ hilar 
neurons in the L-NAME pre-treated group (vi) indicated by a box (c) showed 
eccentric nuclei and irregular cell margins compared to the vehicle pre-treated 
group (vii) indicated by a box (e). Scale bar: 100 pm.
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Figure 4.11 Hilar neuron counts from sections representing approximately the same 
region of the dentate gyrus from drug or vehicle treated animals. There was a 
significant reduction in ADNP+ neurons in L-NAME treated (3 hr post-KA group; p < 
0.05, n=3) compared to vehicle. KA had no effect on ADNP+ at this time point. The 
number o f NeuN+ neurons also did not change between drug or vehicle treatment. 
However, in the 3 d post-KA group (B) KA caused a decrease in the number of 
NeuN+ neurons compared with vehicle control (p < 0.05, ** p< 0.01, n=3) and 
ADNP+ neurons also decreased in L-NAME pre-treated compared to vehicle pre­
treated group p < 0.05, n=3).
4.4 Discussion
The DG is widely considered as an epileptogenic zone, however, other areas of the brain 
regions may be equally or even more important in orchestrating the generation and/or the 
control of spontaneous seizure (Heinemann et al., 1992; Bertram 1997, Bertram et ah,
1998). The dentate gyrus is also an important region of the brain since it is the site of 
postnatal neurogenesis that occurs throughout the lifespan of the mammalian species. For 
a decade, there has been more emphasis on identifying the role of neurotrophins, such as 
BDNF in activity-dependent modification of synaptic plasticity in the hippocampus and 
the dentate gyrus (Tandon et ah, 1999; Schinder and Poo, 2000; Simsek-Duran and 
Lonart, 2008). The previous chapter demonstrated the regulation of activity-dependent 
neuroprotective protein (ADNP) by the NO-cGMP pathway in the CA3 and CA1 regions 
of the hippocampus in the KA induced rat model of seizure (Cosgrave et ah, 2008). In 
this chapter observations from the same animal model were extended to different layers 
of the DG.
It has been demonstrated in the DG of epileptic rats that kainate receptors contribute to an 
enhanced synchronised network activity (Epsztein et ah, 2005). In the normal brain, the 
DG, the granule cells in particular, are less susceptible to cell death when compared to the 
CA3 and CA1 regions of the hippocampus. This is probably due to strong GABAergic 
inhibition and a high threshold for generation of action potential (Staley et ah, 1992). 
Therefore, decrease in activity or loss of interneurons in the hilus and/or changes in the 
subgranular zone of the dentate gyrus may predispose this area of the brain to 
epileptogenesis.
In view of this, this chapter investigates the basal level expression of ADNP and its 
regulation by the NO-cGMP pathway in normal DG and in the KA-induced seizure 
model to understand the differential response of the layers of the dentate gyrus. L-NAME 
treatment alone caused suppression of ADNP in the hilar neurons in the 3 hr group, 
however, by three days ADNP expression returned to basal levels except in the KA- 
treated group implying hilar cell loss. Early morphological studies identified at least 21
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types of intemeuron in the dentate hilus alone (Amaral, 1978).It has been demonstrated 
that large numbers of hilar neurons die in the KA model of self sustained status 
epilepticus (SSSE) (Buckmaster & Jongen-Relo, 1999; Sloviter et al., 2003; Zappone and 
Sloviter, 2004). Amongst the hilar neurons, nearly 65% are mossy cells which are 
excitatory and the rest are believed to be inhibitory GABAergic intemeurons. In the KA- 
SSSE model about 50% of mossy cells and 13% of GABAergic neurons were lost 
(Buckmaster & Jongen-Relo, 1999). Neither 7-NI nor ODQ caused any significant 
changes in ADNP expression in the DG implying that the neuronal source of NO and 
cGMP are not involved in ADNP regulation/expression in this region. It can be inferred, 
however, that NO may exert neuroprotective effects on intemeurons via ADNP following 
seizure.
The seizure model used in this study is mild since the animals were treated with diazepam 
after the onset of the first generalised seizure. However, a recent study claims that a rat 
model similar to the one used in the present study is classified as a severe model (Yang et 
ah, 2008). It has been previously demonstrated by Du et al. (1995) that diazepam rescues 
neurons from calcium-induced death in a KA model of epilepsy. But recent studies claim 
that diazepam’s protective effect is limited to the CA region of the hippocampus 
(Pitkanen et al., 2005) which maybe why we see cell loss in the DG but not the 
hippocampus. Therefore, the decrease or absence of ADNP in a subpopulation of hilar 
neurons in the DG in KA-treated animals that were pre-treated with L-NAME suggests 
that the NO-ADNP pathway may modulate hilar neuronal survival following an initial 
seizure. This in turn could potentially contribute to additional recurrent excitatory 
circuitry, which subsequently may lead to epileptogenic events and SSSE if left for 
longer periods of time. Higher concentrations of NO are neurotoxic. Diazepam limits the 
severity of seizures (Pitkanen et al., 2005) and this would be predicted in turn to reduce 
excessive NO production by preventing excessive calcium influx, thus reducing the 
neurotoxic actions of NO (Rajasekaran, 2005; Chuang et al., 2007).
Large neurons in the hilus and neurons close to the SGZ did not show ADNP in their cell 
bodies following treatment with L-NAME but expression was seen again by 3 days.
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These cells resemble basket cells or mossy cells in their morphology. It is speculative at 
this stage that basal levels of NO in the normal brain may cause ADNP production and 
expression in the granule cells of the SG. NO inhibition may facilitate the trafficking of 
ADNP towards dendrites, possibly, for modulating synaptic plasticity as increased ADNP 
expression was seen in nerve fibres in the outer molecular layer following L-NAME 
treatment by 3 hrs (Fig. 4.1 (iv)). It has been suggested that the neurotrophins undergo 
activity-dependent regulated release from neurons or glia, enabling them to act as 
synaptotrophins (Gall et al., 1989; Zafra 1990; Schinder et al., 2000). Exposure to 
neurotrophins also facilitates the induction of long-term potentiation (Figurov et ah, 
1996; Akaneya, 1997). NO may regulate ADNP for similar functions, possibly to 
modulate synaptic plasticity, neuronal survival and/or neurogenesis in the DG.
In summary, the DG of the nonnal brain contains ADNP+ neurons and astrocytes which 
appear to be regulated by endogenous NO. Inhibiting NO by L-NAME treatment 
suppresses ADNP in the soma of granule cells and in hilar neurons. However, treating 
animals with L-NAME prior to KA-induced seizure causes ADNP synthesis in granule 
cells by 3 hrs which was later restricted to the SGZ by 3 days, but hilar neuron numbers 
were reduced and the remaining neurons showed eccentric nuclei and irregular cell 
boundaries. These results indicate that NO regulation of ADNP in the DG of normal and 
pathological brains may have different implications for epileptogenesis and that ADNP 
may be providing trophic support for new cells in the SGZ.
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CHAPTER 5
The Regulation o f VIP in the Hippocampus 
& Dentate Gyrus via the NO-cGMP Pathway
Following Seizure
5.1 Introduction
Vasoactive Intestinal Peptide (VIP) was originally isolated from porcine duodenum and 
was described as having ‘strong and unusually prolonged’ vasodilator actions on the 
peripheral and splanchnic circulations (Said & Mutt, 1970). Since then, this neuropeptide 
has been found to be widely distributed in both the peripheral and central nervous 
systems (CNS) and is secreted by immune cells (Delgado et al., 2004). Its physiological 
effects have been described in the regulation of the pituitary gland, pancreas, adrenal 
glands, respiratory system, gastrointestinal tract, reproductive system and the immune 
system (Nussdorfer & Malendowicz, 1998; Bailey et al., 1990; Lundberg et al., 1984; 
Mazzocchi et al., 2002; Dalsgaard et al., 2003; Delgado et al., 2004). In the CNS, VIP 
can act as a neuromodulator, neurotransmitter, neurotrophic or neuroprotective factor 
(Gozes, 2002). It exerts its effect through specific membrane G protein-coupled 
receptors (GPCRs), where the C-terminal of the receptor protein is located in the 
extracellular space and the N-terminal is located inside the cell and can undergo 
glycosylation.
VIP is composed of 28 amino acids and belongs to a family of structurally related 
polypeptides including; pituitary adenylate cyclase activating polypeptide (PACAP), 
peptide histidine-isoleucine (PHI), peptide histidine-methionine (PHM), secretin, 
glucagon and glucagon-like peptide (GLP) and glucose-dependent insulinotropic peptide 
(GIP) (Sherwood et al., 2000). The main receptors characterized for VIP are PACi (8  
variants), which have a poor affinity for VIP and VPACi and VPAC2 receptors which 
have a much higher affinity for VIP. Upon binding to the latter two receptor sub-types, 
VIP causes activation of the adenylyl cyclase (AC) -  cyclic adenosine 3’5’-mono- 
phosphate (cAMP) signal transduction pathway (Vaudry et al., 2000; Dejda et al., 2004). 
VIP receptors are the subject of current research interest for their role in circadian 
rhythm, cancer and neuroprotection (Vosko et al., 2007; Moody & Gozes, 2007; 
Brenneman 2007).
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NO has been shown to regulate the release of VIP. In studies using nNOS knockout mice 
there was a decrease in the number of VIP immunopositive neurons and VIP mRNA in 
the cerebral cortex (Kim et al., 2003). In the suprachiasmatic nucleus (SCN), NO 
colocalizes with VIP in the subpopulation of nNOS-containing neurons, suggesting the 
involvement of NO, nNOS and VIP in circadian rhythm (Reuss et al., 1995). VIP is 
thought to play a role in neurodevelopment and has been linked to disorders such as 
autism, Downs Syndrome and foetal alcohol syndrome (FAS) (Hill 2007). VIP has also 
been implicated in epilepsy (de Lanerolle et al., 1995; Marksteiner et al., 1989). In a 
rodent model of epilepsy, VIP+ neurons were spared in the hippocampus (Sloviter, 1987) 
and VIP receptor expression was shown to increase in human TLE (de Lanerolle et al., 
1995). In the previous chapters it was found that ADNP, a VIP-responsive gene, is 
regulated by the NO-cGMP pathway in the hippocampus and via NO in the DG during 
basal conditions and post seizure. Following on from these observations, I have 
investigated the regulation of VIP following KA induced seizure and whether this is via 
an NO-cGMP dependent mechanism in the DG and hippocampus.
5.2 Materials and Methods
Materials and methods were earned out as previously described for in vivo injections of 
NO inhibitors and KA. Tissues were processed for immunofluorescence and RT-PCR, 
described in the methods section.
5.3 Results
5.3.1 Effect o f  NOS or sGC inhibition on VIP and GFAP expression in the dentate gyrus 
by 3 hours following KA
GFAP and VIP immunostaining revealed that VIP was predominantly present in 
astrocytes in the DG and that VIP was uniformly distributed in the cytoplasm of the cell 
bodies of astrocytes (Fig. 5.1 A (v)). Astrocytic processes did not show VIP expression 
(Fig. 5.1 A (v)). In the DG, VIP+ cells were mainly distributed in the SGZ, the 
polymorphic cell layer and the hilus and were largely absent in the SG (Fig. 5.1 A (i)).
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Some nNOS+ cells co-immunostained with VIP+ cells, however, these were not 
quantified and this is the subject of further work.
To investigate whether the NO-cGMP pathway has a role in the expression of VIP 
following seizure, animals were treated with the NOS or sGC inhibitor with and without 
the induction of seizure by KA. VIP immunostaining did not show any significant 
differences in VIP immunopositive cells following treatment with the broad spectrum 
NOS inhibitor, L-NAME or the nNOS inhibitor 7-NI in the DG. However, the sGC 
inhibitor ODQ revealed a significant increase in VIP+ cells compared to the appropriate 
control in the hilus, SGZ and SG (Fig. 5.IB, Fig. 5.2) by 3 hrs. However, following 
seizure (KA), ODQ treatment caused a significant decrease in the number of VIP+ cells 
by 3 hours. A significant decrease in the number of VIP+/GFAP+ cells was also seen in 
this treatment group (Fig. 5.2). RT-PCR of the whole hippocampus using VIP primers 
revealed an increase in VIP mRNA expression by 3 hours (Fig. 5.9).
5.3.2 Effect o f  NOS or sGC inhibition on VIP and GFAP expression in the dentate gyrus 
by 3 days following KA
Immunostaining with VIP and GFAP showed that treatment with 7-NI and ODQ caused a 
significant increase in the number of VIP+ cells (mainly in the SGZ) by 3 days compared 
to the appropriate control (Fig. 5.3B, Fig. 5.4). Following seizure, pre-treatment with the 
NOS inhibitor L-NAME caused a significant increase in the number of VIP+ cells by 3 
days (Fig. 5.3A, Fig. 5.4). RT-PCR of the whole hippocampus using VIP primers 
revealed no significant changes by 3 days in VIP mRNA expression (Fig. 5.9).
5.3.3 Effect o f NOS or sGC inhibition on VIP and GFAP expression in the hippocampus 
by 3 hours following KA
VIP mRNA and protein was present in the DG and hippocampus as revealed by RT-PCR 
and immunostaining (Fig. 5.1, Fig. 5.5 & Fig. 5.9). Immunostaining revealed VIP 
expression in the CA3 was different to that with ADNP, as VIP staining was not seen in 
the pyramidal cell layer and was present mainly in astrocytes (GFAP+ cells) in the CAI 
and CA3 regions of the hippocampus (Fig. 5.5A, Fig. 5.5B, Fig. 5.7A & Fig. 5.7B). In
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order to investigate whether the NO-cGMP pathway has a role in the expression of VIP in 
the hippocampus during basal conditions or following seizure, animals were treated with 
the NOS or sGC inhibitor as described previously.
Immunostaining with VIP showed that pre-treatment with L-NAME, 7-NI and ODQ 
caused no significant increase in the number of VIP+ cells in the CA3 by 3 hours 
compared to the appropriate controls (Fig. 5.6). Co-immunostaining with GFAP also 
showed that no significant differences were observed in the number of VIP+/GFAP+ cells 
in any of the pre-treatment groups compared to the appropriate controls (Fig. 5.6). 
However, following seizure pre-treatment with L-NAME caused a significant decrease in 
the number of VIP+ cells in the CA3 compared to the appropriate control by 3 hours 
(Fig.5.6). There was also a significant decrease in the number of V1P+/GFAP+ cells in the 
CA3 by 3 hours, compared to the appropriate control (Fig. 5.6).
5.3.4 Effect o f NOS or sGC inhibition on VIP and GFAP expression in the hippocampus 
by 3 days following KA
Immunostaining with VIP also showed that pre-treatment with 7-NI and ODQ caused no 
significant increase in the number of VIP+ cells in the CA3 by 3 days compared to the 
appropriate controls (Fig. 5.8).
Following seizure, pre-treatment with L-NAME caused a significant increase in the 
number of VIP+ cells in the CA3 compared to the appropriate control (Fig.5.8). However, 
this increase in the number of VIP+ cells was accompanied by a highly significant 
decrease in the number of VIP+/GFAP+ cells in the CA3 by 3 days, compared to the 
appropriate control (Fig. 5.8). RT-PCR of the whole hippocampus using VIP primers 
revealed no significant changes by 3 days in VIP mRNA expression (Fig. 5.9).
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Figure 5.1 A. Immunostaining in the DG. All 
sections were immunostained for VIP (red), GFAP 
(blue) and nNOS (green). Treated and taken no more 
than 3 hrs post KA as follows (i) vehicle (DW), (ii) 
vehicle (DW)+KA, (iii) L-NAME, (iv) L- 
NAME+KA. Scale bar: 100 pm (i-iv). (v) Higher 
magnification to show in more detail VIP in the 
soma o f an astrocyte. Scale bar: 10 pm (v).
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Figure 5.1 B. Immunostaining in the DG. All sections were immunostained for VIP 
(red), GFAP (blue) and nNOS (green). Treated and taken no more than 3 hours post 
KA as follows (i) vehicle (DMSO), (ii) vehicle (DMSO)+KA, (iii) 7-NI, (iv) 7- 
NI+KA, (v) ODQ, (vi) ODQ+KA. ODQ treatment caused an increase in VIP staining 
in the hilus, SGZ and SG. Scale bar: 100 pm
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Figure 5.2 Quantification of VIP+ and VIP+/GFAP+ cells in the DG at 3 hours for 
treatment with; vehicle (DW), vehicle (DW)+KA, L-NAME, L-NAME+KA, 
vehicle (DMSO), vehicle (DMSO)+KA, 7-NI, 7-NI+KA, ODQ, ODQ+KA. 
Following sGC inhibition with ODQ an increase in the number o f VIP+ cells was 
observed* conversely a decrease in the number o f VIP+ and GFAP+/VIP+ cells was 
observed with ODQ and KA treatment (*p <0.05, **p <0.01, ***p <0.001; n = 3).
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Figure 5.3 A. Immunohistochemistry in the DG at 3 days. All sections were 
immunostained for VIP (red), GFAP (blue) and nNOS (green). 3 days post KANO 
inhibition caused an increase in the number VIP+ cells on the OML, SGZ and hilus. 
Scale bar: 100 pm
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Figure 5.3 B. Immunohistochemistry in the DG. All sections were immunostained 
for VIP (red), GFAP (blue) and nNOS (green). Treated and taken 3 days post KA as 
follows (i) vehicle (DMSO), (ii) vehicle (DMSO)+KA, (iii) 7-NI, (iv) 7-NI+KA, (v) 
ODQ, (vi) ODQ+KA. Scale bar: 100 pm
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Figure 5.4 Quantification of VIP+ and VIP+/GFAP+ cells in the DG at 3 days for 
treatment with; vehicle (DW), vehicle (DW)+KA, L-NAME, L-NAME+KA, vehicle 
(DMSO), vehicle (DMSO)+KA, 7-NI, 7-NI+KA, ODQ, ODQ+KA. A significant 
increase in the number of VIP+ cells was seen with 7-NI and ODQ pre-treatment and 
L-NAME+KA caused an increase in the number o f VIP+ cells in the DG also, 
suggesting the role of NO in VIP and seizure (*p <0.05, **p <0.01, ***p <0.001; n = 
3).
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Figure 5.5 A. Immunostaining in the CA3. All sections were immunostained for 
VIP (red), GFAP (blue) and nNOS (green). Treated and taken no more than 3 hours 
post KA as follows (i) vehicle (DW), (ii) vehicle (DW)+KA, (iii) L-NAME, (iv) L- 
NAME+KA. NO inhibition caused a decrease in VIP+ cells by 3 hrs following 
seizure (L-NAME+KA treatment) Scale bar: 100 pm
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Figure 5.5 B. Immunohistochemistry in the CA3. All sections were immunostained 
for VIP (red), GFAP (blue) and nNOS (green). Treated and taken no more than 3 
hours post KA as follows (i) vehicle (DMSO), (ii) vehicle (DMSO)+KA, (iii) 7-NI, 
(iv) 7-NI+KA, (v) ODQ, (vi) ODQ+KA. No significant changes were observed 
with any o f the NOS/ sGC inhibitors. Scale bar: 100 pm
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Figure 5.6 Quantification o f VIP+ and YIP+/GFAP+ cells in the CA3 at 3 hours for 
treatment with; vehicle (DW), vehicle (DW)+KA, L-NAME, L-NAME+KA, vehicle 
(DMSO), vehicle (DMSO)+KA, 7-NI, 7-NI+KA, ODQ, ODQ+KA. Following 
seizure, L-NAME pre-treatment caused a significant decrease in the number of VIP+ 
cells in the CA3. (*p <0.05, **p <0.01, ***p <0.001; n = 3).
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Figure 5.7 A. Immunohistochemistry in the CA3 at 3 days. All sections were 
immunostained for VIP (red), GFAP (blue) and nNOS (green). Treated and taken 3 
days post KA as follows (i) vehicle (DW), (ii) vehicle (DW)+KA, (iii) L-NAME, (iv) 
L-NAME+KA. By 3 days NO inhibition caused an increase in the number of VIP+ 
cells post-KA- Scale bar: 1 0 0  pm
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Figure 5.7 B. Immunohistochemistry of the CA3. All sections were immunostained for 
VIP (red), GFAP (blue) and nNOS (green). Treated and taken 3 days post KA as follows 
(i) vehicle (DMSO), (ii) vehicle (DMSO)+KA, (iii) 7-NI, (iv) 7-NI+KA, (v) ODQ, (vi) 
ODQ+KA. Scale bar: 100 pm
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Figure 5.8 Quantification of VIP+ and VIP+/GFAP+ cells in the CA3 at 3 days for 
treatment with; vehicle (DW), vehicle (DW)+KA, L-NAME, L-NAME+KA, vehicle 
(DMSO), vehicle (DMSO)+KA, 7-NI, 7-NI+KA, ODQ, ODQ+KA. Cell counts 
revealed an increase in the the number o f VIP+ cells corresponded with a decrease in 
the number o f GFAP+/VIP+ cells (*p <0.05, **p <0.01, ***p <0.001; n = 3).
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Figure 5.9 RT-PCR analysis o f VIP mRNA revealed that ODQ pre­
treatment causes an increase in VIP mRNA by 3 hours. Treating with 
the sGC inibitor ODQ prior to KA causes a decrease in VIP mRNA by 3 
hours.
5.4 Discussion
The role of VIP has previously been described in both in vitro and in vivo models with 
various neurotoxic insults such as ethanol, hydrogen peroxide (H2O2) and (1-amyloid. 
Here, the regulation of VIP via the NO-cGMP pathway in vivo following KA-induced 
seizure was investigated. Following a seizure, pathological changes take place as 
described previously (see introduction, section 1 .6 ), these events could serve to change 
the hippocampal circuitiy to potentiate the next seizure or could be to protect cells from 
subsequent cell death. The neuroprotective mechanism of action of VIP is still largely 
unknown but it is thought to be via activation of the adenylyl cyclase (AC)-cAMP—> 
protein kinase A (PKA) and mitogen -activated protein (MAP) kinase pathways and 
inhibition of caspase 3 (Nowak et al., 2007). It has also been suggested that VIP may 
exert its neuroprotective effects via a mechanism involving astrocytes and that these VIP- 
stimulated astrocytes secrete neuroprotective/neurotrophic proteins such as activity- 
dependent neurotrophic factor (ADNF), activity-dependent neuroprotective protein 
(ADNP), interleukin (IL)-l and 6 , macrophage inflammatory protein (MIP), 
neurotrophin-3, protease nexin-1 and RANTES (Brenneman et al., 2003; Dejda et al., 
2005; Zusev & Gozes, 2004). Conversely, VIP can inhibit the production of 
inflammatory mediators in activated microglia which in turn, may lead to 
neurodegenerative processes. These results showed that the sGC inhibitor, ODQ caused a 
significant increase in VIP+ cells by 3 hours in the DG (Fig. 5.2), suggesting that the NO- 
cGMP pathway is involved in the regulation of VIP at basal levels in the DG. However, 
following a seizure, ODQ caused a significant decrease in the number of VIP+ cells by 3 
hours in the DG. A significant decrease in the number of VIP+/GFAP+ cells was also seen 
in this treatment group (Fig. 5.2), suggesting the involvement of the NO-cGMP pathway 
in the DG in the regulation of VIP and glial activation following seizure.
VIP-mediated cyclic AMP responses have been shown to be larger in glial cultures 
compared to neuronal cultures. This suggests that astrocytes may be the primary target 
for VIP (Nowak et al., 2007). It has also been shown in the rat brain, that pathological 
conditions such as hypoxia can lead to changes in VIP-driven cyclic AMP-dependent 
signalling, this may also be the case for the NO-cGMP pathway where NO may be
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influencing molecular processes occurring at the level of receptor protein or receptor-Gs 
protein coupling. In the previous chapters immunostaining has shown ADNP expression 
in both neurons and glia. It may be that ADNP secreted from glia acts on neurons. These 
results show that VIP expression is mainly in astrocytes (Fig. 5.1 A (v)). Following a 
seizure, this VIP glial regulation could indicate a mechanism to increase the excitability 
of neurons via ADNP following the initial seizure, configuring the circuitry for 
subsequent seizures or it could be activating the processes involved in cell survival and 
the potential for injury in a seizure focus.
An autopsy study of hippocampi taken from patients with TLE with extrahippocampal 
temporal lobe lesions revealed a significant increase in VIP receptors in the dentate 
molecular layer and lowers levels in the CA fields and subiculum compared to normal 
patients. However, in patients with no temporal lobe lesions but considerable 
hippocampal neuronal loss there was a significant increase in VIP receptor binding in all 
CA fields and subiculum (de Lanerolle et al., 1995). Although the findings in this chapter 
showed no significant changes after a seizure, they did, however, reveal changes in VIP 
expression following NO inhibition, providing an insight into the mechanism by which 
VIP is regulated in the initial stages following a seizure.
These results showed that following a seizure, NO inhibition caused a significant 
decrease in the number of VIP+ cells in the CA3 compared to the appropriate control by 3 
hours (Fig.5.6), there was also a significant decrease in the number of VIP+/GFAP+ cells 
in the CA3 by 3 hours, compared to the appropriate control (Fig. 5.6). This suggests that 
NO is involved in the regulation of VIP and glial activation following a seizure. NO is 
well known for its role in neural transmission (Garthwaite 2008) and its role in neuron- 
glia communication is also becoming increasingly evident (Thippeswamy et al., 2007) 
and it is clearly established that astrocytes are involved in synaptic transmission and 
synaptogenesis. Factors released by glial cells that participate in neural communication 
are termed ‘gliotransmitters’ (Volterra & Meldolesi, 2005). Endozepines, the endogenous 
ligands for benzodiazepine receptors can act as gliotransmitters. These are derived from 
diazepam-binding inhibitor (DBI), an 8 6 -amino acid polypeptide that is exclusively
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expressed in astrocytes (Guidotti et al., 1983; Biirgi et al., 1999). VIP can stimulate the 
release of endozepines via the PACi receptor (Masmoudi et al., 2003). Consequently, 
VIP-induced endozepine release may also indirectly regulate GABAergic transmission 
(Papadopoulos et al., 2006) and so during seizure VIP could indirectly be acting as the 
brain’s endogenous diazepam via an NO mediated mechanism. Alternatively, this could 
present a mechanism via which patients with refractory epilepsy do not respond to anti­
epileptic drugs.
In summary, in the DG, following seizure, VIP expression appears to be mediated via an 
NO-cGMP mechanism since the inhibition of sGC decreases VIP expression. However, 
in the hippocampus, VIP appears to be regulated by NO following seizure. This may be 
via a glial-mediated mechanism.
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CHAPTER 6
The Effects o f Nitric Oxide on ADNP and 
Cell Proliferation in the Dentate Gyrus 
Following Seizure
6.1 Introduction
Neurogenesis involves the proliferation, survival, differentiation and maturation of 
dividing precursor cells. The DG is one of the few regions of the adult brain where this 
phenomenon takes place. New granule cells are generated from dividing precursor cells 
located in the SGZ, the border between the hilus and the granule cell layer (Fig. 6.1). In 
the rat dentate gyrus, it is estimated that approximately 9000 new cells are formed every 
day (Cameron & McKay, 2001). Within the first few days after mitosis, the fate of these 
precursor cells is determined and the factors deciding whether they die or differentiate 
into mature neurons are not yet fully understood (Dayer et al., 2003). New neurons 
integrate into the pre-exisiting hippocampal circuitry and by four weeks their 
electrophysiological properties are identical to those of mature neurons (van Praag et al.,
2002). This integration of new neurons into the hippocampal circuitry is thought to be 
important for adapting to novel situations, e.g. enriched environments increase 
neurogenesis and promote learning and memory (Kempermann, 2002; Gould et al.,
1999). However, stress and pathological conditions can also have an effect on 
neurogenesis.
Seizures can alter the amount and pattern of neurogenesis depending on the type of 
seizure. Acute seizures are thought to augment neurogenesis and the migration of newly 
bom neurons into ectopic regions such as the hilus and molecular layer. Animal models 
of TLE have shown prolonged seizures lead to an increase in the proliferation of granule 
cell progenitors in the DG (Parent et al., 1997; Bengzon et al., 1997; Gray et al., 1998). It 
is postulated that this aberrant migration and integration of new neurons may contribute 
to an epileptogenic hippocampal circuitry following acute seizures, status epilepticus and 
traumatic brain injury (Parent et al., 1997). However, reduced neurogenesis is associated 
with recurrent spontaneous seizures e.g. with chronic temporal lobe epilepsy in humans 
(Hattiangady et al., 2004).
NO has been implicated in epilepsy and is thought to have a pathophysiological role in 
convulsions. Studies on patients with intellectual disability (ID) who suffer from epilepsy
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showed higher levels of NO metabolites and IL-6 in serum compared to ID patients 
without epilepsy (Carmeli et al., 2008). NO is also believed to negatively regulate 
neurogenesis (Pacer et al., 2003). It is becoming increasingly evident that ADNP plays a 
role in development, cancer cell growth and neurogenesis. The human ADNP gene was 
mapped to the chromosome 20ql2-13.2, a region that is amplified in many neuroplasias 
and is associated with cancer cell growth (Bassan et al., 1999; Zamostiano et al., 2001; 
Gozes, 2007). ADNP knockout mice exhibit neural tube closure defects and death at 
E8.5-9.5 (Pinhasov et al., 2003). Also ADNP-deficient embryos exhibit a decrease in 
organogenesis/neurogenesis-related transcripts. Heterozygous ADNP+/- mice display 
neuronal/glial pathology and reduced cognitive functions (Viluh-Shultzman et al., 2007). 
In chapter 4, immunohistochemistry and PCR revealed that NO inhibition caused an 
increase in ADNP expression in the subgranular zone of the dentate gyrus by 3 days 
following seizure. The role of ADNP in hippocampal neurogenesis has not been 
previously investigated. The aim of this chapter was to investigate whether these effects 
seen in the dentate gyrus in chapter 4 were associated with neurogenesis.
6.2 Materials and Methods
Materials and methods were earned out as previously described for in vivo injections of 
NO inhibitors and KA. Tissues and cultures were processed for BrdU immunostaining as 
described in the methods section.
6.3 Results
6.3.1 In vivo effect o f  NO inhibition on ADNP and BrdU expression in the dentate gyrus 
following KA
Four groups of animals were treated with BrdU (lOOmg/kg) prior to administration of 
vehicle (DW), vehicle (DW)+KA, L-NAME, L-NAME+KA. BrdU and ADNP 
immunostaining revealed that BrdU staining was predominantly present in the SGZ of the 
DG and that ADNP was uniformly distributed in this cytoplasm of cells in this area (Fig.
6.1 A). Following KA treatment there were no significant changes in BrDU+ cells 
compared to vehicle control (Fig. 6.1A(v), Fig. 6.1A(ii)Fig. 6.2). However, following L- 
NAME treatment there was a significant increase in the number of BrDU+ cells (Fig.
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6 .1 A(viii), Fig. 6.2) compared to vehicle control (Fig. 6.1 A(ii)Fig. 6.2). Notably, this 
increase in the number of BrDU+ cells appeared to be in ectopic regions such as the hilus 
and molecular layer, indicated by white arrows (Fig. 6.1A(viii)).
Following seizure, NO inhibition caused a significant increase in the number of BrDU+ 
cells in the SGZ (Fig. 6.1A(xi), Fig. 6.2), which was accompanied by a significant 
increase in the number of BrDU+ and ADNP+ cells (Fig. 6.1 A(xii), Fig. 6.2). 
Immunostaining with doublecortin (DCX) (a cell marker for newly bom neurons) of the 
DG from animals treated with L-NAME+KA, showed that some of these BrdU+ cells 
were also immunopositive for DCX (Fig. 6.3A(i),(ii)) suggesting a relationship between 
NO ADNP and neurogenesis.
6.3.2 In vitro expression o f ADNP in DG cells and the effect o f  NO inhibition following 
KA treatment
To investigate these effects further, endogenous precursor cells were isolated from the rat 
DG and grown in vitro. Hence, the hippocampi of 7-10 day old wistar rats were removed 
and the DG dissected from the rest of the hippocampus (Fig. 2.2). DG cells were plated 
and grown in vitro (Fig. 6.4A) for 7 days before treatment. Immunostaining with TUJ-1, 
NeuN showed the differentiation of cells into neurons (Fig. 6.4A(iv), Fig. 6.5A).
Triple immunostaining with TUJ-1, ADNP and BrdU, showed that both neuronal and 
proliferating cells expressed ADNP (Fig. 6.5B). Triple immunostaining with DCX, 
ADNP and BrdU revealed that ADNP was also expressed in newly bom neurons (Fig. 
6 .6A), however, staining with GFAP, BrdU and ADNP only showed ADNP to be present 
in some but not all astrocytes (Fig. 6 .6 B).
Double immunostaining with ADNP and BrdU revealed that NO inhibition caused a 
significant increase in the number of BrDU+ cells (Fig. 6.7A(xi), Fig. 6 .8 ) compared to 
KA alone (Fig. 6.7A(v), Fig. 6 .8 ), which was accompanied by a significant increase in 
the number of BrDU+ and ADNP+ cells (Fig. 6.7A(xi), Fig. 6 .8 ) compared to KA alone 
(Fig. 6.7A(v), Fig. 6 .8 ).
Cells grown in vitro at 9 DIV for long pulse BrDU and 7 DIV for short pulse BrDU were 
treated with vehicle (DW), vehicle (DW)+KA, L-NAME, L-NAME+KA and 
immunostained for BrdU, NeuN, ADNP, GFAP and nestin. Merged images showed no
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co-localisation with BrdU and NeuN (Fig. 6.9A (i)), however, an increase in ADNP+ 
astrocytes was seen with NO inhibition is shown following KA (Fig. 6.9A (iii)) compared 
to control (Fig. 6 .6 B (iv)). Immunostaining for nestin, a precursor cell marker, showed 
co-localisation of BrdU and nestin (Fig. 6.9A(iv)) suggesting that NO and ADNP may be 
involved in the proliferation of precursor cells following seizure.
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Figure 6.1 Photomicrographs o f the DG taken from animals treated with BrdU prior 
to administration o f vehicle (DW), vehicle (DW)+KA, L-NAME, L-NAME+KA. 
Immunostaining with ADNP (red) and BrdU (green) shows increased hippocampal 
neurogenesis with NO inhibition following seizure (xi). (viii) shows an increase in 
ectopic neurogenesis (indicated by white arrows). Scale bar: 100pm.
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Figure 6.2 Histogram of cell counts to show increased hippocampal neurogenesis 
with NO inhibition and NO inhibition following seizure. Values are expressed as 
mean ± SEM. Significant differences are determined by one-way ANOVA with 
Bonferroni post-hoc test (*p <0.05, **p <0.01, ***p <0.001).
Figure 6.3 Photomicrographs o f the DG taken from an animal treated with BrdU 
prior to administration o f L-NAME+KA.(i) Immunostaining with doublecortin 
(DCX) (red) and BrdU (green) shows BrdU+ cells co-localise with doublecortin, a 
cell marker for newly bom neurons (indicated by arrows). Immunostaining with 
ADNP (red) and BrdU (green) revealed an increase in neurogenesis in the SGZ 
following seizure with L-NAME pre-treatment. Scale bars: 100pm in (i) and 20pm 
in (ii).
AFigure 6.4 Photomicropgraphs o f DG cells grown in vitro at (i) 2 days in 
vitro (DIV), (ii) 4 DIV, (iii) 6  DIV showing the proliferation and migration of 
cells in vitro, (iv) Merged image of immunostaining with TUJ-1 (red), NeuN 
(green) and ADNP (blue) to show differentiation of neuronal cells in vitro. 
Scale bar: 100pm.
(i) TUJ-1
: •
(ii) ADNP ('ii) BrdU (iv) Merge
j f -  -A  *
f  §
/  i
Figure 6.5 Photomicropgraphs of DG cells grown in vitro at (i) 7 DIV, treated with 
BrdU and immunostained in (A) with Tuj-1 (red), NeuN (green) and in (B) Tuj-1 
(green), ADNP (red) and BrdU (blue), (iv) Merged image of immunostaining with 
TUJ-1 (green), ADNP (red) and BrdU (blue) show ADNP is expressed in the 
cytoplasm of both neurons and proliferating cells. Scale bar: 50pm in (A) and 20pm 
in (B).
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Figure 6 .6  Photomicropgraphs o f DG cells grown in vitro at (i) 7 DIV, treated with 
BrdU and immunostained in (A) with DCX (red), BrdU(green), ADNP (blue) and in 
(B) GFAP (green), BrdU (blue) and ADNP (red). Merged images o f immunostaining 
with ADNP show ADNP is expressed in the cytoplasm of both newly bom neurons 
and is some (indicated by an arrowhead), but not all, astrocytes (indicated with an 
arrow). Scale bars: 20pm
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Figure 6.7 Light microscopy images show an increase in ADNP+ proliferating cells 
with NO inhibition following KA treatment 8 DIV. Immunostaining with ADNP 
(red) and BrdU (green) revealed an increase in ADNP+ proliferating cells with L- 
NAME+KA treatment. Scale bar: 100pm.
□ BrDU+ BrdU+and ADNP+
Figure 6.8 Histogram of cell counts to show an increase in ADNP+ proliferating 
cells with NO inhibition following KA treatment 8 DIV. Values are expressed as 
mean ± SEM. Significant differences are determined by one-way ANOVA with 
Bonferroni post-hoc test (*p <0.05, **p <0.01, ***p <0.001).
A.
Figure 6.9 Photomicropgraphs of DG cells grown in vitro at 9 DIV (i) and (ii),for 
long pulse BrDU and 7 DIV (iii) and (iv) for short pulse BrDU. All cells were treated 
with L-NAME+KA and immunostained in (i) with NeuN (blue) ADNP (red), 
BrdU(green), in (ii) and (iii) GFAP (green), ADNP (red) and BrdU (blue). In (iv) 
cells were immunostained for Nestin (blue), ADNP (red), BrdU (green). Merged 
images show no merge with BrdU and N euN ' however, an increase in ADNP+ 
astrocytes with NO inhibition is shown following KA (iii), suggesting NO and ADNP 
are involved in the proliferation of precursor cells in vitro. Scale bar: 50pm in 
(i),(iii) and 2 0 pm in (ii),(iv).
6.4 Discussion
One of the most recent neurophysiological roles of NO to be unveiled is its importance in 
the regulation of neurogenesis, although the proliferative roles of NO have already been 
described in that it reversibly inhibits cell division (Garg and Hassid, 1990) and inhibits 
cell proliferation in the adult mammalian brain (Packer et al., 2003). The dual role of NO 
in neuroprotection and neurotoxicity seems to extend to neurogenesis, as NO produced 
from nNOS appears to have antiproliferative effects (Park et al., 2002), whereas the 
induction of neurogenesis is attributed to the production of NO via iNOS or eNOS (Reif 
et al., 2004; Zhu et al., 2003). The isoform nNOS has been shown to be expressed by 
differentiated neurons surrounding the SVZ and also in neuronal precursors in the dentate 
gyrus (Moreno-Lopez et al, 2000; Islam et al., 2003) suggesting the role of NO in 
neurogenesis. Moreover, it has been shown that the systemic administration of 7- 
Nitroindazole (7-NI), a relatively selective nNOS inhibitor, causes an increase in the 
number o f mitotic cells in the SVZ, the olfactory bulb and the rostral migratory stream 
(RMS), however, this was not the case in the dentate gyrus (Park et al., 2002).
So far, the mechanisms via which NO regulates neurogenesis are largely unknown. In this 
chapter, I have used the general NOS inhibitor L-NAME with BrdU labelling in 
combination with immunocytochemistry in both in vivo and in vitro experiments to 
investigate the regulation of ADNP following KA-induced seizure. Results shown 
correlate with previous findings by Packer et al that NO negatively regulates adult 
neurogenesis, as an increase in BrdU+ cells were observed following L-NAME 
administration (Fig. 6.1A(viii) and (Fig. 6.2). However, this was accompanied by a 
pattern of ectopic expression (Fig. 6.1A(viii) indicated by arrows) in the DG, which has 
not been previously reported. This may have been due to age or species differences. It 
may also be due to differences in L-NAME administration. In these experiments L- 
NAME was administered 3 times over a period of 24 hrs and so a more sustained 
inhibition of NO may lead to processes determining ectopic expression.
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Previous findings have also shown that acute seizures augment neurogenesis and the 
migration o f newly bom neurons into ectopic regions such as the hilus and molecular 
layer (Parent et al., 1997; Bengzon et al., 1997; Gray et al., 1998). However, I did not 
observe such an effect following KA (Fig. 6.1A(v)). This may be because animals were 
administered diazepam after the initial seizure. Previous findings have employed animal 
models o f TLE with prolonged seizures whereby an increase in the proliferation of 
granule cell progenitors is observed in the DG (Parent et al., 1997; Bengzon et al., 1997; 
Gray et al., 1998).
ADNP has been shown to play a role in development and neurogenesis, as ADNP 
knockout mice exhibit neural tube closure defects and death at E8.5-9.5 (Pinhasov et al.,
2003). Furthermore, ADNP downregulation by small hairpin RNA technology causes a 
reduction in embryoid body formation and neurite numbers linking ADNP with neuronal 
differentiation and maturation (Mandel et al., 2008). My results show that NO inhibition 
causes a significant increase in the number of BrdU+ and ADNP+ BrdU cells following 
seizure or KA treatment (Fig. 6.1A(xii), Fig. 6.2, Fig. 6.7A(xii), Fig. 6 .8 ), suggesting NO 
may regulate ADNP during proliferation, which may directly have an effect on cell 
proliferation or provide neurotrophic support to newly bom cells.
NO is thought to play a role in most stages of neurogenesis, for example, via the growth 
factors involved in precursor proliferation e.g. BDNF, bFGF and EGF and NMDA 
receptor activation, which NO has been shown to regulate itself (Contestabile, 2000). 
During migration, a number of attractive and repulsive chemotropic factors such as 
ephrins, integrin subunits and reelin regulating migration may themselves be regulated by 
NO. In fact, recent studies using Reeler mutants demonstrated a down-regulation in 
nNOS protein expression in the olfactory bulb (Herrmann et al., 2007). The regulation of 
the molecular processes governing differentiation, integration and survival are thought to 
involve astrocytic signaling, and certainly, NO is known to regulate apoptosis and the 
survival o f new cells (Kim et al 1999). Therefore, ADNP may well be involved in this 
astrocytic signaling, as an increase in the number of ADNP+ astrocytes was observed
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following L-NAME+KA treatment (Fig. 6.9A(iii)) compared to control treated (Fig. 
6 .6 B(iv)).
ADNP is co-expressed with the PACAP receptor (PAC1R), a receptor involved in the 
release of gliotransmitters such as endozepines, which is regulated by PACAP,VIP, 
GABA and somatostatin (Masmoudi-Kouki et al., 2007). In the hippocampus, ADNP has 
been shown to co-immunostain with the neuron marker, neuron-specific enorase and all 
ADNP-immunopositive cells co-localize with PAC1R immunoreactivity. Interestingly, in 
the cerebral cortex, ADNP-immunoreactive cells co-immunostained with the astrocyte 
marker GFAP (Nakamachi et al., 2007). In 2003, Hiittmann et al showed an increase in 
proliferating radial glia-like astrocytes in the dentate gyrus after kainate-induced seizures, 
consistent with a recruitment of precursors for seizure-induced neurogenesis. It could be 
possible that during seizures, by regulating ADNP/VIP, NO causes astrocytes in the 
cortex/hippocampus to release these gliotransmitters.
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CHAPTER 7
General Discussion
7.1 General Discussion & Future Directions
In vivo and in vitro experiments were carried out to investigate the role of the NO-cGMP 
pathway on ADNP/VIP expression following seizure/KA treatment. Animals were 
administered either L-NAME, a paradigmatic inhibitor of NOS, 7-NI a specific inhibitor 
of the neuronal isoform of NOS or ODQ which is a selective inhibitor of soluble guanylyl 
cyclase. This was to determine whether any changes in ADNP/VIP expression could be 
attributed to the direct effects of NO and more specifically via the neuronal iso form or via 
a cGMP mediated mechanism. Griess assays showed decreased levels of nitrite, the stable 
breakdown product of NO, in vivo with these compounds (Fig. 3.1). An increase in 
nitrite levels following seizure was also observed. This was accompanied by an increase 
in nNOS and iNOS expression in the hippocampus (Fig. 3.2), also consistent with other 
findings (Chuang et al., 2003; Zaja-Milatovic et al., 2008). When inteipreting this effect 
of NO as anti-convulsant or pro-convulsant, caution must be applied as NO is previously 
reported to display both anti-convulsant (Penix et al., 1994, Kendrick et al., 1996; Gabriel 
et al., 2000; Sardo and Ferraro, 2007; Royes et al., 2007) and pro-convulsant effects (De 
Sarro et al., 1993; Tutka et al., 1996), depending on the species studied and epilepsy 
model employed. Such differences in findings on the effects of NO in epilepsy 
emphasizes the complexity of this molecule and factors such as NO concentrations, cell 
types, species and model must be taken into account.
In these studies, behavioural observations (Cosgrave et al., 2008) and other observations 
in our lab in mice show that NO inhibition with L-NAME advances the onset of the first 
full generalized seizure and that (50mg/kg) of L-NAME in mice can cause death. These 
results suggest NO to be an endogenous anti-convulsant in our model, however, as 
seizures were halted with diazepam administration after the initial seizure, we cannot 
conclude what the longer term effects of NO inhibition on seizure would be. NO cannot 
simply be categorized as anti- or pro-convulsant and the use of NO inhibitors/donors in 
the treatment of epilepsy may largely be dependent on concentration and timing. Further 
experiments, using highly specific inhibitors of each NOS isoform administered at
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various time points could be used to determine the role each that isoform plays in the 
induction and maintenance of seizure.
As discussed in Chapters 3 to 6 , it was shown that the NO-cGMP pathway is involved in 
the regulation of ADNP/VIP expression in the hippocampus/DG under both physiological 
and pathological conditions. One obvious conclusion to be drawn is that ADNP/VIP 
regulation is region-specific and that NO is regulating these proteins via different 
mechanisms in the DG and hippocampus. This may be due to the different cell types and 
the different roles each region plays in seizure activity. Patterns of immunostaining 
showed ADNP to be expressed in neurons and glia of the hippocampus, whilst VIP 
immunostaining was more glial-specific. ADNP is thought to be regulated by VIP (Giladi 
et al., 2007), however, a direct correlation between VIP and ADNP regulation in the 
hippocampus and DG was not always observed, suggesting other pathways and factors to 
be involved in their regulation. However, in the hippocampus it appears that NO 
inhibition causes an increase in both ADNP and VIP following seizure by 3 days. This 
was accompanied by a decrease in the number of VIP+/GFAP+ cells (and ADNP+/GFAP+ 
cells, but not quantified). Neuronal ADNP may, therefore, play a role in this region of the 
hippocampus after the onset of an initial seizure. As the cells of the CA1 and CA3 region 
are susceptible to cell death following KA-induced seizure, NO could serve to inhibit this 
ADNP neuronal regulation following seizure, leading to neuronal cell death. Hence, the 
initial rise in NO following seizure could be inhibiting the neuroprotective properties of 
VIP/ADNP.
Interestingly, the decrease in the number of GFAP+ VIP and ADNP cells with NO 
inhibition following seizure also implies the regulation of glial cells via NO in the 
hippocampus following an initial seizure. Astrocyte and microglial activation occurs 
following seizure, a process involved in epileptogenesis, and studies in GFAP knockout 
mice showed hippocampal CA3 neurodegeneration following cerebral injury (Shapiro et 
al., 2008; Otani et al., 2006). GFAP knockout mice were also more susceptible to KA- 
induced seizures and had an increased number of pyknotic damaged CA3 neurons than 
WT mice (Otani et al., 2006). My findings suggest that an increase in NO following a
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seizure is synonymous with an increase in glial activation in the hippocampus and hence 
NO inhibition causes a decrease in GFAP+ cells in the hippocampus following seizure. 
These actions could pertain to the role of glial cells in neuroinflammation following 
seizures and the inverse relationship with VIP/ADNP infers NO regulated VIP/ADNP 
neuronal-glial signaling may be inhibited following a seizure, leading to the detrimental 
effects of neuroinflammation and neurotoxicity. In addition to the neuroinflammatory 
role of glial cells, another point for consideration in this area is that progenitors in the 
posterior SVZ migrate into the CA1 and CA3 fields and differentiate into glial cells 
(Parent et al., 2002). Could it be that NO augments glial cell differentiation in the CA1 
and CA3 following a seizure? This could be a question for further investigation and 
analysis.
The distribution of these two proteins differed between the hippocampus and DG. VIP 
was found to be expressed at lower levels in the CA1 and CA3 regions than ADNP. 
However, in the DG a similar pattern of expression is seen between the two proteins, 
although one notable difference was a lack of VIP immunostaining in intemeurons, 
despite previous findings to the contrary (Sloviter et ah, 1987). However, I did see some 
co-immunostaining of VIP with nNOS in hilar neurons. Therefore, studies could be 
carried out to discern the intemeuronal cell types involved in the regulation of VIP via the 
NO-cGMP pathway.
In the DG, NO inhibition caused an increase in ADNP expression by 3 hrs following 
seizure, this was accompanied by an increase in VIP mRNA expression by 3 hrs. By 3 
days there was an increase in VIP+ cells with NO inhibition following seizure suggesting 
a possible feedback mechanism/neuron-glial communication between ADNP and VIP+ 
cells in this region. As the DG is one of the few sites to display neurogenesis, BrdU 
labeling experiments were carried out to investigate if this increase in ADNP expression 
was related to neurogenesis. In vitro and in vivo experiments did confirm that NO is 
indeed involved in the regulation of cell proliferation following seizure. Previous work by 
Packer et ah (2003) corroborate these findings that NO negatively regulates mammalian 
adult neurogenesis. It could be argued then, that if there is an increase in NO following
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seizure, this should attenuate neurogenesis which may seem contradictory to previous 
findings where animal models of TLE have shown prolonged seizures lead to an increase 
in the proliferation of granule cell progenitors in the DG (Parent et al., 1997; Bengzon et 
al., 1997; Gray et al., 1998). However, an explanation for this may lie in findings that 
reduced neurogenesis is associated with recurrent spontaneous seizures e.g. with chronic 
temporal lobe epilepsy in humans (Hattiangady et al., 2004). It is probable that the 
regulation of NO in neurogenesis, may like many of its other effects, be time and 
concentration dependent. I have shown that ADNP is involved in precursor cell 
proliferation and is regulated by NO following KA treatment both in vitro and in vivo. 
The antiproliferative properties of NO appear to depend on the inhibition by p53 of 
cyclin-dependent kinases and transcription factors by the Rb protein. However, the 
proliferative aspect of NO in the adult brain could be due to an increase in cGMP as 
demonstrated by pharmacological studies using sildenifil, an inhibitor of 
phosphodiesterase 5, leading to the accumulation of cGMP and causing an increase in 
neurogenesis (Gibbs, 2003; Zhang et al; 2003). cGMP is also thought to be involved 
modulating axonal guidance and neurite outgrowth of newly differentiated neurons 
(Hindley et al., 1997). Further BrdU-labelling experiments with sGC inhibitors could be 
carried out to determine if the cGMP pathway is involved in the regulation of 
neurogenesis and ADNP expression during seizure. Studies of SGZ cells in vitro have 
found that they retain the potential for self-renewal and the ability to differentiate into 
neurons, astrocytes and oligodendrocytes (Palmer et al., 1997). Hence, further 
experiments could determine the role of the NO and VIP/ADNP in cell differentiation in 
the DG and co-immunostaining with VIP and other cell markers could be carried out.
The actual mechanism via which NO interacts with the proteins ADNP and VIP cannot 
be determined from the work presented in this thesis and further investigations into how 
NO directly or indirectly modifies these proteins could be the subject for further 
investigation e.g. using the biotin switch assay to investigate post-translational 
modification via nitrosylation. The biotin switch assay converts nitrosylated cysteines to 
biotynylated cysteines which can then be detected by immunoblotting or avidin-affinity 
chromatography (Jaffrey & Snyder, 2001). In conjunction with NO donors, this technique
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could be used to investigate whether ADNP or VIP are post-translationally modified via 
NO. Also, the human and mouse ADNP genes contain potential phosphorylation sites, 
which indicates the possibility of the protein being activated or deactivated through 
phosphorylation or dephosphorylation via cGMP produced via NO. Hence, proteomic 
and other protein phosphorylation detection methods could be used to further elucidate 
the mechanisms via which the NO-cGMP pathway regulates ADNP/VIP protein 
expression.
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Activity-dependent neuroprotective protein (ADNP) is widely dis­
tributed in the cytoplasm of neurons and astrocytes of the hippocam­
pus. Kainic acid (KA)-induced seizures increases neuronal nitric oxide 
synthase (nNOS) in neurons and inducible NOS (iNOS) in glia cells 
which coincides with a reduction in ADNP in the hippocampus. 
Inhibitors of NOS or soluble guanylyl cyclase (sGC) activity reduce 
ADNP under basal conditions in the absence of seizures. Treating 
animals with these inhibitors prior to KA-induced seizure, in 
particular, L-NAME (/V°-nitro-i.-arginine methyl ester), advances 
the onset of the first seizure but reverses the loss of ADNP by 3 days 
after the first seizure. This suggests that the NO-cGMP pathway has a 
role in regulating ADNP under both basal physiological conditions and 
in the pathophysiological changes produced during epileptogenesis.
© 2008 Elsevier Inc. All rights reserved.
K e y w o r d s :  Epilepsy; Kainic acid; Neuroprotection; ADNP; Nitric oxide 
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Cornu Ammonis; cGMP, cyclic guanosine monophosphate; CREB, cAMP 
response element-binding protein; KA, kainic acid; L-NAME, V'-nitro-L- 
arginine methyl ester; MARK, mitogen-activated protein kinase; 7-NI, 7- 
nitroindazole; NMDA, jV-methy-D-aspartate; ODQ, lH-[1.2.4]oxadiazolo 
[4,3-aJquinoxalin-1 -one; NO, nitric oxide; nNOS, neuronal NO synthase; 
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Introduction
Activity-dependent neuroprotective protein (ADNP) was first 
identified as a ‘vasoactive intestinal peptide (VIP) responsive’ gene 
product (Bassan et al., 1999; Gozes, 2007). The critical role of VIP in 
nervous system development and synapse formation suggested that 
ADNP may have similar important liinctions. ADNP contains the 
NAPVSIPQ (NAP) motif which is also found in another VTP- 
responsive protein and this peptide has been shown to have a 
neuroprotective function (Bassan et al., 1999; Zemylak et al., 2000; 
Gozes et al., 2003; Furman et al., 2004; Zaltzman et al., 2005). In a 
mouse model of head trauma, NAP protected neurons from death 
(Gozes et al 2005; Zaltzman et al., 2005). In another study using tire 
hydrogen peroxide-induced stress model, ADNP reduced pro- 
apoptotic p53 protein in rat pheochromocytoma (PC 12) cells (Steingart 
and Gozes, 2006). Importantly, a recent study by Vulih-Shultzman et 
al. (2007) demonstrated that ADNP+/~ mice have cognitive deficits and 
increased phosphorylated tau, the hallmark of neurodegenerative 
diseases. ADNP has also been shown to be essential for brain 
fonnation and development (Pinhasov et al., 2003; Mandel et al., 
2007), however, its role during postnatal pathophysiology of disease 
processes such as epilepsy has not been explored in vivo.
The kainic acid (KA)-induced animal model of epilepsy, that 
closely resembles human temporal lobe epilepsy (TLE) in some 
aspects, has been used to explore the effects o f therapeutic 
interventions on epileptogenesis and seizure severity (Nadler, 1981; 
Cole et al., 2002; Velisek and Moshe, 2003; Scantlebury et al., 2007). 
Analysis of hippocampal pathology in human TLE has revealed 
neuronal loss and gliosis (Nadler et al., 1978; Ben-Ari, 1985; De 
Lanerolle et al., 2003) and, importantly, gene expression in TLE 
samples was consistent with increased glutamate release by astrocytes 
(Lee et al., 2007). Several factors contribute to cell death in KA- 
induced status epilepticus (SE), for example, excessive glutamate 
release and subsequent activation o f (V-methy-D-aspartate (NMDA) 
receptors and voltage gated calcium channels, and additionally
0969-9961/$ - see front matter © 2008 Elsevier Inc. All rights reserved, 
doi: 10.1016/j.nbd.2008.02.005
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suppression of GluR2, an a-amino-3-hydroxy-5-methyl4-isoxazo- 
lepropionic acid (AMPA) receptor (Tomita et al., 2007; Friedman 
et al., 1994, 1998). All these factors lead to calcium-induced cell 
death that can be prevented if  the animals are treated with diazepam 
prior to SE (Du et al., 1995).
The calcium influx activates neuronal nitric oxide synthase 
(nNOS) to produce NO (Garthwaite, 2005). The role of NO during 
epileptogenesis is controversial as it has been shown to have both anti­
convulsant (Penix et al., 1994, Kendrick et al., 1996; Gabriel et al., 
2000; Sardo and Ferraro, 2007; Royes et al., 2007) and pro-convulsant 
actions (De Sarro et al., 1993; Tutka et al., 1996), depending on the 
species studied and epilepsy model employed. NO is formed from L- 
arginine by any o f the three NOS isoforms; neuronal NOS (nNOS), 
endothelial NOS (eNOS) or glial inducible NOS (iNOS). All three 
NOS isoforms are expressed during epilepsy. For example, eNOS is 
upregulated in a rodent model of SE within 3-24 h o f intracranial 
injection of KA (Chuang et al., 2007; Liu et al., 2007), while nNOS 
and iNOS are upregulated in a mouse model of electrically-induced 
SE (Catania et al., 2003). NO activates soluble guanylyl cyclase (sGC) 
to generate cGMP which in turn activates protein kinase G (PKG) 
(Garthwaite, 2005). NO can also directly modulate the expression of 
transcription factors, for example, CREB mediates a cGMP/PKG- 
dependent anti-apoptotic signal cascade activated by NO (Nagai- 
Kusuhara et al., 2007; Zhuravliova et al., 2007; Riccio et al., 2006).
In a rodent model o f epilepsy, VIP+ neurons were spared in the 
hippocampus (Sloviter, 1987) and VIP receptor expression was 
shown to increase in human TLE (De Lanerolle et al., 1995). The 
nNOS knockout mouse has been shown to have fewer VIP+ neurons 
in the brain (Kim et al., 2003) and it is therefore plausible that VIP- 
responsive ADNP production may have been reduced. Following on 
from these observations, as NO has been implicated in both 
neuroprotection at low concentrations and neurotoxicity at high 
concentrations (Calabrese et al., 2007), we hypothesised that there 
could be an interaction between NO production during epileptogen­
esis and ADNP synthesis. In order to explore this interaction we 
examined the effects on ADNP production in rats that were treated 
with NOS or sGC inhibitors prior to seizure induction with KA.
Materials and methods
Experiments were carried out on 35-40 day old male Wistar rats, 
which were kept under controlled environmental conditions (19- 
23 °C, 12 h light, 12 h dark) with food and water available ad libitum. 
All experiments were carried out under a UK Home Office project 
licence and had been considered by the University's Ethical Review 
committee.
Experimental design: drug treatment and kainic acid (KA) induction 
o f  seizure
The following drugs were used: NOS inhibitors, /V°-nitro-L- 
arginine methyl ester (L-NAME, 50 mg/kg i.p.) and 7-nitroinda- 
zole (7-NI, 50 mg/kg i.p.); the sGC inhibitor, 1H-[1,2,4] 
oxadiazolo [4,3-a]quinoxalin-l-one (ODQ, 10 mg/kg i.p.); and 
kainic acid (10 mg/kg i.p.). All chemicals were purchased from 
Tocris Cookson Ltd. UK, except 7-NI (Sigma, UK). KA and L- 
NAME were dissolved in distilled water (DW), and 7-NI and ODQ 
were dissolved in 20% DMSO. As appropriate, DW and 20% 
DMSO were used as vehicle controls. The effective drug doses 
were derived from previous studies (Gabriel et al., 2000; Bagetta 
et al., 2002; Catania et al., 2003; Gupta and Dettbam, 2003; Kato
et al., 2005; Thippeswamy et al., 2007a,b). In addition, a nitrite 
assay and/or cGMP immunoreactivity were carried out on samples 
of hippocampus to asses whether the NOS and sGC inhibitors were 
effective in blocking the NO and cGMP production, respectively.
Animal groups and treatments
In total, 120 animals were divided into 5 groups of 24 animals 
each. Each group received one of the following pre-treatments which 
were given over 24 h as three equally spaced doses: DW, 20% 
DMSO, L-NAME, 7-NI or ODQ. Subsequently, all animals were 
assigned to one of four groups (A to D) each consisting of 30 animals 
(six animals derived from each treatment group). Approximately 27 h 
after the first pre-treatment injection of drug or vehicle, groups C and 
D received KA (10 mg/kg i.p.), while groups A and B received DW 
(vehicle control for KA). Three hours later (i.e. 30 h after the first pre- 
treatment injection), groups A and C were euthanized and 3 days later 
groups B and D were euthanized. Group D animals were injected 
with diazepam (10 mg/kg, i.p.) after onset o f the first lull seizure 
(maximum of 3 h after receiving KA) to prevent development of 
SE which may lead to death. The amount o f seizure activity the 
animals experienced was standardised as far as possible by permitting 
the animals to only experience a maximum of two seizures each 
lasting around 10-15 s, which represents a very mild insult. Although 
L-NAME pre-treated animals responded to KA earlier (25 ± 15 min, 
n= 6) than the vehicle pre-treated group, the number and duration of 
seizure was still limited to two by administration of diazepam (3 day 
group) or euthanasia (3 h group). The 3 h (post-KA) time point was 
chosen because i) the onset of the first full seizure (see below) was 
variable, typically between 45 and 90 min. However, as described 
above, the number and duration o f seizures during this period did not 
exceed two and all those animals that did not fall into this category 
were excluded from the experiment, ii) This allowed time for the KA 
to cross the blood-brain barrier and to initiate a chain of events 
following from direct receptor activation, through cell depolarisation, 
network activation, paroxysmal discharge, calcium influx to gene 
expression and protein synthesis prior to complete clearance or 
metabolism (for example, a review from Ben-Ari and Cossart, 2000).
Seizures were classified according to the Racine scale (Racine, 
1972) using the following criteria: stage 1, freezing, facial 
twitching; stage 2, head nodding, salivation and arching of the 
back; stages 3—4, vigorous roaming around the cage, forelimb 
clonus, and rearing; and stage 5, rearing and falling followed by a 
series of muscle contractions. Tissues were only collected from 
those animals that showed full generalised seizures (tonic-clonic 
seizure) in the KA-treated groups C and D and extra animals were 
used to bring the group numbers back to 30/group. Further control 
experiments without KA were also carried out to confirm the direct 
effects o f diazepam on nNOS, iNOS and ADNP production.
Half the animals from each group were deeply anaesthetised and 
fixed by vascular perfusion with 4% paraformaldehyde. Brain tissues 
harvested from these animals were processed for immunohistochem- 
istry. The brains collected from the remaining were not fixed but were 
divided in half down the midline, one half o f the hippocampus being 
used for RNA extraction and the other half for protein extraction.
RNA isolation
Experimental and control hippocampi were isolated and rapidly 
snap frozen in liquid nitrogen. Total RNA was extracted from each 
hippocampus using a Trizol-chloroform mixture (Gibco, UK), DNA 
and proteins were removed by salt-precipitation using isopropanol.
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The RNA pellet was re-suspended in RNase-free water and each 
sample treated with RNase-free DNase to eliminate genomic DNA 
contamination (Promega, UK). The RNA concentration was 
determined with a Gene Meter spectrophotometer (ABgene, UK) 
and stored at -4 0  °C until further use.
Reverse transcription
The reverse transcription was c arried out on 200 ng o f total RNA 
for each sample using Invitrogen's Superscriptll system according to 
the manufacturer's instructions. Initially, a 12 pi reaction mixture 
containing 25 pg/ml oligo dT primers and 0.5 mM dNTP incubated at 
65 °C for 5 min, then the following were added to each sample: 4 pi of 
5X First Strand Buffer [250 mM Tris-HCl (pH 8.3), 375 mM KC1, 
15 mM MgCl2], 10 mM DTT and 40 U RNaseOUT Recombinant 
Ribonuclease Inhibitor. Each reaction was mixed and then incubated 
at 42 °C for 2 min, 200 U o f Superscriptll was then added to each 
sample and incubated at 42 °C for a further 50 min. The reaction was 
then inactivated at 70 °C for 15 min, further held at 4 °C for 5 min and 
the cDNA was stored at -4 0  °C.
Semi-quantitative polymerase chain reaction
The polymerase chain reaction (PCR) was used for semi- 
quantitative analysis of ADNP, nNOS and ¡NOS transcripts. PCR 
was performed in an Eppendorf Mastercycler Gradient (Eppendorf, 
UK) thermal cycler. Appropriate primers were obtained from MWG 
Biotech, Germany, prepared as a 100 pM stock and stored at -4 0  °C. 
The following rat primer sequence was used: ADNP forward 5'-GGA 
CCA CAT TGT CAA TTC ACA CC-3' and reverse primer 5'-GGA 
CAA GCG CTG CAG CAG AAA GG-3'; nNOS forward primer 5'- 
GAA CCC CCA AGA CCATCC and reverse primer 5'-GGT TTG 
CTC CCA CTG TT-3'; iNOS forward primer 5'-AGC ATC ACC CCT 
GTG TTC CAC CC-3' and reverse primer 5'-TGG GGC AGT CTC 
CAT TGC CA-3'; and P-actin forward 5'-ACG GTC AGG TCATCA 
CTA TGG-3'and reverse primers 5'-AGC CAC CAA TCC ACA 
CAG-3'. A 50 pi reaction mixture was prepared in 0.2 ml capped thin 
walled tubes containing: 200 ng of cDNA template, 0.4 pi Taq DNA 
polymerase (Promega), 1.5 mM MgCl2 (Promega), 0.2 mM dNTP 
(Invitrogen), 1 pi of each forward and reverse primer and 5 pi of 1 Ox 
PCR buffer (Promega). PCR programmes were adapted from a standard 
protocol. As a control for the amount of cDNA used in the reactions, rat 
p-actin levels were analysed. PCR products from the RT-PCR reactions 
were electrophoresed on a 1 % agarose gel, visualised with an Evenscan 
broadband dual wavelength transluminator in a Multilmagell Light 
Cabinet and digital images were captured using the Alphalmager unit 
(all equipments from Alpha Innotech Corporation, UK).
Quantitative polymerase chain reaction
Quantitative PCR was carried out using the Dynamo SYBR 
Green qPCR Kit (Finnzymes). Using an Opticon qPCR machine 
(GRI) a standard curve for each gene o f interest or housekeeping 
gene was generated to determine copy numbers for unknown 
samples and a melting curve (65-95 °C with 0.2 °C increments) 
analysis was performed to confirm purity of products. Relative 
amounts o f unknown samples were calculated from the amount 
of target gene and normalized to the amount o f housekeeping gene 
(P-actin). Each experiment was carried out in triplicate and primer 
sequences were as described above. Thermal cycling conditions 
were as follows: 95 °C for 10 min, followed by 45 cycles of
amplification at 94 °C for 10 s, 60 °C for 20 s, and 72 °C for 20 s 
followed by data acquisition. Data was analysed using Opticon 
Monitor 3.1 software (MJ Research, UK) and expression o f target 
gene was normalized per 1000 copies o f P-actin.
Western blotting
The hippocampi were dissected and homogenised in 500 pi RIPA 
buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS) containing a cocktail of protease 
inhibitors (Sigma, UK). Protein concentrations were determined 
using the BCA Protein Assay Kit (Pierce, USA). Proteins were 
resolved using the NuPAGE Novex 10% Bis-Tris gel system 
(Invitrogen, UK) and electrophoretically transferred to nitrocellu­
lose membranes. Membranes were blocked with 10% donkey serum 
for 1 h, then incubated with primary antibodies (ADNP, 1:1000, 
Chemicon, UK; or P-actin 1:500, Sigma, UK) for a further 1 h at RT, 
washed with PBS (x3) and processed with secondary antibodies 
conjugated to a chromogen. After thorough washing with PBS (x 3), 
membranes were visualised using the Westembreeze chromogenic 
immunodetection system (Invitrogen, UK).
lmmunohistochemistry
The animals were euthanized using halothane and perfused 
intracardially with 0.1 M phosphate buffered 4% paraformaldehyde 
(PBS-PFA). The brains were then dissected and further post-fixed in 
PBS-PFA overnight, cryo-preserved in 25% sucrose for a few days 
and frozen in liquid nitrogen cooled-isopentane prior to sectioning 
on a cryostat (Bright, UK). The brains were cut transversely into 
15 pm sections and thaw mounted onto chrome-alum-gelatine 
coated slides (three sections/slide). Sections were washed in PBS to 
remove PFA and blocked with 10% donkey serum (DS) for 1 h at 
room temperature (RT). Double or triple immunostaining was 
carried out simultaneously on control and dmg treated sections using 
the same reagents and antibodies. All antibodies were diluted in a 
diluting solution (PBS, 0.1% Triton X-100, 2.5% DS and 0.25% 
sodium azide). Sections were incubated overnight at 4 °C with the 
following primary antibodies in a combination of two or three 
depending on the species: ADNP (raised in rabbit, 1:500; Chemicon, 
UK), nNOS (raised in sheep, 1:1000, gift from Dr PC Emson, 
Cambridge, UK), GFAP (raised in rabbit/mouse 1:200; Chemicon, 
UK), iNOS (raised in rabbit 1:100; Chemicon, UK) and NeuN 
(raised in mouse 1:100: Chemicon, UK). The specificity o f these 
primary antibodies are published elsewhere (Thippeswamy and 
Morris, 2001; Thippeswamy et al., 2007b). Primary antibody 
omission was routinely used as a negative control and a tissue 
section from a known positive control was also used in parallel (for 
example, axotomized dorsal root ganglion for nNOS and ADNP 
Thippeswamy and Morris, 2001; Thippeswamy et al., 2007b). On 
the following day sections were washed in PBS (x 3) and appropriate 
anti-species antibodies, for example, donkey anti-rabbit Cy3 
conjugated (1:300) and biotinylated donkey anti-sheep (1:500) 
were applied for 1 h at RT. All secondary antibodies are from 
Jackson Immunoresearch Laboratories, Inc., USA. After washing 
with PBS (x3), sections were treated with streptavidin-FITC (1:80, 
Vector Laboratories) for 1 h and then washed in PBS. For triple 
staining a third antibody was applied and sections were processed as 
above followed by a third fluorochrome, streptavidin-marina blue 
(1:50; Molecular Probes, USA) for 1 h. Sections were covered with 
VectaShield (Vector Laboratories), coverslipped and viewed with a
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Fig. 1. Effect of NOS orsGC inhibition on ADNP in the hippocampus in vivo. (A) ADNP mRNA expression. L-NAME, 7-Nf and ODQ reduced the amount of ADNP 
mRNA 30 h after the first dose of the drug compared with control. Three days after the end of drug treatment, ADNP mRNA levels returned to the pre-treatment control 
level. (B) lmmunohistochemistry—effect of NOS or sGC inhibition (30 h) on ADNP+ (red/pink in all), nNOS+ (green except in iii) and GFAP+ (blue in all) cells in the 
CA3 region. Control vehicle treatments (i) DWand (v) 20% DMSO had no effect on ADNP staining or distribution. Thirty hours after L-NAME treatment (ii) ADNP 
was markedly reduced in the CA3, with a smaller but similar reduction being seen after 7-NI (vi) and ODQ (vii) treatment. At higher magnification, ADNP can be seen 
to be co-localized in both neurons (iii, green cells are NeuN+) and in astrocytes (iv, blue cells are GFAP+). Scale bar: 100 pm (all) (For interpretation of the references to 
colour in this figure legend, the reader is referred to the web version of this article.). (C) Quantification of ADNP+ neurons. By 30 h after die first dose of NOS or sGC 
inhibitor treatment, the number of ADNP+ neurons significantly reduced compared with the appropriate control (*p<0.05, **p<0.0l, ***p<0.001; n=3). By 3 days 
post treatment the number of ADNP* neurons had nearly returned to control values.
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Fig. 2. Kainic acid (KA)-induced seizures increase NOS expression in the hippocampus. RT-PCR analysis (A) and immunocytochemistry (B) for nNOS and 
iNOS show that KA increases gene transcription by 3 h after KA treatment (A) and protein synthesis by 3 days, but not by 3 h (not shown). Green cells indicated 
by arrows in (i) and (ii) in ‘B’ represent nNOS+ neurons and red cells in (iii-vi) are iNOS+ (predominantly glia), (v) and (vi) represent higher magnification views 
of the iNOS+ cells denoted by the box in (iii) and (iv) respectively. Note that there is an increase in nNOS+ and iNOS+ cells in KA-treated animal compared to the 
control. Scale bar: 100 pm (all). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Nikon inverted microscope (Nikon, UK) using appropriate wave­
length filters for the fluorochrome. Images were captured by 
scanning sections using the appropriate filter for each fluorochrome 
and merged using IPL laboratory software (Nikon, UK).
Cell quantification
Immunopositive neurons were counted from the stratum pyrami- 
dale (SP) of CA1 (NeuN1", ADNP+) and CA3 (ADNP+ only) regions 
of the hippocampus from animals receiving NOS or sGC inhibitors 
and/or KA to explore the effects o f each treatment on ADNP 
synthesis. The average numbers (see below) were expressed as the 
percentage of ADNP+ neurons against the total number of neurons 
(NeuN1") in the CA1 region. In the CA3 region the average number of 
ADNP+ neurons is presented instead of the percentage. This is 
because of the difficulty to count closely packed and overlapping 
neurons in the CA3 SP region compared to the CA1. Tire nNOS and 
iNOS immunopositive cell counts were made in the lacunosum 
moleculare (SLM) and stratum lucidum since nNOS+ and iNOS+ cells
were predominant in these areas compared to other areas of the 
hippocampus, and moreover iNOS expression was inconspicuous in 
the stratum pyramidale of CA regions. Quantification of glial cells 
(GFAP+) with respect to ADNP expression was not undertaken due to 
variability of GFAP expression in astrocytes as a result o f the drug 
treatment.
Sections from approximately the same region of the hippo­
campus were selected for counting from control and drug treated 
animals which were processed for double/triple immunostaining 
simultaneously using the same reagents and/or antibodies. All 
slides were given a code and the code was revealed after cell count 
and statistical analysis. The appropriate wavelength filter for each 
fluorochrome was used to distinguish immunopositive cells from 
the rest and image captured, and then the filter was changed 
(without changing the field of view) to view a second or a third 
marker. Using IPL image analysis software, a threshold was set for 
each fluorochrome to distinguish positive versus negative staining 
and the same threshold was used for both drug and appropriate 
control. A minimum of three animals from each group were used
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Fig. 3. KA-induced seizures markedly reduce ADNP mRNA (A and B) and protein as revealed by immunochemistry (C), cell counts (D) and Western blotting 
(E), 3 days after KA treatment (group D). Pre-treatment with the NOS blockers, L-NAME or 7-NI or the sGC blocker, ODQ reverses the effects of KA-induced 
ADNP suppression. (A, B) RT-PCR (A) and QPCR (B) analysis of ADNP mRNA revealed that KA suppresses ADNP mRNA by 3 days post-KA treatment, but 
not at the 3 h (A) time point tested. Treating with the NOS or sGC blockers for 30 h prior to KA reverses ADNP mRNA levels to nearly basal levels by 3 days. 
(C) Immunohistochemistry — appropriate vehicle (i, DW and vi, DMSO) treatments for both drugs (without KA) produced no reduction in ADNP staining, 
while KA treatment following these controls (ii, DW+KA, vii, DMSO+KA) produced a marked reduction in ADNP by 3 days. Pre-treatment with the NOS or 
the sGC blockers (v, L-NAME+KA, viii, 7NI+KA, ix, ODQ+KA) reversed this reduction. The higher magnification shows more detail of the marked reduction 
of ADNP in the soma of CA3 neurons after KA treatment (iv) compared with vehicle control (iii) (the areas correspond to the boxed regions in i and ii.). Scale 
bar: 100 pm (all). (D) Quantification of ADNP+ neurons. KA treatment for 3 days significantly decreased the number of ADNP+ neurons in the CA3 region 
compared with the appropriate control and pre-treatment with NOS or sGC blockers reverses KA-induced ADNP reduction (*p<0.05, **p<0.01, ***p<0.001; 
n=3). (E) Western blot analysis of ADNP from the whole hippocampus also reveals a reduction in the amount of ADNP protein following KA treatment which is 
partially reversed by pre-treatment with L-NAME.
for cell counting. The average cell numbers were calculated for 
each rat, the SEM calculated for each treatment group and p values 
obtained using ANOVA (Graphpad software Inc, USA) by 
comparing drug treated versus appropriate control. A ‘p ‘ value 
less than 0.05 was considered to be significant.
Results
Effect o f  NOS or sGC inhibition on ADNP expression under basal 
physiological conditions in the hippocampus
ADNP mRNA and protein was present in the hippocampus as 
revealed by RT-PCR and immunocytochemistry (Fig. 1). Cellular 
localization using cell-specific markers with double/triple immu- 
nostaining revealed that ADNP was present in both neurons and glia 
cells in the CA1 and CA3 regions of the hippocampus (Fig. IB). 
Interestingly, apical dendrites in the stratum oriens (SO) o f the CA1 
pyramidal neurons were intensely stained for ADNP (Fig. 4A), 
while mossy fibres in the SLM were not stained (not shown). Several 
pyramidal cells in the CA1 and CA3 and intemeurons and astrocytes 
in the SO, stratum radiatum (SR) and stratum lucidum (SL) also 
contained ADNP in their cell bodies (Figs. IB, 4A).
In order to explore whether the NO-cGMP pathway has a role in 
the physiological expression of ADNP under control conditions in 
the hippocampus, animals treated with the NOS or sGC inhibitor 
(without the induction o f seizure with KA, groups A and B) were 
examined. ADNP mRNA expression was reduced by L-NAME, 7N1 
or ODQ compared to controls (DW or DMSO) in group A (control 
group for 3 h post-KA group C, euthanized 30 h after the first drug 
dose) but not in group B (control group for 3 days post-KA group D,
euthanized 3 days after the last drug dose) (Fig. 1 ). This shows that 
after a transient block o f the NO-cGMP signalling system, ADNP 
production is inhibited but recovers to control levels within 3 days.
The effect of NOS or sGC inhibition on the topographic 
distribution of ADNP containing neurons in the CA3 and CAI 
regions of the hippocampus was further examined by immunostain- 
ing (Fig. IB). Both nitrite and cGMP immunoreactivity o f the 
hippocampus from the NOS and sGC inhibitor-treated animals 
decreased in group A (30 h after the first dose) but had recovered in 
group B (3 days after the last dose) (data not shown). In group A 
animals, the number o f ADNP+ neurons in the CA3 region of the 
hippocampus was significantly reduced in the L-NAME treated 
group compared to the vehicle control (Figs. IB, C). Similarly, 7-NI 
or ODQ treatment also caused a reduction in the number of ADNP+ 
neurons in the CA3 as compared to the DMSO control group 
(Figs. IB, C). However, 3 days post drug treatment (group B) there 
was no significant difference in ADNP+ neuron numbers compared 
with appropriate vehicle control groups (Fig. 1C). Similar observa­
tions were made from the CAI region (data not shown).
Kainic acid treatment increases nNOS and iNOS mRNA and 
protein synthesis in the hippocampus
PCR analysis of mRNA for nNOS and iNOS revealed a 
significant increase in their expression in the hippocampus of KA- 
treated animals (3 h post-KA, group C), compared to the vehicle 
control (Fig. 2A), but increased protein synthesis occurred later. 
Immimostaining of the 3 days post-KA hippocampi (group D) for 
nNOS and iNOS protein revealed an increase in the number of 
nNOS+ cells (predominantly neurons) and iNOS+ cells (predomi-
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Fig. 4. Effect of KA and NOS or sGC inhibition on ADNP in CA1 region of the hippocampus in vivo. (A) Immunohistochemistry. (i) In control vehicle treated 
staining for ADNP is seen in the cell bodies of CA1 pyramidal neurons in the stratum pyramidale (sp). (ii) Higher magnification of the area shown by the box in (i), 
shows intense ADNP staining in apical dendrites of the pyramidal neurons traversing the stratum oriens (so), (iii) KA-induced seizure increases the number of 
nNOS+ cells (green) while dramatically reducing ADNP+ (red) in the pyramidal cells of CA1 region of the hippocampus, iv. Increased nNOS is primarily in the 
soma and dendrites of neurons, while the residual ADNP is confined mainly to the nucleus of a few neurons in the stratum pyramidale (sp). (v) Higher 
magnification of the area indicated by the box in iii (in the ‘so’ region) shows the loss of ADNP staining from the apical dendrites and reveals nNOS staining in 
some fibres. Scale bar: 100 pm (all). (B) ADNP+ neurons quantification. The percentage of ADNP+ neurons were derived from counting all the neurons that were 
identified by NeuN staining, and ADNP positive neurons from the CA1 stratum pyramidale. In controls, approximately 30% of neurons expressed ADNP and this 
was markedly reduced by 3 days after KA treatment. Almost complete reversal was seen with the NOS or sGC blockers. *p<0.05, **><0 .0 1 , ***^<0.001; n=3. 
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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nantly microglia and astrocytes) compared with the control 
(Fig. 2B). For example. 3 days post-KA treatment, in the SL and 
SLM together, in control animals there were 5 ±3 nNOS+ and 9 ±4 
iNOS+ cells, and this increased to 22±7 and 38±11 cells, 
respectively. The SL and the SLM had greater numbers of nNOS 
and iNOS cells (Fig. 2B) compared to other areas of the 
hippocampus. In addition, in 3 days post-KA treatment there was 
increased nNOS staining in the neurites, whose cell bodies were 
located in the outer margins o f the SP (Fig. 4B) in the CA3 and 
CA1 regions suggesting an increase in the local release of NO. The 
number of nNOS+ and iNOS+ cells did not change in control 
animals treated with diazepam (without KA).
Effect o f NOS or sGC inhibition prior to kainic acid treatment on 
ADNP in the hippocampus
The KA treatment caused a marked reduction o f both ADNP 
mRNA and protein synthesis in the 3 days post-KA animals (group 
D) as revealed by RT-PCR/qPCR, immunocytochemistry and 
Western blot analysis (Fig. 3). In haematoxylin and eosin, and 
TUNEL stained sections o f the hippocampus from both 3 h (group 
C) and 3 day (group D) post-KA animals did not reveal any 
abnormal morphology or cell death (data not shown) indicating that 
the reduction in ADNP is not due to cell loss. Since group D animals 
received diazepam to prevent status epilepticus and subsequent cell 
death in the CA regions, it might be argued that the reduction in 
ADNP was in some way due to this treatment. However, control 
experiments (without KA) to check this possibility revealed that 
diazepam alone had no effect on ADNP levels (data not shown).
The suppression of ADNP mRNA by KA alone (without the 
NOS or sGC inhibitor pre-treatment) was evident in the 3 day post- 
KA-treated animals (group D) but not in the 3 h post-KA group 
(group C). However, L-NAME, 7-NI or ODQ pre-treatment reduced 
ADNP mRNA levels in the 3 h post-KA group C, compared to 
appropriate vehicle pre-treatment groups within this group (vehicle 
+KA) (Figs. 3A, C, D). This implies that this initial reduction in 
ADNP mRNA levels was due to reduced production of NO and 
cGMP as opposed to the effects o f KA (for 3 h), which correlates 
with the effects o f these drugs seen under basal conditions (Fig. 1). 
Interestingly, by 3 days post-KA treatment (group D), ADNP 
reduction was reversed in the hippocampus in the NOS or sGC 
inhibitor pre-treated group but not in the vehicle pre-treated groups 
(Fig. 3). This indicates that increased NO levels, as evident from 
greater numbers o f nNOS+ neurons and iNOS+ glia cells (Fig. 2B) 
following KA treatment (by 3 days), decreases ADNP. Immunocy- 
tochemical analysis o f the CA3 and CA1 regions of the 3 day post- 
KA-treated animals (group D) for ADNP suggested that a reduction 
of ADNP synthesis was evident in both neurons (Figs. 3C, 4A) and 
astrocytes (Fig. 3C). In the control group ADNP was observed 
throughout the soma (SP) and apical dendrites of the CA1 pyramidal 
neurons (SO), while in the 3 day post-KA treatment group ADNP 
staining was observed in clusters and/or in punctate fonn within the 
nucleus of a few neurons in the SP. ADNP was almost completely 
suppressed in the apical dendrites in the SO (Fig. 4A).
Effect o f NOS or sGC inhibition prior to kainic acid treatment on 
the onset o f  the first seizure
Following KA administration, animals were monitored and the 
symptoms leading to the onset o f the first full tonic-clonic
(generalised) seizure were scored according to Racine's seizure 
severity scale (stages 1-5) as described previously. In the KA-treated 
group, without the NOS or sGC blocker pre-treatment, animals 
progressed steadily from stages 1 to 5 within 90 min of KA treatment. 
In L-NAME pre-treated animals there was no significant difference in 
the symptoms at each stage leading up to the onset o f the first 
generalised seizure (stage 5), but the duration of symptoms at each 
stage from 1 to 4 decreased. However, the duration of stage-5 
symptoms did not exceed 10-15 s in all KA-treated groups. In general, 
L-NAME pre-treated animals exhibited the first full tonic-clonic 
seizure sooner (25±15 min) than animals that had been pre-treated 
with the vehicle control (DWor DMSO), 7-NI or ODQ (70±20 min), 
and the number of stage-5 seizures did not exceed more than two in 
any group (euthanized by 3 h without diazepam or seizures were 
terminated by treating them with diazepam in 3 day post-KA group). 
This may suggest that the non-specific block of all NOS isoforms by 
L-NAME, somehow, facilitates KA-induced early onset of seizure 
activity while more selective block does not. It is speculated that the 
decreased ADNP by L-NAME treatment prior to KA may be one 
reason for early onset of the first seizure.
Discussion
A neuroprotective role for VIP-responsive ADNP and its 
derivative peptides, such as NAP, has been identified (Gozes, 
2007). Although studies o f ADNP in experimental epilepsy have 
not been reported VIP does seem to have a role. VIP levels fall acutely 
in experimentally induced seizures (Romualdi et al., 1992), while 
post-mortem hippocampus samples from human TLE have increased 
VIP binding (De Lanerolle et al., 1995). Initial studies o f ADNP 
suggested that it was primarily located in glia cells (Gozes, 2007). 
Previously, Bassan et al. (1999) showed increased basal levels of 
ADNP mRNA in astrocytes in response to VTP and, interestingly, VIP 
and/or its derivative peptides induce NO and cGMP production in 
cortical cultures (Ashur-Fabian et al., 2001). We have previously 
demonstrated an important role for NO in neuron-glia communication 
and neuroprotection (Thippeswamy et al., 2005, 2007a). It is thus 
plausible that NO could be involved in regulating VTP-responsive 
ADNP function. In the present study ADNP was detectable under 
basal conditions in the pyramidal neurons and intemeurons o f the 
hippocampus in addition to astrocytes. The antibodies used were 
raised against the peptide sequence 989-1015 of the human ADNP 
which is identical in rat and mouse, and does not share homology with 
other proteins when used in a BLAST search. Interestingly, ADNP 
staining in the apical dendrites o f the pyramidal cells in the SO was 
intense under basal conditions, suggesting large amounts of the 
protein (Fig. 4A), but was conspicuously absent in the SL and mossy 
fibres. This reveals a highly selective distribution indicating a cell- 
specific as opposed to a generalised function.
Experimental-induced seizures provide a simple model for 
producing neuronal stress leading to neuronal death. Several 
methods have been employed to induce seizures (Nadler, 1981; 
Cole et al., 2002; Vellsek and Moshe, 2003; Scantlebury et al., 
2007) and for the present study we used KA. At the doses used in 
these experiments, KA initially activates kainate receptors in the 
hippocampus (Ben-Ari and Cossart, 2000) but this rapidly leads to 
more widespread neuronal depolarisation and release of transmit­
ters such as glutamate acting on both AMPA and NMDA receptors. 
The neuron depolarisation and NMDA channel activation leads to 
calcium influx resulting in activation of NOS and subsequent NO 
production (Kato et al., 2005). NO released from nNOS activates
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sGC to produce cGMP in many areas of the brain including the 
hippocampus (Garthwaite et al., 1989; Teunissen et al., 2001). To 
explore the effects o f NO and cGMP on ADNP distribution and 
synthesis we examined its distribution in the presence and absence 
o f NOS and sGC inhibitors. The sGC inhibitor, ODQ was used to 
block cGMP production to understand whether ADNP is also 
regulated by the sGC-cGMP pathway. Several others have used 
these NOS or sGC blockers, in vivo, via the intraperitoneal route 
and have demonstrated that they cross the blood-brain barrier 
(Bagetta et ah, 2002; Catania et ah, 2003; Gupta and Dettbam, 
2003; Kato et ah, 2005; Chuang et ah, 2007; Liu et ah, 2007; 
Parathath et ah, 2007). The decreased nitrite content and lack of 
cGMP immunoreactivity in the hippocampus of animals treated 
with NOS or sGC inhibitor confirmed that the drugs were effective 
in blocking NO and cGMP production.
The KA treatment dramatically reduced ADNP mRNA and 
protein synthesis by 3 days post-KA treatment but not at earlier 
time points examined (3 h and 24 h post-KA, data not shown for 
24 h) suggesting a complex pathway involved in KA-induced 
ADNP suppression. The morphological analysis together with 
TUNEL staining for apoptosis in the hippocampus from these 
animals confirmed that there was no cell loss. The delay in 
suppression of ADNP synthesis coupled with the later widespread 
loss of ADNP staining in all the CA regions studied could result 
from increased NO production by KA-induced seizures. The 3 day 
post-KA group was treated with diazepam before onset o f SE to 
prevent neuronal death. It has been previously demonstrated by Du 
et al. (1995) that diazepam rescues neurons from calcium-induced 
death in a KA model o f epilepsy. Therefore, the decrease in ADNP 
mRNA and protein in KA-treated animals is not due to cell loss. 
Diazepam limits the severity o f seizures (Pitkanen et al., 2005) and 
this would be predicted in turn to reduce excessive NO production, 
thus reducing the neurotoxic actions of NO (Rajasekaran, 2005; 
Chuang et al., 2007). In the present study, the animals that received 
diazepam and the NOS or sGC blocker showed complete reversal 
o f the ADNP loss 3 days after KA treatment. These results suggest 
that the use of antiepileptic drugs combined with NOS inhibition 
may be beneficial (Paul, 2003; Luszczki et al., 2006).
The precise mechanism of KA-mediated ADNP suppression by 
NO will require much more detailed research to elucidate. 
However, following KA treatment it was noted that ADNP was 
mainly located in the nuclei o f the pyramidal neurons while in the 
animals pre-treated with the NOS blocker, it was distributed 
throughout the soma and dendrites. As ADNP is synthesised in the 
cytoplasm, the presence of peptide in the nucleus is indicative of 
translocation and it is possible that ADNP may function as a DNA- 
binding protein/transcription factor to regulate gene expression. 
Zemlyak et al. (2007) have recently shown that the ADNP- 
derivative, NAP protects KA-treated hippocampal neurons in 
culture by interacting with microtubule-associated protein (MAP). 
ADNP and NAP can also modulate polyADP-ribosylation to 
promote neuronal differentiation and survival via MAPK-PLK/Akt 
pathways (Mandel et al., 2007; Mandel and Gozes 2007; Pascual 
and Guerri, 2007), similar to the effect caused by NGF on PC 12 
cells (Visochek et al., 2005).
Increased NO concentration in the CNS causes DNA damage, 
altered mitochondrial membrane potential and activation of 
polyADP-ribosylation leading to neuronal death (Zhang et al., 
1994; Dawson and Dawson, 1995; Wallis et al., 1996). Depending 
on the NO levels, it can modulate DNA-binding activities o f the 
cAMP response element-binding protein (CREB, a transcription
factor) to mediate the cGMP-PKG-dependent anti-apoptotic signal 
induced by NO (Nagai-Kusuhara et al., 2007; Zhuravliova et al., 
2007; Riccio et al., 2006). Interestingly another VIP-derived 
peptide, ADNF-9, also protects neurons from iNOS-mediated 
toxicity in the hippocampus in a hypoxic-ischemia model (Kumral 
et al., 2006). Low concentrations of NO found under basal 
conditions are known to be beneficial (Contestabile and Ciani, 
2004; Thippeswamy et al., 2006; Calabrese et al., 2007). The 
reduction o f ADNP produced by blockade of NOS or sGC (in the 
absence of seizure) suggests that the basal production of NO may 
be important for maintaining ADNP synthesis in the hippocampus. 
Based on these observations it is plausible that ADNP and NO may 
interact to regulate neuronal survival. Recent studies have shown 
that NO interacts with ADNP downstream targets. Stroissnigg et al. 
(2007) have demonstrated that MAP can undergo 5-nitrosylation 
which is another action of NO and this is involved in the regulation 
of growth cones morphology. In the present study, KA-induced NO 
suppression of ADNP in apical dendrites o f the pyramidal neurons 
may also suggest an NO-ADNP interaction in orchestrating the 
onset o f seizure during epileptogenesis.
In summary, under physiological conditions, a low concentra­
tion of NO appears to promote ADNP synthesis since the block of 
NO decreases ADNP and it advances the onset o f the first seizure 
in the KA-induced epilepsy model. KA increases NO production as 
evident from greater numbers of nNOS+ and iNOS+ cells in the 
hippocampus and, interestingly, this high level of NO suppresses 
ADNP. Treating animals with the NOS or sGC inhibitor prior to 
KA reverses ADNP suppression, by 3 days post-KA treatment, 
implying its regulation by the NO-cGMP pathway.
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